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“No citizen has a right to be an amateur in the matter of physical training. What 
a disgrace it is for a man to grow old without ever seeing the beauty and strength 
of which his body is capable.”
Socrates (469-399 BC)
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ABSTRACT
MicroRNAs (miRNAs) are short strands of ribonucleic acid (RNA) that play an 
essential role in maintaining tissue homeostasis. miRNAs specifically target 
and bind to mRNA molecules and are potent regulators of protein translation. 
Skeletal muscle miRNAs are involved in many biological processes, including 
the development of disease and ageing and respond to external stimuli such as
diet and exercise. Dysregulation in miRNA expression is also associated with 
deleterious adaptation processes such as age-related muscle wasting. 
Maintaining skeletal muscle mass is critical for the maintenance of 
independence and quality of life. Ageing is associated with a number of 
conditions including arthritis, diabetes and frailty syndrome, all of which are 
linked to a loss of skeletal muscle mass. Age-related muscle wasting is partly 
associated with a reduced capacity for skeletal muscle to synthesise new 
proteins in response to anabolic stimuli such as resistance exercise. 
Understanding the regulation of molecular mechanisms controlling muscle 
protein synthesis (MPS) as we age is essential for the development of effective 
and targeted therapeutic treatments for age-related muscle wasting. One major 
pathway that regulates MPS is the Akt-mTOR pathway, which is dysregulated 
with age. The role of miRNAs in the regulation of Akt-mTOR signalling in 
skeletal muscle with ageing is poorly understood. The aim of this thesis was to 
improve our understanding of the role of miRNAs in regulating MPS during the 
ageing process, with a specific focus on Akt-mTOR signalling. 
To address the aims of this thesis, a high-throughput miRNA screen was 
performed on skeletal muscle biopsy samples taken from young and old 
subjects following an acute bout of resistance exercise that is known to 
stimulate MPS. Chapter 3 identifies 26 miRNAs that are differentially regulated 
with age, exercise or a combination of both factors. From this study, 2 miRNAs
were selected for in vitro modulation to provide a proof-of-concept for their 
direct role in regulating MPS. miR-99b is a miRNA belonging to the miR-
99/100 family of miRNAs and is predicted to target key members of the Akt-
mTOR signalling pathway. Chapter 5 shows for the first time that miR-99b 
xv
directly downregulates protein synthesis in human primary myotubes. mTOR-
Akt signalling was not established as a mode of action for miR-99b, however 
its family members miR-99a and miR-100 were downregulated in association 
with miR-99b overexpression, suggesting the existence of complex 
compensatory mechanism. In Chapter 6 miR-499 is shown to downregulate 
protein synthesis in human primary myotubes derived from old subjects only. 
miR-499 was predicted to target eIF4G2, a direct regulator of protein translation 
and downstream member of mTOR signalling. Although eIF4G2 mRNA 
expression was reduced with miR-499 overexpression, protein levels remained 
unaltered and furthermore, a direct binding interaction was not observed 
between miR-DQGLWVSUHGLFWHGELQGLQJVLWHLQWKHH,)*މ875$OWKRXJK
Akt-mTOR signalling was not implicated in the downregulation of protein 
synthesis, an age-related mechanism is at play in this model and warrants 
further investigation.
The findings of this thesis have extended our understanding of miRNAs and 
their role in MPS and their potential role in age-related muscle wasting. 
Collectively, this thesis presents miRNAs as regulators of protein synthesis and 
potentially important molecules contributing to age-related muscle wasting. 
This thesis provides a proof-of-concept that miR-99b and miR-499 are 
regulators of protein synthesis and identifies 24 other miRNAs potentially 
implicated in the skeletal muscle response to acute resistance exercise and 
adaptation to ageing. Although the field of miRNAs is still relatively recent, 
they represent potential therapeutic targets for disease management. 
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CHAPTER 1
LITERATURE REVIEW
1
1. LITERATURE REVIEW
A component of this literature review has been published in Frontiers in Physiology; Evelyn 
Zacharewicz, Sèverine Lamon and Aaron P. Russell. MicroRNAs in skeletal muscle and their 
regulation with exercise, ageing and disease 30 December 2013 doi: 
10.3389/fphys.2013.00266. (Appendix A)
1.1 Introduction
The majority of the human genome does not code for proteins, but rather 
consists of regulatory sequences, introns, non-coding ‘junk DNA’ and non-
coding ribonucleic acids (RNA), including microRNAs (miRNAs) (Bartel 
2004). Since their discovery in 2001 miRNAs have reformed our traditional 
understanding of gene and protein expression. In eukaryotes miRNAs
predominantly function as negative regulators of gene expression and it is 
believed that miRNAs account for at least 33% of all gene expression 
(Beitzinger et al. 2007; Hu & Bruno 2011; Huili et al. 2010). Therefore it is 
palpable that miRNAs are closely studied as regulators of good health as well 
as the onset and progression of disease.
Ageing is a long physiological process that results in general physical decline 
due to the accumulation of bodily damage. On a molecular level ageing is the 
result of a number of changes within molecular pathways that lead to overall 
growth arrest (Smith-Vikos & Slack 2012). Our recent advances in health and 
medicine have led to significant improvements in life expectancy. However, we 
are now facing a global health issue due to an increased morbidity and financial 
strain that is associated with the elderly population.
Skeletal muscle represents a large fraction of the human body, making up ~40% 
of the body’s mass (Rasmussen & Phillips 2003). It provides us with structural 
support and an important site for nutrient storage (Bassel-Duby & Olson 2006;
Rasmussen & Phillips 2003). Sarcopenia refers to the normal loss of skeletal 
muscle mass that occurs with ageing and results in a significant loss of 
independence and quality of life. The loss of muscle mass that occurs with 
sarcopenia is multifactorial. One significant factor involved in the onset and
progression of sarcopenia is reduced muscle protein synthesis (MPS) 
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(Cuthbertson et al. 2005; Greiwe J.S et al. 2001; Kumar et al. 2009). While the 
molecular pathways involved with skeletal muscle mass are well described 
(Bodine et al. 2001b; Rommel et al. 2001) the role of miRNAs as translational 
regulators controlling MPS is poorly understood. Understanding how miRNAs
regulate skeletal muscle health during ageing should be of great global interest 
as they represent real potential targets for selective modulation to improve 
health outcomes for our elderly citizens.
1.2 MicroRNAs
Although miRNAs have previously been mentioned in the literature (Lee, 
Feinbaum & Ambros 1993; Reinhart et al. 2000) they were first defined and 
described in 2001 following the cooperative work of three research groups 
(Lagos-Quintana et al. 2001; Lau et al. 2001; Lee & Ambros 2001). Prior to the 
work of Lagos-Quintana, Lau, Lee and colleagues two miRNAs, previously 
termed small temporal RNAs (stRNAs), lin-4 and let-7, were studied for their 
developmental role in Caenorhabiditis elegans larva (Lee, Feinbaum & 
Ambros 1993; Reinhart et al. 2000). There were three notable findings from the 
studies that triggered further investigations and the subsequent discovery of 
miRNAs. First, lin-4 and let-7 loss-of-function and gain-of-function 
experiments resulted in incorrect larval development demonstrating that these 
two small RNA species possess important functional roles in development. 
Second, close examination of the gene structure and gene location showed that 
the two RNA species did not code for a protein product. Finally, lin-4 and let-
7 both contain sequential base VHTXHQFHVWKDWDUHFRPSOHPHQWDU\WRWKHމ875
of lin-14 and lin-41, two genes that are critical for the correct development of 
larva. This proposed a possible mechanism of action for lin-4 and let-7 whereby 
lin-4 and let-7 may suppress specific gene exprHVVLRQE\ELQGLQJWRLWVމ875
Since the discovery of lin-4 and let-7 thousands of miRNAs have been 
identified and studies in various models for health and disease.
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1.2.1 What is a MicroRNA?
The first set of miRNAs were identified by amplification, concatamerization, 
cloning and sequencing of short-stranded RNAs in C. elegans and Drosophila 
melanogaster (Lagos-Quintana et al. 2001; Lau et al. 2001; Lee & Ambros 
2001). The critical work of these three studies resulted in the development of 
the guidelines presently used to study and define new miRNAs.
miRNAs are described as being 20-24 nt in length and their precursor molecules 
contain a stable stem-loop structure made of guanine:uracil (G:U) wobbles and 
non-Watson-Crick base-pairing (Denli et al. 2004; Gregory et al. 2004; Lee, 
Feinbaum & Ambros 1993). It was also observed that during miRNA
biogenesis one strand of the double-stranded precursor molecule is degraded, 
although it is now known that that is not always the case (Khvorova, Reynolds 
& Jayasena 2003; Schwarz et al. 2003). miRNAs can be transcribed from the 
genome from within protein coding regions (introns and exons) and non-protein 
coding regions (Rodriguez et al. 2004). Moreover, many miRNAs are closely 
located on the chromosome and miRNAs that are clustered together tend to 
have similar expression patterns.
In order to keep track of newly discovered miRNAs Lagos-Quintana, Lau, Lee 
and colleagues defined a set of instructions for miRNAs nomenclature. 
miRNAs are identified by number and the numbering system is sequential; the 
number assigned to a miRNA corresponds to the order of its discovery relative 
to the known miRNAs. Mature miRNAs are designated miR while the precursor 
transcript and the DNA sequence that encodes the mature miRNA is designated 
mir. Multiple genomic copies of the same miRNA are annotated by a dash 
followed by another number, while highly homologous miRNAs are designated 
the same gene number followed by a lower case letter. For example mir-2a-1
and mir-2a-2 are miRNA precursor molecules that both code for the mature 
product miR-2a and miR-2a and miR-2b are closely related miRNAs, differing 
by only 1 or 2 bases. Initially it was believed that following the processing of a 
miRNA precursor molecule one strand was destined to be a mature functional 
miRNA whilst the other was degraded. However, in some cases both strands
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become mature miRNA products (Khvorova, Reynolds & Jayasena 2003;
Schwarz et al. 2003). In the cases where two miRNA products originate from 
the same precursor species the miRNAs are annotated to indicate which arm of 
the precursor molecule the miRNA originated from; -3p IRUWKHމDUPDQG-5p
IRUWKHމDUP,IWKHUHODWLYHDEXQGDQFe of the two miRNAs is known the lesser 
abundant miRNA is designated an asterisk and the -3p and -5p labels are not 
used. The only exceptions to these nomenclature rules are lin-4 and the let-7
family of miRNAs whose names remain for historical reasons.
The studies by Lagos-Quintana, Lau, Lee and colleagues established the 
significant biological importance of miRNAs. They demonstrated that miRNAs
are highly abundant in tissue, some miRNAs are enriched in specific tissues and 
that they have highly conserved sequences between C. elegans and D. 
melanogaster as well as humans and other vertebrates. Following this 
investigation into miRNAs thousands of new miRNAs have been discovered 
and many have been implicated in disease. However, there is still a great deal 
that remains unknown about miRNAs and how they impact on health and 
disease.
1.2.2 MicroRNA Biogenesis
MiRNAs are transcribed from the genome as primary miRNAs (pri-miRNA)
and contain a number of stem-loop structures created by imperfect 
complementarity between base pairs, a distinguishing feature of miRNAs in 
general (Denli et al. 2004; Gregory et al. 2004; Lee, Feinbaum & Ambros 
1993). The pri-miRNA, 100s nt in size, is then cleaved by the microprocessor 
complex that contains the double-stranded RNA-binding protein SiGeorge 
critical region 8 (DGCR8) and the RNase III enzyme, Drosha (Lee et al. 2003).
Processing by Drosha/DGCR8 results in a precursor molecule referred to as the 
precursor miRNA (pre-miRNA) of ~80 nt. The pre-miRNA is then transported 
from the nucleus to the cytoplasm by Exportin-5 (Exp5) (Lund et al. 2004).
Once in the cytoplasm, the pre-miRNA is cleaved again by another RNase III 
enzyme, Dicer, and a ~22 nt miRNA duplex remains (Lee et al. 2003). The two 
strands are then unwound by RNA helicases and each strand is incorporated 
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into an RNA-induced silencing complex (RISC), but with varying efficiencies 
resulting in a strand bias (Khvorova, Reynolds & Jayasena 2003; Schwarz et al. 
2003). Once a miRNA is incorporated into the RISC it is fully functional (Bartel 
2004). Figure 1.1 schematically illustrates miRNA biogenesis. A number of 
non-canonical miRNA biogenesis pathways  are emerging in the literature 
(Babiarz et al. 2008; Ruby, Jan & Bartel 2007), adding a degree of complexity 
to the regulation of miRNA expression. 
Figure 1.1 Biosynthesis of miRNAs. MiRNAs are initially transcribed as pri-miRNA in the 
nucleus and processed by Drosha/DCRG8 into a shorter pre-miRNA. The pre-miRNA is 
exported to the cytoplasm by Exp5 and processed for a second time by Dicer. The resultant 
duplex miRNA is separated and incorporated into RISC.
DNA
TranscriptionPri-mir
Pre-mir
Drosha /
DCGR8
Dicer
Exp5
mir duplex
Mature miR
RISC
Nucleus
Cytoplasm
މ މ
މ މ
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1.2.3 Post-transcriptional repression of mRNAs by microRNAs
miRNAs are responsible for the regulation of multiple gene networks and 
pathways that regulate homeostasis, proliferation, differentiation, growth, 
metabolism, communication and motility. Mature miRNAs exert their effect by 
binding to their target messenger RNAs (mRNAs) and preventing protein 
translation either by inhibiting protein synthesis machinery or by mRNA 
degradation (Hu & Bruno 2011). Inhibition of mRNA protein translation by 
miRNAs can occur at either the translation initiation step of elongation step 
(Humphreys et al. 2005; Lee et al. 2004; Mathonnet et al. 2007; Olsen &
Ambros 1999; Pillai et al. 2005; Wightman, Ha & Ruvkun 2004). Studies also 
show that on rare occasions miRNAs can enhance the protein translation of their 
targets (Henke et al. 2008; Ørom, Nielsen & Lund 2008; Vasudevan & Steitz 
2007; Vasudevan, Tong & Steitz 2007). Overall, mRNA degradation by 
miRNAs accounts for 84% of all miRNA activity in humans (Huili et al. 2010).
MiRNAs UHJXODWHP51$VSUHGRPLQDQWO\E\ELQGLQJWKHމXQWUDQVODWHGUHJLRQ
(UTR) of the mRNA (Carthew & Sontheimer 2009; Hu & Bruno 2011). There 
are two known binding classes for miRNAs (Brennecke et al. 2005). The first 
class of binding is perfect Watson-Crick complementary binding between the 
5މHQGRIWKHP51$DQGWKHމ875RIWKHWDUJHWP51$)LJXUH1.2 A). This 
region of the miRNA is known as the ‘seed’ region, occurring at base positions 
2-RQWKHމHQGRIWKHmiRNA (Lewis et al. 2003). Perfect binding between 
WKHVHHGUHJLRQDQGމ875RILWVWDUJHWP51$LVVXIILFLHQWWRVXSSUHVVP51$
activity with no further binding between the two molecules (Brennecke et al. 
2005). The second class of binding is imperfect binding between the seed region 
DQGWKHމ875DQGFRPSHQVDWRU\ELQGLQJDWWKHމHQGRIWKHmiRNA with the 
މ875)LJXUH1.2 B).
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Figure 1.2 A schematic diagram demonstrating the two different classes of miRNA-
mRNA binding. Figure 2A demonstrates perfect Watson-Crick base-pairing between the seed 
region of the miRNA UHGDQGމ875RIWKHP51$EOXHZLWKQRVLJQLILFDQWEDVH-pairing at 
WKHމ HQGRI WKHmiRNA. Figure 2B demonstrated imperfect base-pairing between the seed 
UHJLRQ DQG މ875ZLWK VXSSOHPHQWDU\ EDVH-SDLULQJ DW WKH މ HQG RI WKHmiRNA. MiRNA
binding to a mRNA can either block protein translation or signal for the degradation of the 
mRNA molecule. (Zacharewicz, Lamon & Russell 2013)
Understanding how miRNAs bind to their target mRNAs has led to the 
development of a number of different algorithms used to predict miRNA-
mRNA binding. However, miRNA-mRNA binding rules are complex and still 
not completely understood and poses considerable challenges for scientists and 
bioinformaticians studying miRNA targeting. To date, many associations 
between miRNAs and specific mRNA targets or signalling pathways have been 
described in the literature. However, there is a lack of direct cause-and-effect 
data between miRNAs and mRNAs. Validating specific mRNA targets for 
miRNAs is the key to understanding the underlying molecular mechanisms 
behind health and disease and thus the development of effective and targeted 
therapies.
1.2.4 MicroRNAs and Ageing
Over a lifespan, humans are exposed to a number of deteriorative factors such 
as injury and disease as well as stress, toxins and pollutants. The damage caused 
by such factors accumulates in the body resulting in a gradual degeneration of 
the body as it ages. There is also a genetic component to ageing that occurs on 
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a cellular level called senescence. Cellular senescence is defined as a permanent 
growth arrest of the cell. The accumulation of senescent cells results in ageing 
(Campisi 2005).
miRNAs play a major role in the ageing process. A natural reduction in the 
miRNA pool is observed in aged C. elegans (de Lencastre et al. 2010; Ibáñez-
Ventoso et al. 2006). Reducing the global miRNA pool in the adult worm 
reduces lifespan (Kato et al. 2011). Lin-4 is a miRNA crucial to worm 
development and its knockdown significantly reduces lifespan in association 
with an accumulation of senescent cells (Boehm & Slack 2005). The 
knockdown of miR-71 and miR-246 also increases lifespan. miR-34, a miRNA
WKDW GHFOLQHV ZLWK DJH GLUHFWO\ ELQGV WKH މ 875 RI the Silent Information 
Regulator T1 (SIRT1) (Yamakuchi & Lowenstein 2009), a gene that 
downregulates the process of senescence (Langley et al. 2002). Let-7
expression is also reduced with ageing in the worm and binds a number of 
genes, including DAF-12 and PHA-4, involved in cellular senescence 
(Großhans et al. 2005). Notably, let-7 regulates these genes is a tissue 
dependent manner that is comparable to the ageing process of mammals 
including humans (Smith-Vikos & Slack 2012).
This literature review will focus on miRNAs regulated in skeletal muscle during 
the process of human ageing with reference to other animal studies where 
appropriate. The following sections will discuss the importance of skeletal 
muscle health, the molecular factors regulating behind the determination of 
skeletal muscle mass and the potential of miRNAs as biomarkers for skeletal 
muscle health during ageing.
1.3 The Therapeutic Potential of MicroRNAs
The dysregulation of miRNAs in skeletal muscle is highly correlated with 
disease (Eisenberg et al. 2007). The regulatory roles of these miRNAs still need 
to be validated in human disease models. miRNAs that regulate muscle health 
represent potential targets for selective modulation that could potentially alter 
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the course of the disease. For miRNAs with reduced expression, the 
reintroduction of the specific miRNA may restore appropriate target gene 
regulation. Similarly, the inhibition of over expressed miRNAs may also restore 
healthy tissue function. One such therapy has recently completed a phase 2a
human clinical trial (van der Ree et al. 2014). Miravirsen is a locked nucleic 
acid (LNA) antimiR™ olginucleotide that has been developed to target and 
inhibit miR-122 (Santaris Pharma A/S 2012). MiR-122 is highly abundant in 
hepatocytes and is involved in the propagation of the hepatitis C virus (HCV) 
(Haussecker & Kay 2010). Administration of miravirsen for 5 weeks followed 
by peginterferon therapy resulted in a sustained reduction in HCV in 58% of 
the patients. Importantly miravirsen is reported to be highly tissue specific, well 
tolerated by the patients and there is no evidence of viral resistance (Lanford et 
al. 2010; Ottosen et al. 2015; van der Ree et al. 2014). These studies 
demonstrate that miRNAs, as therapeutic targets, may be preferential to other 
drugs due to their specificity and limited adverse physiological consequences. 
Locked nucleic acids (LNAs) are already being used in various biological 
models to study miRNA physiology and pathophysiology, such as cardiac 
disease, non-small cell lung cancer, liver cancer, allergy and asthma (Castoldi 
et al. 2007; Jackson & Linsley 2010; Lundmark, Kørner & Nielsen 2010).
1.4 The Importance of Skeletal Muscle
Skeletal muscle represents a large fraction of the human body, making up ~40% 
of the body’s mass (Rasmussen & Phillips 2003). It serves as a structural 
support unit, enabling the body to maintain posture and perform gross and fine 
motor movements (Bassel-Duby & Olson 2006). Additionally, skeletal muscle 
is an important storage unit for energy and nitrogen, a vital substitute fuel 
supply for the brain and immune system during periods of malnutrition and 
starvation, injury and serious disease (Rasmussen & Phillips 2003). Skeletal 
muscle houses 50-75% of the body’s total protein pool, that is critical for the 
maintenance of health and wellbeing (Rasmussen & Phillips 2003). During 
periods of serious stress skeletal muscle can be called upon as an energy supply 
source. A loss of just 30% of the body’s proteins results in severe muscle 
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weakness, impaired respiration, circulation and immune function eventually 
leading to death (Rasmussen & Phillips 2003). It follows that skeletal muscle is 
a highly plastic tissue able to alter is size, structure and function in response to 
various exogenous and endogenous stimuli such as disease and trauma, and also 
exercise, nutrition and hormones (Adams & McCue 1998; Al-Majid & 
McCarthy 2001; Bohé et al. 2001; Degens 2006; Urso 2009).
The skeletal muscle protein pool is regulated by the fine balance between 
muscle protein synthesis (MPS) and muscle protein degradation (MPD) (Eley 
& Tisdale 2007). Muscle hypertrophy is the increase in muscle mass that occurs 
when the rate of protein synthesis exceeds the rate of protein degradation 
(Bodine et al. 2001b; Ferrando et al. 1997; Rommel et al. 2001). Resistance 
exercise is a potent stimulator of muscle protein synthesis (Koopman et al. 
2011; Kumar et al. 2009). On the other hand, muscle atrophy is a decrease in 
muscle mass that occurs when the rate of protein degradation exceeds protein 
synthesis (Eley & Tisdale 2007; Wang et al. 1998). Muscle atrophy is a 
devastating condition present in a number of chronic diseases such as Duchenne 
muscular dystrophy (DMD), amyotrophic lateral sclerosis (ALS), cancer
cachexia, chronic obstructive pulmonary disease (COPD), sepsis, chronic heart 
failure (CHF), rheumatoid arthritis and acquired immunodeficiency syndrome 
(AIDS) (Skipworth et al. 2006). Muscle atrophy is also a component of 
sarcopenia that is characterised by a loss of muscle mass with increasing age
(Evans 1995; Evans & Campbell 1993). The underlying molecular mechanisms 
behind many skeletal muscle atrophy diseases are not well understood. 
Understanding the muscle atrophy associated with age-related muscle wasting
is of great global interest as it affects everyone.
1.4.1 Age-related Muscle Wasting in Australia
Age-related muscle wasting represents a significant global health issue. In 
2009-2010 the number of fall-related cases for persons aged 65 and over 
increased by 6% from 2008-2009 (Bradley 2013). The lifetime cost of falls is 
estimated to exceed $1 billion, which is a considerable strain on our healthcare 
system (Bradley 2013). Muscle wasting abates one’s independence and quality 
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of life as it encompasses severe impairments in strength, mobility, balance and 
endurance. Advancing in adult age results in profound changes in body 
composition; most commonly an increase in body fat and a decrease in lean 
mass, predominantly skeletal muscle mass (Cohn et al. 1980; Novak 1972).
Although studies vary in their reports of the kinetics of muscle loss, generally 
there is a 1-2% decrease in muscle mass per year from the age of 40 years
(Cuthbertson et al. 2005; Hughes et al. 2002; Sehl & Yates 2001). This loss can 
also contribute to the onset of other age-related diseases such as osteoporosis, 
obesity, insulin resistance and heart disease. It is important to note that age is 
not the sole factor contributing to muscle mass decline. There are a number of 
exogenous and endogenous factors associated with muscle loss in the elderly. 
Exogenous factors may include disuse atrophy due to injury, bed rest, reduced 
physical activity (Bialek et al. 2011), malnutrition (Roberts et al. 1996) and 
presence of disease and drugs (Andreyev et al. 1998). Endogenous factors 
include changes in hormonal secretion and response (Schlenska & Kleine 
1980), loss of motor units (Campbell, McComas & Petito 1973) and an altered 
metabolism (Roberts et al. 1996).
The onset and progression of age-related muscle wasting is linked to impaired 
muscle protein turnover and a reduced regenerative capacity, both contributing 
to smaller muscle fibres (Brack & Rando 2007; Conboy et al. 2003; Kumar et 
al. 2009; Penna et al.). Currently there are few therapeutic treatments that 
attenuate and none that stop age-related muscle wasting. Testosterone levels are 
significantly reduced in elderly men and is associated with impaired physical, 
cognitive and other physiological functions (Bhasin & Buckwalter 2001).
Although testosterone replacement can improve muscle mass in frail, elderly 
men, improvements following testosterone treatment are only modest (Srinivas-
Shankar et al. 2010). Furthermore testosterone replacement is associated with 
negative health outcomes in particular the development of cancer (Curran & 
Bihrle) and therefore is not a suitable long-term solution for the treatment of 
muscle wasting. Antioxidants and creatine supplementation have been 
suggested as therapies but their specific targets in muscle are not defined and 
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the effects of long-term supplementation are unknown (Fusco et al. 2007;
Waters et al. 2010).
Resistance exercise is a natural and effective approach for increasing skeletal 
muscle mass (Bickel et al. 2005; Camera et al. 2010; Koopman et al. 2011;
Mitchell et al. 2014; Zhang et al. 2015). Resistance exercise also increases MPS
in elderly subjects (Drummond et al. 2008b; Kumar et al. 2009), however this 
increase is significantly attenuated when compared to younger subjects. This 
demonstrates an ‘anabolic resistance’ that is present with ageing (Cuthbertson 
et al. 2005) and will be discussed in the following section. Understanding the 
molecular mechanisms underlying the regulation of MPS in elderly subjects is 
a key research priority. Identifying therapeutic targets to increase MPS in the 
elderly is required for the development of effective treatment strategies to 
maintain muscle mass, enhance quality of life in our elderly population and 
reduce the economic burden on our healthcare system.
1.5 The Molecular Regulation of Skeletal Muscle Mass
There are multiple anabolic and catabolic pathways that regulate protein 
turnover in skeletal muscle. The Akt (Acute transforming retrovirus thyoma) 
signalling pathway is a major regulator of MPS and MPD (Bodine et al. 2001b;
Latres et al. 2005; Rommel et al. 2001; Stitt et al. 2004) (Figure 3). The 
activation of Akt increases protein synthesis by activating several downstream 
signalling proteins, particularly eukaryotic initiation factors (eIFs), involved in 
protein initiation and translation (Bodine et al. 2001b; Rommel et al. 2001). Akt 
also decreases protein degradation by inactivating the forkhead box O (FoxO) 
transcription proteins that stimulate the transcription of atrophy related genes 
(Bodine et al. 2001b; Rommel et al. 2001; Sandri et al. 2004; Stitt et al. 2004).
1.5.1 Basal Regulation of Akt
Akt can be activated via phosphorylation by insulin-like growth factor-1 (IGF-
1), insulin and growth hormone (GH) or deactivated via dephosphorylation by 
WXPRUQHFURVLVIDFWRUĮ71)ĮDQGP\RVWDWLQJURZWKGLIIHUHQWLDWLRQIDFWRU
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GDF8) (Amirouche et al. 2009; Frost, Nystrom & Lang 2003; Haar et al. 2007;
Hayashi & Proud 2007; Rommel et al. 2001). Akt activity is therefore a pivotal 
factor controlling the balance between protein synthesis and degradation in 
skeletal muscle.
Akt has two regulatory target amino acids for phosphorylation; threonine308 and 
serine473 (Alessi et al. 1996; Alessi et al. 1997; Stokoe, Stephens & Copeland 
1997). Following its activation, Akt stimulates the serine/threonine kinase 
mammalian (or mechanistic) target of rapamycin (mTOR) (Inoki et al. 2002b;
Rommel et al. 2001). mTOR has two downstream targets; p70 ribosomal 
protein kinase (p70S6K) and eukaryotic initiation factor 4E binding protein 1 
(4EBP1) (Inoki et al. 2002b). In turn p70S6K activates via phosphorylation the 
ribosomal protein S6 that is directly involved in the translation of a specific 
class of mRNAs containinJDމWHUPLQDOROLJRS\ULPLGLQHVWUXFWXUH(Kawasome 
et al. 1998). Phosphorylation of 4EBP1 by mTOR removes its inhibition on 
translation initiation factor eIF4E (Brunn et al. 1997; Pause et al. 1994). Once 
released, eIF4E is activated by phosphorylation and interacts with other 
initiation factors including eIF4F, eIF4A and eIF4G (Pause et al. 1994). eIF4E 
is considered to be the rate limiting step in translation initiation and is essential
for the recruitment of the mRNA to the 40S ribosomal subunit for translation 
(Duncan, Milburn & Hershey 1987). Protein translation is also regulated via 
Akt’s other downstream target JO\FRJHQV\QWKDVHNLQDVHȕ*6.ȕ (Rommel 
et al. 2001). Phosphorylation of GSKȕ by Akt results in its inactivation and 
thus release of eIF2B (Welsh et al. 1998). eIF2B is a guanine nucleotide 
exchange protein that removes guanosine diphosphate (GDP) from eIF2. In 
turn, eIF2 can bind a guanosine triphosphate (GTP) then the eIF2-GTP complex 
recruits methionyl-transfer RNA (met-tRNAi) to the 40S ribosomal subunit, 
resulting in the initiation of translation of cytoplasmic mRNAs (Proud 2005).
Akt also inhibits protein degradation by phosphorylating the FoxO transcription 
proteins, resulting in their sequestering from the nucleus. Consequently FoxO’s 
transcription of muscle specific atrophy-regulating genes (atrogenes), muscle 
atrophy F box (MAFbx or atrogin-1) and muscle RING finger 1 (MuRF-1) is 
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inhibited (Bodine et al. 2001a; Lee et al. 2004; Sandri et al. 2004; Stitt et al. 
2004). Figure 1.3 summaries the Akt-mTOR signalling pathway schematically.
The aberrant activity of Akt signalling and its downstream targets is implicated 
in many models of skeletal muscle atrophy and hypertrophy. Ageing studies 
show that reduced IGF-1 activity in association with increased FoxO activity in 
the nucleus is associated with a reduced lifespan in C. elegans, D. melanogaster
and mice (Dillin, Crawford & Kenyon 2002; Holzenberger et al. 2003;
Hwangbo et al. 2004). IGF-1/Akt signalling may also be important in the 
regulation of skeletal muscle mass in ageing.
Figure 1.3 Schematic summary of Akt signalling in skeletal muscle to regulate protein 
synthesis and protein degradation. Akt is stimulated by upstream factors such as GH, IGF1 
and insulin and subsequently activates protein synthesis via eIFs and inhibits protein 
degUDGDWLRQE\VXSSUHVVLQJWKHWUDQVODWLRQRIDWURSK\JHQHV:KHQ$NWLVLQKLELWHGE\71)Į
or myostatin (GDF8) protein degradation is increased and protein synthesis is reduced.
1.5.2 The Regulation of Skeletal Muscle Mass in the Elderly Following 
Resistance Exercise
Many regulators of Akt and its downstream targets are differentially expressed 
in the muscle of elderly subjects (Dennis 2008; Greiwe et al. 2001; Léger et al. 
2008; Lenk, Schuler & Adams 2010). There is a significant reduction in IGF1 
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expression and phosphorylation of Akt and p70S6K in the skeletal muscle of 
old subjects when compared to young subjects (Dennis 2008; Kumar et al. 
2009; Léger et al. 2008). Negative regulators of protein synthesis are also 
XSUHJXODWHG LQ VNHOHWDOPXVFOHZLWKDJH LQFOXGLQJ71)ĮP\RVWDWLQ*6.ȕ
and 4EBP1 phosphorylation levels (Dennis 2008; Greiwe J.S et al. 2001;
Kumar et al. 2009; Léger et al. 2008). Resistance exercise, also known as 
weight-training exercise, is a potent stimulator of the Akt signalling pathway 
(Baar & Esser 1999; Bickel et al. 2005; Camera et al. 2010; Dalbo et al. 2011;
Greiwe et al. 2001; Terzis et al. 2010). Hence, resistance exercise also 
stimulates muscle protein synthesis (Koopman et al. 2011; Kumar et al. 2009;
Phillips 2009). Following an acute bout of resistance exercise, myofibrillar 
protein synthesis is maximal at an exercise intensity of 60% of the 1 repetition 
maximum (1RM) 2 hours after the initial exercise bout (Figure 1.4 A) (Kumar 
et al. 2009). However, myofibrillar protein synthesis following resistance 
exercise is attenuated in elderly subjects (Figure 1.4 B) (Kumar et al. 2009).
The increase in MPS in the young subjects is associated with an increase in 
phosphorylated p70S6K and 4EBP1 (Kumar et al. 2009).
Figure 1.4 Dose-response and time-course relationship between myofibrillar protein 
synthesis in young and old men. (A) The fractional synthetic rate (FSR, %h-1) for 5 young
and 5 older men measured at 1-2 hours post exercise at various exercise intensities (%1RM). 
(B) The FSR of 15 young and 15 older men measured at various time points at 50-90% of 
1RM. The response of the young men in (A) was greater than those of older men (P<0.04). 
*P<0.05 for time response and age in (B) (Kumar et al. 2009)
A B
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Three months of resistance exercise training significantly improves baseline 
MPS in elderly subjects (Greiwe et al. 2001). This improvement is associated 
ZLWK D VLJQLILFDQW GHFUHDVH LQ 71)Į JHQH H[SUHVVLRQ DQG SURWHLQ FRQWHQW
However, the study did not use a young, healthy control group for comparison, 
so it is not cOHDULISURWHLQV\QWKHVLVUDWHVDQG71)ĮOHYHOVDUHFRPSDUDEOHWR
expected levels in healthy, young subjects.
A resistance exercise training study where old subjects were compared to young 
subjects, suggests that MPS is still attenuated in the older subjects following 
training. This study consisted of two exercise phases. First, all subjects trained 
at 75-80% of their 1RM 3 days/week for 16 weeks with progressive overload 
to maintain the exercise intensity (Bickel et al. 2005). For the second phase, all 
the subjects were randomised into three different groups for another 32 weeks: 
detraining, 1/9 maintenance volume and 1/3 maintenance volume (where 
subjects maintained the phase 1 exercise training at a 1/9 intensity or 1/3 
intensity respectively). Initially, there was no difference in myofibre cross-
sectional area (CSA) between the young and old subjects at baseline and 
following phase 1 of the trial. However, following phase 2 there was a clear 
bias towards the young subjects in their ability to continue building muscle at 
the reduced exercise intensities. While the old subjects were still able to 
maintain their muscle mass during phase 2 of the study, it is clear from this 
study that there is an anabolic resistance in the older subjects. Elderly subjects 
suffering from sarcopenia would not able to complete a resistance exercise 
regime at 75-80% intensity in order to improve their condition. 
Life-long exercise is still not sufficient to completely counteract the age-related 
decline in muscle mass and function. A comparison between young (27.3 ± 4.2 
y.o.) active males, old (71.4 ± 3.0 y.o.) sedentary males and old (70.2 ± 4.0 y.o.) 
sportsmen revealed that muscle function measures, such as maximal isometric 
torque and muscle fibre diameter is significantly improved in the older 
sportsmen when compared to the older sedentary subjects. However, these 
values were still not comparable to the younger subject cohort (Zampieri et al. 
2015).
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Therefore, understanding the onset and progression of age-related anabolic 
resistance from a molecular perspective is essential for the development of a 
targeted and effective therapeutic treatment.
1.5.3 The Regulation of Muscle Protein Breakdown with Ageing
The maintenance of skeletal muscle function and strength is dependent on 
sufficient protein turnover. The breakdown and removal of damaged contractile 
units and replacement with new proteins is imperative to the maintenance of 
muscle function and consequently the preservation of independence with 
ageing. The breakdown of skeletal muscle is under the control of two different 
systems; the Ubiquitin Proteasome Pathway (UPP) and the autophagy-
lysosomal pathway (Lecker et al. 1999; Mammucari, Schiaffino & Sandri 
2008). The UPP is primarily associated with acute and accelerated muscle 
atrophy that occurs in stress conditions such as disease and fasting (Lecker et 
al. 1999). The progressive loss of skeletal muscle mass that occurs with age is 
linked to a reduction in the autophagic flux (O'Leary et al. 2013; Penna et al. ;
Sakuma et al. 2015; Wohlgemuth et al. 2010). An accumulation of the 
downstream autophagy marker sequestosome 1 (p62/SQSTM1) in skeletal 
muscle of old when compared to young rats has been observed. The p62 protein 
binds to the phagosome and its accumulation indicates a reduced efficiency in 
the autophagic flux (Bjorkoy et al. 2009). To date the activity of autophagy in 
skeletal muscle in the context of ageing has been investigated in few human 
studies. Fry et al. investigated the mRNA and protein expression of various 
markers of autophagy in young (27 ± 2 y.o.) and older (70 ± 2 y.o) males at 
baseline and following an acute bout resistance exercise that consisted of a leg-
extension effort at 70% of 1 RM (Fry et al. 2013). While there was no difference 
in autophagy markers at baseline, the mRNA expression of GABA(A) receptor-
associated protein (GABARAP), a protein involved in the formation of the 
phagosome (Weidberg et al. 2010), was elevated in the skeletal muscle of older 
subjects 3 h after the exercise bout. There was also an elevation in Beclin-1
protein expression in parallel with a reduction in the 1A/1B-light chain 3 protein 
(LC3 II/I) ratio in the old subjects. Beclin-1 is a protein that can induce 
autophagy (Nishida et al. 2009) while the LC3B proteins regulate the formation 
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of the phagosome (Weidberg et al. 2010). LC3 I, a cytosolic protein, undergoes 
lipidation to form LC3 II. LC3 II is then recruited to the phagosome. The LC3II 
protein is reduced in elderly, sarcopenic adults (Carnio et al.). Similar 
observations have been made in some ageing rodent studies (Carnio et al. ;
Wenz et al. 2009) but not all (Wenz et al. 2009).
The regulation of autophagy is linked to mTOR activity. The inhibition of 
mTOR activates autophagy, while the re-activation of mTOR . halts autophagy 
(Yu et al. 2010). Life-long exercise and calorie restriction can improve 
autophagy flux with ageing (Carnio et al. ; Wohlgemuth et al. 2010; Zampieri 
et al. 2015). The improvement in autophagic flux with exercise and calorie 
restriction may be due to an improvement in mTOR regulation and 
subsequently more efficient removal of damaged proteins. 
1.6 The Regulation of MicroRNAs in Healthy and Diseased 
Skeletal Muscle
Many miRNAs are enriched in specific tissues or cell-types and play a 
significant role in the activities of that cell. Skeletal/cardiac enriched miRNAs 
include miR-1, miR-133a, miR-133b, miR-206, miR-208, miR-208b, miR-486
and miR-499 (Russell 2010). The transcriptional regulation of muscle specific 
miRNAs is under the control of myogenic regulatory factors (MRFs) (Rao et 
al. 2006; Rosenberg et al. 2006). Many of these miRNAs exist in polycistronic 
clusters and are transcribed together and/or with protein-coding genes 
(Sweetman et al. 2008). MiRNAs are modulated during multiple facets of 
skeletal muscle development and maintenance including hypertrophy and 
atrophy (McCarthy & Esser 2007; McCarthy, Esser & Andrade 2007;
McCarthy et al. 2009). miRNA profiling in skeletal muscle across ten primary 
muscle disorders, including several dystrophy and inflammatory diseases found 
185 miRNAs that were dysregulated (Eisenberg et al. 2007). Five miRNAs, 
miR-146b, miR-155, miR-214, miR-221 and miR-222, were increased in 
almost all of the samples. Investigating if and how these miRNAs contribute to 
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muscular disorders could lead to the development of novel, targeted therapies 
for debilitating muscular disorders.
Skeletal muscle atrophy and hypertrophy models have been used to characterise 
the regulation of miRNAs in the maintenance of skeletal muscle mass. 
Following 7-days of functional overload (FO) of the mouse plantaris muscle, 
the expression of miR-1 and miR-133a was decreased by 50% from control 
plantaris muscle (McCarthy & Esser 2007). This change was associated with a 
45% increase in wet muscle weight. MiR-1 and miR-133a may contribute to 
muscle hypertrophy following FO by the removal of their transcriptional 
inhibition on growth factors, such as IGF-1. In support of this hypothesis a
regulatory feedback loop was demonstrated where IGF-1 regulates miR-1 via 
an Akt/FoxO3a pathways (Elia et al. 2009). On the other hand, FoxO3a 
increases levels of miR-1 that results in reduced IGF-1 protein levels. However, 
whether miR-1 regulates protein synthesis was not determined.
Unloading of skeletal muscle, as caused by microgravity during space flight 
and hind limb suspension (HS), decreases muscle mass (Allen et al. 2009;
McCarthy et al. 2009). Following 11 days of space flight, miR-206 was 
decreased in parallel with an increase in FoxO1, atrogin-1 and myostatin gene 
expression (Allen et al. 2009; McCarthy et al. 2009). Following rat HS for 7-
days, miR-107, miR-221, miR-499 and miR-208b are all downregulated 
(McCarthy et al. 2009). A model of rat muscle injury induced by surgical 
laceration to the tibialis anterior, resulted in a decrease in miR-1, miR-133a and 
miR-206 1 day following the injury (Nakasa et al. 2010). The levels of these 
miRNAs gradually returned to pre-injury levels by day 7. miR-206 has been 
shown to promote differentiation of C2C12 myoblasts (Kim et al. 2006) and 
skeletal muscle regeneration following muscle injury in mice (Liu et al. 2012)
via the direct regulation of paired box 7 (PAX7) expression (Cacchiarelli et al. 
2010). While the direct mechanism of action is not clear, maintaining miR-206
levels with aging may be essential to maintaining muscle regenerative 
capacities. miRNAs are essential in skeletal muscle physiological and 
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pathophysiological adaptation. Whether these miRNA species directly decrease 
muscle protein synthesis is not known.
1.6.1 Age-associated Expression of MicroRNAs in Skeletal Muscle
At baseline, a microRNA array and subsequent PCR analysis revealed two
miRNAs, let-7b and let-7e, were significantly upregulated in older men (70 ±1 
years) when compared to the young (30 ±2 years) cohort (Drummond et al. 
2011).  In contrast to this, the let-7 miRNAs are decreased with age in C. 
elegans with age (de Lencastre et al. 2010; Ibáñez-Ventoso et al. 2006).
However, differences in sequence homology exist between the let-7 miRNAs 
sourced from C. elegans and humans. This difference may be sufficient to 
change the expected mRNA targets for these miRNAs. However, the function 
of let-7 miRNAs is anti-proliferative in humans and C. elegans (Johnson et al. 
2007; Reinhart et al. 2000) which is consistent with the definition of a senescent 
cell. Therefore, in skeletal muscle, the elevation of these miRNAs may be 
responsible for the reduction in the satellite cell (muscle stem cell) pool, which 
is implicated with impaired muscle regeneration in the elderly (Brack & Rando 
2007). Bioinformatics analysis by Drummond and colleagues identified cell 
cycle regulation as the most highly ranked cellular process likely to be regulated 
by let-7b and let-7e (Drummond et al. 2011). The elevated let-7b and let-7e 
miRNAs in old subjects were associated with a decrease in PAX7 mRNA 
expression, a marker for satellite cell abundance, and reduced mRNA 
expression of the cyclin-dependent kinase CDK6, and the cell division cycle 
regulators CDC25A and CDC34. Let-7 miRNAs are also implicated in the 
regulation of mTOR signalling (Dubinsky et al. 2014). Overexpression of let-7
in primary neurons results in a reduction in the phosphorylation levels of mTOR 
and S6K1 while let-7 inhibition increases the phosphorylation levels of mTOR 
and S6K1 protein expression. Inhibition of let-7 expression in mice also results 
in an increase in lean muscle mass. Interestingly, overexpression of let-7 in 
neuron cells leads to an accumulation of LC3 II protein, indicating an increase 
in autophagy activity. This increase in autophagy occurred in an mTOR 
dependent manner. The increase in some let-7 miRNAs in old skeletal muscle 
may be, in part, involved in the reduction in muscle mass with ageing. However, 
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whether let-7 miRNAs regulate mTOR signalling in skeletal muscle and how 
let-7 expression regulates autophagy in skeletal muscle has not been 
investigated. 
A similar study in mice identified 57 miRNAs that were differentially regulated 
in the skeletal muscle of old (24 months) compared to young (12 months) mice, 
including the muscle specific miR-206 (Hamrick et al. 2010b). Bioinformatics 
analysis has linked many of these miRNAs to genes involved in myogensis 
including myogenin, myocyte enhancer factor 2 (Mef2), serum response factor 
(SRF), cardiotrophin and cell cycle regulator type IIA activing receptor. In 
order to elucidate which of these miRNAs are important in the ageing process, 
miRNAs need to be investigated individually to confirm specific mRNA targets 
and how their modulation in muscle tissue affects muscle phenotype. MiRNAs 
may play a significant regulatory role in anabolic resistance in elderly people. 
Further studies are needed to determine the regulation of miRNA expression in 
young and old subjects following an acute bout of resistance exercise.
1.6.2 MicroRNAs Linked to the Regulation of Autophagy
The primary focus of this PhD is on miRNAs and their regulation of muscle 
protein synthesis via the Akt-mTOR signalling pathway. However, as is the 
case with most cellular processes, many pathways are closely intertwined. As 
described in section 1.5.3 the autophagy-lysosomal pathway is closely 
regulated by mTOR signalling in a reciprocal manner. It is therefore important 
to ensure that mTOR-targeted therapies, including miRNA therapies, do not 
negatively impact on cellular autophagy and vice versa.
One such interaction to consider is the link between miR-451, skeletal muscle 
anabolic resistance and autophagy. An upregulation of miR-451 is linked to a 
reduced capacity to build muscle following a resistance training protocol in 
humans (Davidsen et al. 2011). miR-451 overexpression is also associated with 
reduced autophagy in human cervical cancer cells and rat cardiomyocytes and 
human hypertrophic cardiomyopathy (Song et al. 2014). A binding interaction 
between miR-451 and tuberous sclerosis complex 1 (TSC1), a direct inhibitor 
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of mTOR (Garami et al.), has been demonstrated (Song et al. 2014). It may be 
hypothesised from this evidence that reducing miR-451 in skeletal muscle may 
result in improved muscle mass gains with exercise and increased autophagy 
activity. However, this complex interaction would need to be studied carefully. 
Inhibition of miR-451 may negatively impact on mTOR signalling and the 
long-term effects of this are not known. To date, no study has investigated the 
direct relationship between miR-451 and muscle mass regulation. On the other 
hand, a reduction in mTOR signalling would increase autophagic flux, an 
outcome that may be desirable for the elderly (Penna et al.).
Currently there is very little literature investigating the role of miRNAs on 
skeletal muscle autophagy. Overexpression of miR-182 in C2C12 myotubes 
results in a reduction in markers for UPP and autophagy (Hudson et al. 2014).
Specifically miR-182 can direcWO\ELQGWKHމ875RI)R[2EXWDOVREORFNWKH
dexamethasone induced increase in LC3, cathepsin L and autophagy-related 
protein 12 (ATG12) mRNA expression. MiR-182 has also been shown to bind 
and reduce the mRNA and protein levels of the IGF-1R (Olivieri et al. 2014).
Together, these data suggest that a reduction in miR-182 may improve 
autophagy and signalling through IGF1/Akt. However, to date an aberrant 
expression of miR-182 has not been reported in skeletal muscle atrophy 
conditions. 
1.6.3 The Influence of Exercise on MicroRNA Expression
Investigating the role and regulation of miRNAs in response to natural anabolic 
stimuli will also contribute to our understanding of muscle atrophy diseases 
such as age-related muscle wasting. Resistance exercise is potent anabolic 
stimuli that enhances muscle protein synthesis and muscle size (Fry 2004;
Koopman et al. 2011; Kumar et al. 2009; Léger et al. 2006; Phillips 2009). Few 
studies have investigated the changes in skeletal miRNA species following 
resistance exercise.
miR-1, miR-133a and miR-206 was measured in muscle from young (29 ±2 
years) and old (70 ±2 years) subjects following an acute bout of resistance 
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exercise consisting of 8 sets with 10 repetitions of leg-extension exercise at 70% 
of 1RM and essential amino acid (EAA) ingestion (Drummond et al. 2008a).
Following the exercise bout the expression of miR-133a and miR-206 did not 
change but miR-1 expression was reduced 3 and 6 hours following exercise in 
young subjects only (Drummond et al. 2008b). This reduction in miR-1
expression following resistance exercise may be necessary for IGF-1
upregulation in skeletal muscle to promote protein synthesis (Elia et al. 2009).
A miRNA screen in muscle samples taken from young (22 ±1 years) when 
compared to old (74 ±2 years) subjects, pre and 6 hours post an acute bout of 
resistance exercise, revealed that 17 miRNAs were reduced in young subjects 
only (Rivas et al. 2014). The exercise consisted of three sets with ten repetitions 
of knee-extension and leg-press exercise at 80% of 1RM. Bioinformatics 
analysis revealed that one miRNA, miR-126, may regulate IGF-1 signalling. 
Inhibition of miR-126 in C2C12 myotubes resulted in increased 
phosphorylation of downstream targets of IGF-1 including Akt and FoxO1. 
Therefore the downregulation of miR-126 following resistance exercise may 
also be necessary for optimal IGF-1 singalling.
A resistance exercise training study in 65-80 year old men and women 
investigated the expression of myomiRs miR-1, miR-133a, miR-133b, miR-
206, miR-208b and miR-499 pre and post training (Zhang et al. 2015). A 5 
month training progressive resistance exercise protocol was used that was 
aimed at the lower extremities, particularly quadriceps, hamstrings and triceps 
surae. This study reported a significant decrease in miR-133b expression 
following the exercise training protocol in association with an improvement in 
knee extensor strength and lean muscle mass. The group also reported a 
significant positive correlation between the change in knee extensor strength 
and the change in miR-133a, miR-133b and miR-206 expression. However, 
how these miRNAs influence muscle adaptation to resistance exercise training 
is not clear. While a reduction in miR-133a expression is observed following 
muscle hypertrophy (McCarthy & Esser 2007) it is also decreased in muscle 
atrophy models and injury (Allen et al. 2009; Nakasa et al. 2010). Similarly, 
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miR-206 reduction has also been associated with muscle atrophy (Nakasa et al. 
2010) and inhibition of C2C12 differentiation (Kim et al. 2006).
Life-long exercise also alters the expression of some myomiRs in elderly 
subjects. A study compared the expression of miR-1, miR-133a and miR-206 
in the skeletal muscle of healthy young (27.3 ± 4.2 y.o.) active males, old (71.4 
± 3.0 y.o.) sedentary males and old (70.2 ± 4.0 y.o.) sportsmen (Zampieri et al. 
2015). This study revealed a significant reduction in miR-1 expression in the 
older sportsmen when compared to sedentary older males. Although miR-1
regulates IGF-1 expression in cardiomyocytes (Elia et al. 2009), no differences 
in IGF-1 mRNA levels were reported in skeletal muscle. The protein levels of 
IGF-1 were not measured in this study. However, the reduced levels of miR-1
in the skeletal muscle of older sportsmen may be indicative of a miRNA 
adaptation to life-long exercise and contribute to improved IGF-1 signalling 
and consequently an improvement in muscle mass. MiR-206 expression was 
also elevated in the active older males when compared to the old sedentary 
cohort. Although this study did not investigate the expression of muscle 
regenerative markers, increased miR-206 levels may be indicative of an 
improved regenerative capacity in the older sportsmen (Cacchiarelli et al. 2010;
Kim et al. 2006).
One study has found that two miRNAs were differentially regulated following 
resistance exercise training in the muscle of subjects categorised as ‘low
responders’ when compared to ‘high responders’ to resistance training
(Davidsen et al. 2011). ’High responders’ were subjects whose lean body mass 
(LBM) increase and muscle cross-sectional area increase was within the top 15 
and 20%, respectively from the entire cohort. Low responders were within the
bottom 15 and 20% for LMB gain and cross-sectional area gain, respectively. 
Following the 12-week resistance training protocol, high responders gained 
nearly four-fold more LBM than low responders. MiR-451 expression was 
increased and miR-378 expression was decreased in the low responder group. 
Low response to resistance exercise training in healthy young subjects is due to 
anabolic resistance that attenuates the increase in skeletal muscle size following 
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the training (Baar & Esser 1999; Terzis et al. 2008). miR-451 has tumor 
suppressor properties in human glioma cell lines, where its upregulation is 
associated with a downregulation of the IGF-1/Akt pathway (Tian et al. 2012).
Downregulation in miR-451 has been observed in hypertrophic 
cardiacmyopathy with a direct binding interaction between miR-451 and TSC1 
(Song et al. 2014); the latter a direct inhibitor of mTOR (Garami et al.). In 
cardiomyocytes, miR-378 was shown to directly target the IGF-1 receptor 
(Knezevic et al. 2012). There may be a possible interaction via a negative 
feedback loop between the two miRNAs where miR-451 represses Akt/mTOR
signalling in low responders, and thus miR-378 is downregulated in order to 
allow for an accumulation of IGF-1 receptor to compensate for the reduction in 
IGF-1/Akt activity. However, the role of miR-451 and miR-378 in skeletal 
muscle requires experimental validation. This study is highly relevant to 
sarcopenia as anabolic resistance is a common mechanism in both groups.
Although some skeletal muscle miRNAs have been implicated with age or 
anabolic resistance, there is a significant lack of direct cause-and-effect data to 
link these miRNAs to protein synthesis regulation. Muscle protein synthesis is 
maximised in young, healthy subjects 2 hours following an acute bout of 
resistance exercise at an intensity of 60% of 1RM (Kumar et al. 2009). This 
response is attenuated in old subjects. Members of the Akt signalling pathway 
that stimulate protein synthesis are also activated at this time point (Camera et 
al. 2010; Kumar et al. 2009; Mitchell et al. 2014). Therefore identifying 
miRNAs that are differentially regulated between young and old at this time 
point provides the opportunity to gain a better understanding of the molecular 
mechanisms underlying age-related muscle wasting. Ultimately quality proof-
of-concept investigations are required to establish the role of specific miRNAs 
on physiological processes associated with age-related muscle wasting.
1.7 Summary
MicroRNAs are novel regulatory molecules that have the potential to improve 
our understanding of the underlying mechanisms regulating many 
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physiological processes including skeletal muscle health. Age-related loss of 
skeletal muscle mass is associated with a poor quality of life, a loss of 
independence and an increase in hospitalisation. As our population ages, 
identifying new strategies that can restore the disorder in muscle protein 
balance will enhance the quality of life in elderly people and reduce the 
financial burden on our healthcare system. The onset and progression of 
sarcopenia is linked to decreased muscle protein synthesis and impaired 
regeneration. Although resistance exercise is known to increase muscle protein 
synthesis, the elderly have an impaired response to resistance exercise, which
demonstrates the presence of an anabolic resistance.
Several miRNAs are implicated in healthy skeletal muscle development, 
metabolism and regeneration. Likewise, aberrant expression of miRNAs is 
associated with muscle disease. The observation that resistance exercise, a 
potent stimulator of skeletal muscle hypertrophy, may modulate the expression 
of several muscle specific miRNAs has important implications for 
understanding how miRNAs may maintain skeletal muscle health over the 
human lifespan. The recent development of a miRNA targeted therapy, which 
is currently in phase 2b human clinical trials, demonstrates the potential of 
miRNAs as safe and specific therapies for disease. This thesis is focussed the 
regulation of miRNAs in skeletal muscle and their role in muscle protein 
synthesis in young and old subjects. It will also validate the regulatory role of 
selected miRNAs and identify their potential genes targets involved in protein 
synthesis.
1.8 Specific Aims
1)
a) To perform a large-scale microRNA screening in the skeletal muscle 
samples of young an old subjects following an acute bout of resistance 
exercise
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b) To use statistics and bioinformatics to identify microRNAs potentially 
involved in age-related muscle wasting with a specific focus on Akt-
mTOR signalling
2)
a) To determine if miR-99b overexpression can repress protein synthesis in 
young and old myotubes
b) To determine if miR-99b overexpression would alter the Akt-mTOR 
signalling pathway
3)
a) To determine if miR-499 overexpression can repress protein synthesis in 
young and old myotubes
b) To determine if miR-499 overexpression would alter the Akt-mTOR 
signalling pathway
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2. GENERAL METHODS
2.1 Subjects
Ten healthy young (18–30 years old) and 10 healthy older (60–75 years old)
males gave their written consent to participate in the study. The subjects were 
physically active but had not been involved in any resistance training program 
within 6 months prior to the commencement of the study. Exclusion criteria 
included protein and anabolic hormone supplementation. The study was
approved by the Deakin University Human Research Committee (2011-043).
2.2 Muscle Biopsies
The muscle biopsies were taken from the subjects’ vastus lateralis muscle 
under local anaesthesia (1% Xylocaine) using a Bergstrom needle (Bergstrom 
1962) with suction (Evans, Phinney & Young 1982). Muscle samples were 
immediately frozen in liquid nitrogen and stored at -Û&IRU51$DQGSURWHLQ
analysis. Extra muscle samples from 3 randomly selected young subjects and 3 
randomly selected old subjects was reserved in ice-cold HAMs F-10 medium 
(Life technologies, Mulgrave, Australia) for cell culture preparation (refer to 
section 2.3).
2.3 Establishing Primary Cell Lines
Satellite cells were isolated from the muscle biopsies of 6 randomly selected 
subjects from section 2.1 (3 young and 3 old subjects) by dissociation of the 
biopsy tissue with 0.05% Trypsin/EDTA (Life technologies, Mulgrave, 
Australia). The tissue slurry was then filtered through a ȝP FHOO VWUDLQHU
(Becton Dickinson, North Ryde, Australia). The recovered cell population was 
pre-plated in myoblast proliferation medium made up of HAMs F-10 medium 
(Life technologies, Mulgrave, Australia) containing 20% foetal bovine serum 
(FBS) (French bovine material, Bovogen, Keilor East, Australia), 25 ng/mL 
fibroblast growth factor (bFGF) (Promega, Madison, USA), 1% 
penicillin/streptomycin (Life technologies, Mulgrave, Australia) and 0.5% 
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DPSKRWHURP\FLQ/LIHWHFKQRORJLHV0XOJUDYH$XVWUDOLDDWÛ&DQG&22.
After 30 min the medium was collected and pre-plated for a second time. After 
a further 30 minutes the medium was transferred to a flask coated with 
extracellular matrix (ECM) (Sigma-Aldrich, Castle Hill, Australia) and allowed 
to proliferate to 70% confluence before passaging. Cells were passaged by 
mechanical disturbance 4 times then frozen down in proliferation media 
supplemented with 10% dimethyl sulfoxide (DMSO).
2.4 Cell Culture Maintenance
Myoblasts were thawed in proliferation medium and allowed to proliferate to 
FRQIOXHQFHDWÛ& and 5% CO2. Cells were passaged with Tryple Express 
(Life technologies, Mulgrave, Australia) and plated in either 6-well or 12-well 
plates. At approximately 70-80% confluence proliferation medium was 
replaced with differentiation medium made up of DMEM (Life technologies, 
Mulgrave, Australia) containing 2% horse serum (New Zealand origin,
GibcoTM, Life technologies, Mulgrave, Australia) and 1% 
penicillin/streptomycin. All experiments were performed on the 7th day of 
differentiation at passage 6. Medium was replaced every 48 hours.
2.5 Fusion Index
To ensure that the cell lines contained a myogenic population of cells the fusion 
index was calculated for each cell line. Cells were differentiated for 7 days then 
fixed in 4% paraformaldehyde. Cells were solubilised in 0.1% Triton X-100
(TX-100) (Life technologies, Mulgrave, Australia)/PBS then blocked in 1% 
(w/v) bovine serum albumin (BSA) (Life technologies, Mulgrave, 
Australia)/PBS for 1 h at room temperature. Cells were then incubated in 
sarcomeric myosin (MF 20 was deposited to the DSHB by Fischman, D.A.)
diluted LQ%6$3%6RYHUQLJKWDWÛ&&HOOVZHUHWKHQZDVKHGZLWK
PBS and incubated with a donkey anti-mouse IgG antibody labelled with an 
infrared-fluorescent 488 nm dye (Alexa Fluor®, Life technologies, Mulgrave, 
Australia) diluted 1:1000 in 1% BSA/PBS for 1 h at room temperature. Cells 
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were then washed with PBS and incubated with DAPI nucleic acid stain (Life 
technologies, Mulgrave, AustraliaGLOXWHGWRȝJPL in PBS for 5 minutes. 
Cell images were taken with an Olympus 1X-70 fluorescent microscope
(Olympus, North Ryde, Australia) and Magna Fire camera (Olympus, North 
Ryde, Australia) and NIS-Elements D software (Nikon). The number of nuclei 
per field of view was counted using Image J software. The fusion index was 
determined as the number of nuclei within multi-QXFOHDWHG  QXFOHL
sarcomeres divided by the total number of nuclei per field of view.
2.6 MicroRNA Transfection
Myotubes were transfected with either 20 μM of miRNA mimic (mirVanaTM
miRNA mimic, Life technologies, Mulgrave, Australia) or 20 μM of a mimic 
scramble sequence (mirVanaTM miRNA mimic, negative control #1, Life 
technologies, Mulgrave, Australia) using siPORTTM NeoFXTM Transfection 
Agent (Ambion®, Life technologies, Mulgrave, Australia) diluted 16.7X in 
Opti-MEM® I Reduced serum medium (Life technologies, Mulgrave, 
Australia). This solution was added to differentiation medium at a 10X dilution.
After 8 h the transfection medium was removed and replaced with 
differentiation medium until harvest.
2.7 Protein Synthesis Assay
To assess protein synthesis myotubes were incubated in differentiation medium 
supplemented with 1ȝ&LPL of 3H-tyrosine (GE Healthcare, Sydney, Australia) 
for the 16 h period following on from miRNA transfection. The myotubes were 
also incubated with excess (2 mM) L-tyrosine (Sigma-Aldrich, St Louise, USA) 
to ensure the intracellular tyrosine pool is not altered, giving a more accurate 
indication of protein synthesis rates. At the 24 h time point cells were washed 
with ice-cold PBS then 1 mL of ice-cold trichloroacetic acid (TCA) (Sigma-
Aldrich, St Louise, USA) was added to each well. The cells were then scraped, 
transferred to tubes and incubated on ice for at 1 h to precipitate the protein. 
The cells were then centrifuged at 20,000 x g for 10 minutes and the supernatant 
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removed. The pellets were dissolved in 0.1 M NaOH with 1% TX-100 (Sigma-
Aldrich, St Louise, USA) at room temperature overnight. On the following day, 
ȝ/RIWKHVDPSOHZDVDGGHGWR mL of Ultima Gold scintillation liquid 
(Perkin Elmer, Boston, USA). Radioactivity was measured on a Wallac 1409 
DSA liquid scintillation counter (Perkin Elmer, Boston, USA) and normalised 
to total genomic DNA (gDNA). The gDNA was extracted using the PureLink® 
Genomic DNA Mini Kit (Life technologies, Mulgrave, Australia) according to 
the manufacturer’s protocol and the DNA was quantified using the Nanodrop 
1000 Spectrophotometer (Thermo Fisher Scientifc, MA, USA).
2.8 Protein Degradation Assay
Protein degradation was assessed by the release of 3H-tyrosine from the 
myotubes into the medium. Twenty-four hours prior to transfection cells were 
LQFXEDWHG LQ GLIIHUHQWLDWLRQ PHGLXP VXSSOHPHQWHG ZLWK  ȝ&LP/ RI 3H-
tyrosine. After 24 h the medium was removed and the cells were washed with 
PBS before the onset of transfection. Cells were transfected as described in 
section 2.6. The transfection medium was also supplemented with 2 mM L-
tyrosine. After 8 h the cells were washed again then incubated in serum-free 
DMEM supplemented with 2 mM L-tyrosine for a further 16 h. After this 450 
mL of medium was collected from each well and incubated on ice for 1 h with 
ȝ/RI7&$WRSUHFLSLWDWHWKHSURWHLQ7KHVDPSOHVZHUHWKHQFHQWULIXJHGDW
USPIRUPLQXWHVDQGȝL of the supernatant was added to 4 mL of 
Ultima Gold scintillation liquid. The TCA soluble radioactivity was measured 
on the Wallac 1409 DSA liquid scintillation counter (reading A). The remaining 
medium was removed from the samples and the pellets were solubilised in 500 
ȝ/RI01D2+ZLWK7;-IRUKDW&7KHQȝ/RIWKLV
sample was added to 4 mL of Ultima Gold scintillation liquid and the TCA 
insoluble radioactivity was measured (reading B). The remaining medium was 
removed from the myotubes and they were washed twice with ice-cold PBS. 
7KHP\RWXEHVZHUHWKHQVROXELOLVHGLQȝ/RI01D2+ZLWK7;-
IRUKDW&7KHQȝ/RI7&$ZDVDGGHGWRWKHVDPSOHVDQGWKH
protein was allowed to precipitate at 4°C overnight. The fROORZLQJGD\ȝ/
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of this sample was added to 4 mL of Ultima Gold scintillation liquid and the 
myotube radioactivity was read (reading C). The proteolytic rate was calculated 
as follows:
(TCA soluble radioactivity (A) / (TCA soluble radioactivity (A) + TCA
insoluble radioactivity (B) + myotube radioactivity (C))) x 100
2.9 RNA Extraction and Real-time PCR
Total RNA was extracted with Tri-Reagent Solution (Ambion Inc., Austin, 
USA) according to the manufacturer’s protocol. RNA concentrations were 
determined by using the Nanodrop 1000 Spectrophotometer (Thermo Fisher 
Scientifc, MA, USA) and RNA quality was assessed from a random selection 
of samples using the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa 
Clara, USA) with the Agilent RNA 6000 Nano Reagents kit (Agilent 
Technologies, Santa Clara, USA) and the RNA Nano Chips (Agilent 
Technologies, Santa Clara, USA) according to the manufacturer’s protocol.
RNA was treated with DNase I Amplification Grade (Life Technologies, 
Mulgrave, Australia). First-VWUDQG F'1$ZDV JHQHUDWHG IURP  ȝJ RI 51$
using the High Capacity RT-kit (Life technologies, Mulgrave, Australia)
according to the manufacturer’s protocol. The cDNA was then treated with 
RNase H treated (Life Technologies, Mulgrave, AUS) according to the 
manufacturer’s protocol. For specific miRNA analysis RNA was reverse 
transcribed with the TaqMan® MicroRNA Reverse Transcription Kit (Life 
technologies, Mulgrave, Australia) according to the manufacturer’s protocol 
with modifications specified in specific studies. Real-time PCR was carried 
using a Stratagene MX3000 PCR system (Agilent Technologies, Santa Clara, 
USA). The expression levels for specific mRNA targets were assessed by 
specifically designed human primers (Geneworks, Hindmarsh, Australia). 
TaqMan® MicroRNA Assays were used to assess the expression of specific 
miRNA targets (Life technologies, Mulgrave, Australia). Data was analysed 
using the –delta Ct method and normalised to either ssDNA (as determined by 
Quant it OliGreen ssDNA Assay Kit, (Life technologies, Mulgrave, Australia), 
ribosomal protein S5 (RPS5) (Life technologies, Mulgrave, Australia) or U6 
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snRNA (Life technologies, Mulgrave, Australia) as specified for specific 
chapters.
2.10 Protein Extraction and Western Blot
Total protein was extracted using RIPA buffer (Millipore, North Ryde, 
$XVWUDOLDZLWKȝOP/SURWHDVHLQKLELWRUFRFNWDLO6igma-Aldrich, St Louise, 
86$DQGȝOP/+DOW3KRVSKDWDVH,QKLELWRU6LQJOH-use Cocktail (Thermo 
Scientific, Rockford, USA). Total protein content was determined using the 
BCA Protein Assay Kit (Pierce Biotechnology, Rockford, USA) according to 
the manufacturer’s protocol. Equal amount of protein was separated on either 
self-cast polyacrylamide gels (contents), a 4-12% NuPAGE® Novex Bis-Tris 
Gel (Life technologies, Mulgrave, Australia) or a 4-15% CriterionTM TGX 
Stain-FreeTM Precast gel (Bio-Rad, Parkville, Australia) with the respective 
electrophoresis and transfer buffers provided by the suppliers. All proteins were 
transferred for 1.5 h onto Immobilin-FL PVDF membranes (Millipore, 
Billerica, USA). Membranes were blocked for 1 h at room temperature then 
incubated in primary antibody at 4°C overnight. Following the overnight 
incubation the membranes were washed and incubated for 1 h with either a goat 
anti-rabbit IgG antibody labelled with an infrared-fluorescent 800 nm dye or a 
donkey anti-goat IgG with infrared-fluorescence 680 nm dye (Alexa Fluor® 
800, Life Technologies, Mulgrave, Australia) diluted in a buffer containing 
PBS and Odyssey® blocking buffer (LI-COR Biosciences, Lincoln, USA) at a 
1:1 ratio and 0.01% SDS. After washing, the proteins were exposed on an 
Odyssey® Infrared Imaging System (LI-COR Biosciences, Lincoln, USA) and 
individual protein band optical densities were determined using the Odyssey® 
Infrared Imaging System software. All blots were normalized to the GAPDH 
protein (G8795; Sigma-Aldrich, Sydney, Australia). Specifications are outlined 
within study chapters.
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2.11 Bioinformatics Analysis
Top cellular functions and miRNA-mRNA target interactions were determined 
using online software packages Ingenuity System Interactive Pathway Systems
(version 18488943). Stringency was set at ‘highly predicted’ and 
‘experimentally validated’. Ingenuity pathway analysis (IPA) was used to 
generate figures depicted the relationship between miRNAs predicted target 
mRNAs involved in MPS.
2.12 Statistical Analysis
All data are reported as mean ±SEM. The mixed-model 2-way analysis of 
variance (ANOVA) was used to compare group means. Diagnostic plots of 
residuals and fitted values were checked to ensure homogeneity of variance (a 
key assumption for ANOVA). Consequently, non-homogenous data was 
transformed and analyses were conducted on these transformed scales. The 
least significant difference (LSD) test was used to compare pairs of means. The 
significance levels for both the F-tests in the ANOVA and the LSD tests were 
set at p<0.05.
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3. IDENTIFICATION OF MICRORNAS LINKED TO 
REGULATORS OF MUSCLE PROTEIN SYNTHESIS AND 
REGENERATION IN YOUNG AND OLD SKELETAL 
MUSCLE
The findings of this chapter have been published in PLoS One; Evelyn Zacharewicz, Paul Della 
Gatta, John Reynolds, Andrew Ganham, Tamsyn Crowley, Aaron P Russell and Sèverine 
Lamon. Identification of microRNA linked to regulators of muscle protein synthesis and 
regeneration in young and old skeletal muscle. PLoS One 2 December 2014 9(12) doi: 
10.1371/journal.pone.0114009. (Appendix B)
3.1 Introduction
Skeletal muscle serves as a structural and mechanical unit enabling the 
maintenance of posture and the performance of gross and fine motor 
movements. It is a highly plastic tissue, able to alter its size and metabolism to 
maintain optimal function in response to various exogenous and endogenous 
stimuli. Preserving skeletal muscle mass and health as we age is an essential 
component of whole body health and reduces the risk of chronic disease. 
However, by the age of 50 years, approximately 10% of muscle mass is lost and 
continues to decrease at an accelerated rate until death (Phillips 2012). This age-
related loss of muscle mass and the associated frailty syndrome is linked to a 
reduced capacity for muscle regeneration in aged rodents (Conboy et al. 2003)
and insufficient muscle protein synthesis (MPS) in elderly humans (Kumar et 
al. 2009). While regular physical activity and ingestion of good quality protein 
attenuates age-related wasting, they do not stop or reverse this process.
The Akt-mTOR signalling pathway is a major regulator of skeletal muscle mass 
via the positive and negative modulation of numerous downstream targets 
involved in the MPS process (Rommel et al. 2001). Resistance exercise is a 
potent stimulator of the Akt-mTOR pathway resulting in maximal MPS 
activation at an exercise intensity of 60% of 1 repetition maximum (1RM) two 
hours following the exercise bout. This activation is blunted but not delayed in 
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elderly subjects (Kumar et al. 2009). So far, the molecular mechanisms 
underlying MPS are not fully understood.
MicroRNAs (miRNAs) are short single strands of nucleic acids (20-22 nt) that 
regulate numerous gene networks and signalling pathways (Lim et al. 2005;
Selbach et al. 2008). miRNAs regulate gene expression by binding to 
messenger RNAs (mRNAs) and either directly degrading the mRNA or 
inhibiting protein translation (Huili et al. 2010; Selbach et al. 2008). In rare 
cases, miRNAs can also stabilise mRNA targets (Vasudevan, Tong & Steitz 
2007). miRNAs are therefore essential post-transcriptional regulators in the 
cell. miRNAs are implicated in the process of ageing (de Lencastre et al. 2010;
Ibáñez-Ventoso et al. 2006). In mouse skeletal muscle, 57 miRNAs displayed 
aberrant expression in old mice when compared to young mice, with 
bioinformatics analysis predicting a role in the regulation of myogenesis for 
several of these miRNAs (Hamrick et al. 2010a). In humans, let-7b and let-7e, 
two miRNAs playing an anti-proliferative role in cancer cells (Johnson et al. 
2007), have a greater basal expression in the skeletal muscle of old subjects 
when compared to young subjects (Drummond et al. 2011). Thus far, two 
studies have investigated the association between miRNAs and exercise in an 
elderly population (Drummond et al. 2008b; Rivas et al. 2014). MiR-1
expression was down regulated in young subjects but remained elevated in old 
subjects 3 and 6 hours following an acute bout of resistance exercise combined 
with the ingestion of essential amino acids (EAA) (Drummond et al. 2008b).
miR-1 can inhibit IGF-1 (Elia et al. 2009), the latter a key stimulator or MPS 
(Rommel et al. 2001). Another study investigated a subset of 60 muscle 
enriched miRNAs in young and old subjects following an acute bout of 
resistance exercise. This study found 17 miRNAs that were downregulated 6 
hours after an acute bout of resistance exercise in the young subjects only (Rivas 
et al. 2014), including miR-126, a miRNA predicted to regulate IGF-1
signalling. Further analysis in C2C12 myotubes revealed that following IGF-1
treatment, miR-126 repression resulted in increased phosphorylation levels of 
various downstream targets of IGF-1 when compared to control cells treated 
with IGF-1. A sustained expression in miR-1 and miR-126 post-exercise may 
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partly explain the reduced protein synthesis response observed in elderly 
subjects following resistance exercise. However, the role of miRNAs in the age-
related loss of muscle mass and anabolic resistance requires further 
investigation.
The aim of this study was to perform a large-scale miRNA screening in skeletal 
muscle samples of young and old subjects following an acute bout of protein 
synthesis-stimulating resistance exercise. Discriminant analysis, principal 
components analysis and bioinformatics analysis were performed on the 
miRNAs regulated by age, exercise or a combination of both. This allowed 
identification of miRNAs potentially involved in age-related muscle wasting 
with a specific focus on the Akt-mTOR pathway. Activation of the MPS 
pathways was indirectly assessed by measuring the expression levels of protein 
synthesis regulators.
3.2 Methods
3.2.1 Subjects
Subject characteristics are listed in table 3.1. Ten healthy young (18-30 years 
old) and ten healthy older (60-75 years old) males were recruited to participate 
in the study as described in section 2.1.
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Table 3.1 Subjects’ demographics
Young Old P-value
Age (years) 24.2±0.9 66.6±1.1 <0.05
Height (cm) 180.0±2.0 174.60±1.8 0.06
Body mass (kg) 73.8±3.6 83.4±7.1 0.25
Fat mass (kg) 13.6±2.7 19.5±3.9 0.23
Lean mass (kg) 57.9±1.9 60.2±3.3 0.55
BMC (kg) 3.3±0.2 3.2±0.2 0.67
BMI 23.3±0.9 27.7±1.9 0.10
Lean mass:total body mass 0.8±0.02 0.7±0.02 0.09
1RM (kg) 98.2±7.0 80.9±7.2 0.10
Values are mean±S.E.M.. BMC, bone mass content; BMI, body mass index; 1RM, 1 repetition 
maximum. Statistical significance was determined by unpaired Student’s t-test.
3.2.2 Dual-energy X-ray Absorptiometry (DXA) Scan
Subjects’ total body and regional (arms and legs) body composition was 
assessed by a  DXA scan (Lunar Prodigy, GE Lunar Corp., Madison, WI) Lean 
mass (LM), fat mass (FM), % body fat and areal bone density (ABD) for the 
lumbar spine (L1-L4) and proximal femur (femoral neck and total hip) was 
determined for each subject.
3.2.3 Familiarisation and Preliminary Testing
At least 2 weeks prior to the trial date the subjects attended Deakin University 
to be familiarised with the equipment and exercise and to determine their one-
repetition-maximum (1RM). Participants’ 1RM for the leg extension exercise 
was determined on a Nautilus Leg Extension (Fitness Generation, Rowville, 
Australia) using the 5RM test. The 1RM was then estimated using the Brzycki 
equation (Nascimento et al. 2007):
1RM = weight lifted (kg) / 1.0278 – [reps to fatigue x 0.0278]
3.2.4 Exercise Trial
Subjects had been asked to abstain from strenuous exercise, caffeine and 
alcohol 24 h prior to their trial date. Subjects were given a standardised meal 
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consisting of 20% fat, 14% protein and 66% carbohydrate to consume the night 
before the trial. Following an overnight fast, subjects arrived at the Deakin 
University clinical trial facility. The subjects rested in a supine position for 2 h 
prior to the collection of the resting muscle biopsy (as described in section 2.2). 
Immediately following the biopsy the subjects completed a 3 min light cycling 
warm-up. The subjects then completed the leg extension exercise at 60% of 
their respective 1RM consisting of 3 sets of 14 repetitions with 2 min rest 
periods between each set. The subjects then rested in the supine position for 2 
h prior to the collection of the second muscle biopsy. The second biopsy was 
collected from the contralateral muscle to avoid any local effect of the resting 
biopsy.
3.2.5 RNA Extraction and miRNA Arrays
Total RNA was extracted from muscle biopsies (~10 mg) as described in 
section 2.9. To breakdown the tissue the muscle biopsies were homogenised in 
tubes containing zirconia/silica beads (Daintree Scientific, St. Helens, 
Australia) and Tri-Reagent® Solution using the MagNA Lyser homogeniser 
(Roche, Castle Hill, Australia). RNA (350 ng) was reverse transcribed using the 
Taqman microRNA Reverse Transcription (RT) kit and Megaplex™ RT 
Primers, Human Pool A v2.1 and Human Pool B v3.0 (Applied Biosystems, 
Life Technologies, Mulgrave, VIC, Australia). The RT reaction consisted of 2.7 
mM dNTP, 0.3 U/μL RNase inhibitor, 3 mM MgCl2, 10 U/μL MultiScribe™ 
enzyme, 1 x buffer and 1 x primers. The RT conditions consisted of 40 cycles 
of 16°C for two min, 42°C for one min and 50°C for two min, followed by 5 
min at 85°C to stop the reaction then cooled to 4°C.
miRNA expression in the samples was assessed using the TaqMan® Array 
Human MicroRNA A+B Cards v3.0 (Applied Biosystems, Life Technologies, 
Mulgrave, Australia). Collectively, these cards allow for the accurate 
quantitation of 754 human miRNAs including positive and negative controls. 
The results from the Megaplex™ were then analysed using ExpressionSuite 
Software v1.0 (Applied Biosystems, Life Technologies, Mulgrave, VIC, 
Australia) and the data was normalized using the global normalization function 
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(Mestdagh et al. 2009). Ct values were then transformed into arbitrary units 
(AU).
3.2.5 Protein Extraction and Western Blotting
The biopsy tissue was homogenised using the LabServ D-130 homogeniser 
(Wiggenhauser, Los Lunas, USA) in RIPA buffer as described in section 2.10
according to the following specifications. Equal amount of protein was 
separated on either a 6% polyacrylamide self-cast gel, a 4–12% NuPAGE® 
Novex Bis-Tris Gel or a 4-15% Criterion™ TGX Stain-Free™ Precast gel with 
the respective electrophoresis and transfer buffers provided by the suppliers. 
The following proteins were probed: phospho-AktSer473 (9271), phospho-
4EBP1Thr37/46 (9451), phospho-p70S6KThr389 (9234), phospho-mTORSer2448
(5536), total Akt (9272), total mTOR (2972), total IGF1R (3018), total RPTOR 
(2280) (Cell Signalling Technologies, Arundel, QLD, Australia); and GDF 8/11 
(myostatin; 34781) (Santa Cruz, Scoresby, VIC, Australia). For western 
specifications see table 3.2. All the blots were exposed on the Odyssey® 
Infrared Imaging System and normalised to GAPDH protein expression with 
the exception of phospho-mTOR. The phospho-mTOR gel was transferred onto 
an Immun Blot PVDF membrane (Bio Rad, Parkville, Australia). The blot was 
then probed with a HRP labelled goat anti-rabbit IgG (Perkin Elmer, Glen 
Waverley, Australia) and detected by chemiluminescence (Clarity Western 
ECL Substrate, Bio Rad Laboratories, Hercules, USA) with a 1 min exposure 
time. Phospho-mTOR expression was normalised to total protein load as 
determined by coommasie stain.
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Table 3.2 Western blot specifications
Primary 
antibody
Primary 
antibody 
dilution
Secondary 
antibody
Secondary
antibody 
dilution
System used
phospho-
AktSer473
1:500 Goat anti-
rabbit IgG
1:5000 NuPAGE® 
SDS-PAGE 
Gel System
phospho-4E-
BP1Thr37/46
1:500 Goat anti-
rabbit IgG
1:5000 NuPAGE® 
SDS-PAGE 
Gel System
phospho-p70 
S6 
KinaseThr389
1:500 Goat anti-
rabbit IgG
1:5000 NuPAGE® 
SDS-PAGE 
Gel System
phospho-
mTORSer2448
1:750 Goat anti-
rabbit IgG
1:5000 SDS-PAGE
Total Akt 1:1000 Goat anti-
rabbit IgG
1:5000 Criterion™ 
TGX Stain-
Free™ System
Total mTOR 1:750 Goat anti-
rabbit IgG
1:5000 Criterion™ 
TGX Stain-
Free™ System
Total IGF-1R 1:500 Goat anti-
rabbit IgG
1:5000 NuPAGE® 
SDS-PAGE 
Gel System
Total RPTOR 1:1000 Goat anti-
rabbit IgG
1:5000 Criterion™ 
TGX Stain-
Free™ System
Myostatin 1:1000 Donkey anti-
goat IgG
1:5000 NuPAGE® 
SDS-PAGE 
Gel System
GAPDH 1:20000 Goat anti-
mouse IgG
1:5000 N/A
3.2.6 Bioinformatics Analysis
Bioinformatics analysis for top cellular functions and miRNA-mRNA target 
interactions were determined using Ingenuity System Interactive Pathway 
Systems (version 18488943) as described in section 2.11.
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3.2.7 Real-time PCR
Gene expression for mTOR, RPTOR and IGF1R was determined by qPCR as 
described in section 2.9. Primer sequences and conditions details are in table 
3.3. Gene expression was normalised to total single stranded cDNA determined 
by Quant-it OliGreen ssDNA Assay Kit
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Table 3.3 Primer sequences and conditions
Target Accession 
Number
Primer sequence Primer 
concentration 
(nM)
Probe sequence Probe 
concentration 
(nM)
mTOR NM_004958
F CAAGAACTCGCTGATCCAAATG
R GCTGTACGTTCCTTCTCCTTC 100 TGCATTCCGACCTTCTGCCTTCA
150
IGF-1R NM_000875
F AGTTATCTCCGGTCTCTGAGG
R TCTGTGGACGAACTTATTGGC 100 TCATCTTGCTCAGGCTTGGAGGTG
50
RPTOR AY090663
F TCGTCAAGTCCTTCAAGCAG
R GGGTGATTTGGGTTGATTGC 300 TCCTGCTCCCGCTGTAGTGC
150
Foxo-1 NM_02015
F AAGAGCGTGCCCTACTTCAA
R CTGTTGTTGTCCATGGATGC 300 N/A
N/A
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3.2.7 Statistical Methods
All data are reported as mean ±SEM and analysed by ANOVA as described in 
section 2.12.
Split Plot ANOVA
AU values generated from the microRNA arrays were transformed by first 
adding a small constant (0.0001) and then taking the logarithm to base 2 of the 
result. The log transformation was required to uncouple a variance-mean 
relationship that was evident in preliminary analyses of variance of the AU 
values. A split-plot ANOVA with group (young or old) as the main-plot 
treatment and time (pre or post exercise) as the split-plot treatment was 
conducted on the log (base 2) transformed AU values for each of the 754 
miRNAs. First three contrast were estimated and the p-values of their associated 
F-tests were recorded: (1) Main effect of old versus young, (2) main effect of 
post (exercise) versus pre (exercise), and (3) interaction contrast: (old, post) + 
(young, pre) – (old, pre) – (young, post). This was followed by pairwise 
comparisons and to estimate their associated contrasts and p-values: (4) post 
versus pre in the young age group, (5) post versus pre in the old age group, (6) 
old versus young at the level of pre, and (7) old versus young at the level of 
post. In order to identify notable miRNAs with respect to these contrasts, the 
negative log10 transformation of the p-value was plotted against the associated 
contrast (on the log2 scale) in a “volcano” plot (Jin et al. 2001) for each of the 
seven types of contrast. Target miRNAs for which both the Young and Old age 
groups had means <= 1.219 on the log2 scale (Ct>32) were excluded from 
consideration. Target miRNAs ZLWKDEVROXWHYDOXHVRIWKHLUFRQWUDVWVDQG
transformed p-YDOXHVLHSZere considered to be notable for that 
contrast. Analyses of variance were conducted using routines in the GenStat 
package (Payne, Murray & Harding 2011) and graphs were produced in R 
version 2.15.1 (2012-06-22, Copyright (C) 2012 The R Foundation for 
Statistical Computing).
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Discriminant Analysis
To search for an optimal set of miRNAs to discriminate between the two age 
groups, a stepwise discriminant analysis using forward selection based on 
Wilk’s lambda was performed on a reduced set of the 26 statistically significant 
miRNAs identified in the ANOVAs. The optimal set was determined by
choosing, from models with no more than 10 miRNAs, the model from the 
forward step with the minimum validation error. The misclassification rate of 
this selected model was estimated using 10-fold cross-validation. The 
DISCRIMINATE procedure in the GenStat package was used for this stepwise 
analysis.
Principal Components Analysis
A principal components analysis, using the PCP directive in GenStat, was used 
to identify linear combinations of the miRNAs, in the reduced set of 26, that 
appeared to account for most of the variation between individuals and to 
produce an ordination or “map” of the individuals based on the first two of the 
resulting principal components.
3.3 Results
3.3.1 Subject Characteristics
The physiological characteristics of the subjects are listed in table 3.1. Briefly, 
the average age of the two cohorts was 24.2±3.0 years old and 66.6±3.5 years 
old for the young and old group, respectively. No significant difference were
observed in body mass, tissue composition and maximal voluntary contraction 
(1RM) between the two groups.
3.3.2 MicroRNA Expression in Young and Old Skeletal Muscle 
Following an Acute Bout of Resistance Exercise
The Taqman® Array Human MicroRNA Cards Set 3.0 was used to assess the 
expression levels of 754 human miRNAs in the muscle samples. The relevant 
level of expression cut-off was set at Mean(Ct)<32 for each miRNA as
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recommended by the manufacturers. According to this criterion, 257 miRNAs
(34%) were considered to be sufficiently expressed in skeletal muscle for 
further analysis. The statistical variation for age, exercise and a combination of 
age and exercise was investigated for all 257 miRNAs. A total of 7 contrasts 
were considered in the statistical analysis: (1) Main effect of age, (2) main effect 
of time, (3) interaction contrast: (old, post) + (young, pre) – (old, pre) – (young, 
post), (4) effect of time in the young age group, (5) effect of time in the old age 
group, (6) effect of age at the level of pre, and (7) effect of age at the level of 
post. A first selection based on a statistically significant p-value (p<0.05) and 
fold-FKDQJHIRURQHRUPRUHRIWKHFRQWUDVWV\LHOGHGVHYHQmiRNAs: miR-
149-3p, miR-483-5p, miR-486-3p miR-494-3p, miR-500a-5p, miR-518b, and 
miR-99b-5p. Figure 3.1 depicts a volcano plot representing the interaction 
contrast. Volcano plots for the remaining contrasts can be seen in 
Supplementary Figures S3.1-S3.6 MiRNAs are plotted by fold change against 
p-value. Following this, a relaxed selection criterion that only considered a 
statistically significant p-value was applied. From this analysis, 26 miRNAs
were returned for one or more of the contrasts. A main effect of age and a main 
effect of exercise was observed in 7 and 5 miRNAs, respectively, out of the 26 
miRNAs (Table 3.4). Seven miRNAs had a significant age x exercise 
interaction, indicating that exercise had a differential effect on the expression 
of these miRNAs in young and old subjects (Figure 3.2). Further statistically 
significant differences between pairs of means (age or exercise) of these seven 
miRNAs are depicted in Figure 3.2. An additional seven miRNAs were 
identified to have a significant exercise effect in either the young or old age 
groups with no significant interaction contrast (Figure 3.3). Finally, four and 
seven miRNAs were also differentially expressed between age at the level of 
pre and post respectively (Table 3.5)
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Figure 3.1 Volcano plot for the interaction contrast. This volcano plot depicts the interaction contrast and serves as a representative plot for the 7 contrasts estimated in the 
statistical analysis. The red points correspond to miRNAs with a Ct<32. The black points represent miRNAs ZLWK D &W 6WDWLVWLFDO VLJQLILFDQFH ZDV VHW DV S
corresponding to –log10(p value)=1.3 on the y-axis and is represented by the dashed line plotted perpendicular to the y-axis. The dashed lines perpendicular to the x-axis 
represent a fold-change of 2 corresponding to log2(fold-change)=1 on the x-axis.
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Figure 3.2 Expression levels of miRNAs with significant age x exercise interaction.
Differences in microRNA level in young and old subjects 2 hours post exercise. # Significant 
age x exercise interaction (P<0.05). * Significantly different from pre (P<0.05). $ Significantly 
different from young subjects at corresponding time point (P<0.05). The reported statistical 
significance is based on analysis of the transformed data but the reported means±S.E.M. are on 
the original (untransformed) scale.
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Figure 3.3 Expression levels of microRNAs with a significant exercise effect in one of the 
age groups but no interaction contrast. Differences in microRNA level in young and old 
subjects 2 hours post exercise. *Significantly different from pre (P<0.05). The reported 
statistical significance is based on analysis of the transformed data but the reported means 
±S.E.M. are on the original (untransformed) scale.
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Table 3.4 MiRNAs identified to be regulated with age and with exercise
Main effect of age Main effect of exercise
Target Old/young Target Post/pre
miR-146a-5p
miR-191-5p
miR-320a
miR-483-5p
miR-486-3p
miR-539-5p
miR-628-5p
1.6
1.2
1.3
1.9
0.6
1.8
1.3
miR-151-5p
miR-339-3p
miR-483-5p
miR-574-3p
miR-935
0.8
1.3
0.8
0.8
0.8
Values are fold-change. MicroRNAs are arranged alphanumerically
Table 3.5 MiRNAs identified to be regulated with age at the levels of pre and post
Old v young, pre Old v young, post
Target Old/young Target Old/young
miR-191-5p
miR-320a
miR-483-5p
miR-628-5p
1.3
1.4
2.0
1.4
let-7b
miR-149-3p
miR-199a-3p
miR-483-5p
miR-486-3p
miR-500a-5p
miR-518b
1.4
3.9
1.7
1.8
0.9
0.5
0.5
Values are fold-change. MicroRNAs are arranged alphanumerically
3.3.3 Classification of Young and Old Subjects Using a Subset of 
MicroRNAs
Discriminant Analysis
Discriminant analysis was used to check if a small set of linear combinations of 
the subset of 26 miRNAs could reproduce the classification of the subjects into 
age groups. The optimal model for classifying subjects into the two age groups 
required nine of the 26 miRNAs (mir-196b-5p, miR-518b, miR-935, miR-99b-
5p, miR-500a-5p, miR-494-3p, miR-335-5p, miR-520g-3p and let-7b) and the 
estimated misclassification rate was 0.2%. This particular model allocated all 
20 subjects into their original age groups (Figure 3.4A). A second analysis was 
performed with a model restricted to the first four miRNAs (mir-196b-5p, miR-
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518b and miR-935 and miR-500a-5p) representing the most highly ranked 
components of the model. This particular model classified 18/20 subjects into
their original age groups with an estimated error rate of 11.7%. One young 
subject and one old subject were misclassified (Figure 3.4B).
Figure 3.4 Graphical representation of the discriminant analysis. Two discriminant 
analysis models were used comprising of 9 microRNAs (A) and 4 microRNAs (B) selected 
with the smallest validation error. (A) The first model correctly classified all subjects into their 
original age groups with old subjects (red) receiving negative scores and young subjects (black) 
receiving positive scores. (B) The second model correctly classified 18 subjects into their 
original age groups and misclassified 1 old subject who received a positive score and one young 
subject who received a negative score. The mean for each group is represented by an X and 
standard deviation by vertical lines.
Principal Components Analysis
How much of the overall variation in the 26 miRNAs could be accounted for 
by a smaller number of dimensions or principal components was investigated 
by completing a Principal Components Analysis. Seven principal components 
accounted for 87% of the subject variation. The first principal component, 
which gave most weight to miR-518b, miR-335-5p, miR-500a-5p and miR-
149-3p, separated the subjects into two distinct age groups with young subjects 
carrying mainly positive scores and old subjects carrying mainly negative 
scores (Figure 3.5). However, two young subjects carried negative scores and 
were therefore clustered with the old group and one old subject received a 
positive score. Of the young subjects, there are two distinct groups created from 
the second principal component, one in the upper right quadrant and one in the 
bottom half. On the other hand, most of the old subjects are clustered around 
the central and lower left quadrant but two outlying subjects are located in the 
upper left quadrant. The second principal component gave high weights to miR-
539-5p, miR-518b, miR-99b-5p and miR-500a-5p.
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Figure 3.5 Graphical representation of the principal component analysis using the first 2 
principal components. The first principal component was plotted on the x-axis and second 
principal component was plotted on the y-axis. The first principal component separated the 
subjects by age group with young subjects (black) carrying mainly positive scores and old 
subjects (red) carrying mainly negative scores.
3.3.4 Bioinformatics Analysis of MicroRNA Functional Role and 
Specific Target Predictions
The bioinformatics analysis was performed on the miRNAs identified from five 
out of the seven contrasts: (1) Main effect of age, (2) main effect of time, (3) 
interaction contrast: (old, post) + (young, pre) – (old, pre) – (young, post), (4) 
effect of time in the young age group, and (5) effect of time in the old age group. 
I used Ingenuity Systems Interactive Pathway Systems complete a core analysis 
to identify cellular processes potentially being regulated by the miRNAs and 
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predicted miRNA-mRNA interactions for the 23 miRNAs identified for the 
above-mentioned contrasts. Stringency criteria included that the putative 
interactions needed to be ‘highly predicted’ by the software algorithm or 
‘experimentally observed’ in the literature. The miRNAs included in each 
analysis and the most highly ranked cellular functions likely to be regulated by 
each miRNA group are depicted in Table 3.6. The complete core analysis can 
be found in Appendix C. The analysis revealed that seven miRNAs within the 
five miRNA groups are predicted to regulate cellular growth and proliferation 
(p<0.05), namely miR-100, miR-146a-5p, miR-196a-5p, miR-199a-3p, miR-
489-3p, miR-99aand miR-99b-5p.
In addition, a list of predicted and validated mRNA targets for the 26 miRNAs
included in the analysis was generated using Ingenuity software prediction 
algorithms. The genes known to regulate MPS were then selected for the 
pathway analysis, and figures were generated to illustrate the predicted 
regulatory differences in the MPS signalling cascades between young and old 
subjects (Figure 3.6). MiR-99a, miR-99b, miR-100, miR-149-3p, miR-186-5p
and miR-199a all have validated gene targets within the MPS pathway 
(indicated by red arrows).
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Table 3.6 Top predicted cellular functions for differentially regulated miRNAs
MiRNA
group MiRNAs Molecular and cellular functions
M
ai
n 
ef
fe
ct
 o
f 
ag
e
miR-146a-5p
Cellular function and maintenance
Cellular development
Cell death and survival
miR-191-5p
miR-320a
miR-483-5p
miR-539-5p
miR-628-5p
M
ai
n 
ef
fe
ct
 
of
 e
xe
rc
is
e
miR-339-3p
Cellular assembly and organisation
miR-483-5p
miR-515-5p
miR-574-5p
miR-935
In
te
ra
ct
io
n 
co
nt
ra
st miR-100
Cell cycle
Cellular development
Cellular growth and proliferation
DNA replication, recombination and repair
miR-149-3p
miR-196b
miR-486-3p
miR-489-3p
miR-494-3p
miR-499
Po
st
 v
 p
re
 in
 
yo
un
g 
su
bj
ec
ts
miR-149-3p Cell cycle
Cellular development
Cellular growth and proliferation
Cell death and survival
DNA replication, recombination and repair
miR-486-3p
miR-518b
miR-520g-3p
miR-99b
Po
st
 v
 p
re
 in
 o
ld
 
su
bj
ec
ts
miR-186-5p
Cellular development
Cellular growth and proliferation
Cell cycle
DNA replication, recombination and repair
miR-196b
miR-335-5p
miR-499
miR-628-5p
miR-99a
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Figure 3.6 Ingenuity Pathway Analysis of microRNAs predicted to regulate muscle 
protein synthesis. MicroRNAs predicted to target mRNAs within the muscle protein synthesis 
pathways in (A) post versus pre in young and (B) post versus pre in old subjects. Gene targets 
included in figure are known regulators of muscle protein synthesis.
3.3.5 Gene and Protein Levels of Validated MicroRNA Targets
Following the bioinformatics analysis, the mRNA and proteins levels of mTOR, 
RPTOR, IGF-1R, Akt and Foxo-1, which are validated targets of miR-99a, 
miR-99b, miR-100, miR-149-3p, miR-196 and miR-199a, were measured. Akt 
protein expression was elevated in the old subjects when compared to the young 
subjects (p<0.05) (Figure 3.7A). No significant effect of age and/or exercise 
was found for any of the remaining mRNA or proteins measured
(Supplementary Figure S3.7).
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Figure 3.7 Expression levels of total Akt and phospho-AktSer473 protein in young and old 
following exercise. Differences in total Akt levels in all subjects (A) and in phospho-AktSer473
levels in young (B) and old (C) subjects 2 h post exercise. Fold change is shown for individual 
subjects. †Significant effect of age (p<0.05). *Significantly different from pre (p<0.05).
C
0
1
2
3
4
5
Pre
Post
p-
A
kt
(S
er
47
3)
/G
A
PD
H
[A
U
]
B
Young 
1
Pre
Young 
1
Post
Young 
2
Pre
Young
2
Post
p-Akt
0.0
0.5
1.0
1.5
2.0
Pre
Post
p-
A
kt
(S
er
47
3)
/G
A
PD
H
[A
U
]
*
GAPDH
A Young 
Pre
Young 
Post
Old 
Pre
Old
Post
Akt
Yo
un
g
Ol
d
0
2
4
6
Pre
Post
A
kt
/G
A
PD
H
[A
U
]
†
GAPDH
Old 
1
Pre
Old
1
Post
Old 
2
Pre
Old
2
Post
p-Akt
GAPDH
- 63 -
3.3.6 Validation of Akt-mTOR Signalling Pathway Activation in Young 
and Old Subjects Following an Acute Bout of Resistance Exercise
Western blots were performed to determine if the members of the Akt-mTOR 
signalling pathway were activated through phosphorylation with the exercise 
bout. 2-way ANOVA showed no significant change in the expression levels of 
phospho-Akt , phospho-p70 S6 Kinase, phospho-4E-BP1 and phospho-mTOR 
with age and/or exercise. However, individual t-tests revealed an increase in 
Akt phosphorylation following exercise in the young subject group only 
(p<0.05) (Figure 3.7B and 3.7C).
3.4 Discussion
Age-related muscle wasting is the natural and progressive loss of skeletal 
muscle mass and function that occurs with age. It results in severe impairments 
in strength, mobility, balance and endurance, and consequently, in decreased 
independence and quality of life in the elderly. Age-related muscle wasting is 
partially due to an attenuated activation of protein synthesis in response to 
resistance exercise (Kumar et al. 2009). The signalling proteins of the Akt-
mTOR pathway, one of the major signalling pathways driving MPS (Russell 
2010), are aberrantly expressed in skeletal muscle of elderly subjects when 
compared to young subjects (Drummond et al. 2008a; Fry et al. 2011; Kumar 
et al. 2009; Léger et al. 2008). However, the origin of this dysregulation is 
unknown. The aim of this study was to measure and compare the expression 
levels of miRNA species in young and old subjects at rest and following a 
resistance exercise protocol designed to maximise MPS. A secondary aim was 
to use statistics and bioinformatics analyses to identify miRNAs that may 
contribute to age-related muscle wasting by targeting members of the Akt-
mTOR signalling pathway. This study identified 26 miRNAs that were 
regulated with age and/or exercise. Of these, 7 miRNAs were differentially 
regulated by age and exercise, and a further 7 miRNAs were regulated 
following exercise in either young or old subjects. Five of these 14 miRNAs
have been identified as aberrantly expressed in several muscle disorders such 
as Duchenne muscular dystrophy and Myoshi myopathy (Eisenberg et al. 
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2007). Bioinformatics analysis predicted seven of these miRNAs to regulate 
cellular growth and proliferation pathways. Specific mRNA target prediction 
also revealed that nine of these miRNAs are potentially direct regulators of 
members of the Akt-mTOR signalling pathway. Six of these miRNAs, miR-
99a, miR-99b, miR-100, miR-149-3p, miR-196 and miR-199a, have been 
previously validated to target several mRNAs that encode proteins within the 
protein synthesis pathways in different types of cells (Doghman et al. 2010;
Fornari et al. 2010; Hou et al. 2014; Jin et al. 2013; Lerman et al. 2011; Lin, 
Lin & Yu 2010; Wei et al. 2013). Of particular interest, miR-99a, miR-99b and 
miR-100, members of the miR-99/100 family, share the same seed region and 
KDYHYDOLGDWHGWDUJHWVHTXHQFHVZLWKLQWKHމ875VRIP72553725 and IGF-
1R (Doghman et al. 2010; Jin et al. 2013; Lerman et al. 2011; Wei et al. 2013).
In addition miR-DWDUJHWVWKHމ875 of IGF-1 and mTOR (Fornari et al. 
2010; Jia et al. 2013), while miR-149-3p and miR-196 targeW WKHމ875RI
Akt1 (Lin, Lin & Yu 2010) and Foxo-1 (Hou et al. 2014), respectively. These 
studies also demonstrated concomitant decreases or increases in the protein, and 
in some cases the mRNA, levels of the respective targets following the 
transfection of microRNA mimics or inhibitors, respectively. The mode of 
inhibition of miRNAs LVODUJHO\GHSHQGHQWRQLWVELQGLQJFDSDFLW\WRWKHމ875
(Brennecke et al. 2005). Interestingly, transfection of miR-99a in PHK and 
HaCaT cells results in a decrease in IGF-1R protein but not mRNA expression, 
while transfection of miR-99b and miR-100 into HaCaT cells decreased IGF-
1R at both the mRNA and protein level. All 3 miRNAs share a common seed 
region and therefore a common binding site within the IGF-5މ875DQG
presumably inhibit the target in the same way. There was a significant increase 
in total Akt protein in the older cohort when compared to the young cohort. Akt 
is a direct target of miR-149-3p which was significantly downregulated with 
exercise in the young subjects only. Although no correlation could be made 
between miR-149-5p expression and Akt expression, elevated Akt expression 
in old skeletal muscle is not without precedent in the literature (Léger et al. 
2008).No changes were ibserved in the mRNA and protein expression levels of 
mTOR, RPTOR, IGF-1R and Foxo-1. A similar case has previously been 
reported where differences in miRNA expression in healthy and unhealthy 
- 65 -
muscle tissue were not followed up by differences in the expression of protein 
targets (Gallagher et al. 2010). miRNA regulation of mRNA targets is time-
dependent (Hausser et al. 2013) and may explain why no change was observed 
in mRNA and protein expression 2 hours following an acute exercise bout. It is 
possible that changes in these miRNAs may result in the regulation of their 
targets at a later time point post exercise, however such a temporal response 
requires further investigation. Interestingly, the individual expression patterns 
of miR-99a, miR-99b and miR-100 demonstrate some inconsistencies, and this 
suggests an added degree of complexity with respect to the mode of activity of 
miRNAs. Based on the currently understood principles of target binding, it 
could be expected that these 3 miRNAs are interchangable (Brennecke et al. 
2005). However, in vitro studies have demonstrated that manipulating the 
expression of these miRNAs individually is sufficient to induce changes in 
target mRNA and/or protein expression without a compensatory/rescuing effect 
of the other miRNAs (Doghman et al. 2010; Jin et al. 2013; Lerman et al. 2011;
Wei et al. 2013). How the overall expression of the miR-99/100 family of 
miRNAs affects target mRNA/protein expression in this study is not clear. The 
differential regulation within and between miRNAs sharing a common seed 
region suggests a multifaceted mode of regulation of mRNA targets.
Muscle enriched miRNAs (myomiRs), miR-1, miR-133a, miR-133b, miR-206, 
miR-486-5p and miR-499 were amongst the most highly expressed miRNAs.
With the exception of miR-499, the expression of these miRNAs was not 
altered with exercise or age. One study has investigated the expression of the 
myomiRs miR-1, miR-133a and miR-206 following an acute bout of resistance 
exercise in the skeletal muscle of young and old subjects. Drummond et al. 
reported a decrease in miR-1 expression with a concomitant increase in protein 
synthesis 3 and 6 hours post exercise and ingestion of an essential amino acid 
(EAA) solution in young subjects only (Drummond et al. 2008b). This study 
also reported a delayed increase in protein synthesis in old subjects 6 hours post 
exercise with no change in miR-1 expression (Drummond et al. 2008a;
Drummond et al. 2008b). A regulatory feedback process exists between miR-1
and IGF-1, an upstream regulator of Akt-mTOR, where miR-1 can directly 
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target and inhibit IGF-1 and IGF-1 signalling can inhibit miR-1 expression (Elia 
et al. 2009). Our study demonstrates that miR-1 was not regulated by resistance 
exercise alone 2 hours post exercise. The regulation of miR-1 may be subject 
to EAA availability during MPS as it is also responsive to EAA ingestion alone 
(Drummond et al. 2009). The combined effects of resistance exercise and EAA 
ingestion may also be required for the regulation of other myomiRs, but this is 
yet to be investigated.
Another study investigated the change in 60 muscle miRNA expression 
following an acute bout of resistance exercise (Rivas et al. 2014). This study 
found 17 miRNAs that were reduced 6 hours after an acute resistance exercise 
bout in young subjects only. In contrast I found 13 miRNAs that were either 
upregulated or downregulated in both young and old subjects 2 hours after acute 
exercise. Members of the Akt-mTOR signalling pathway where predicted 
targets for both sets of miRNAs. Overall, these studies suggest a dynamic 
regulation of miRNAs in skeletal muscle following resistance exercise and 
reveal the important role of miRNAs in the regulation Akt-mTOR signalling. 
Determining how these miRNAs might impact on the adaptive response of 
skeletal muscle to exercise will be essential in understanding the mechanisms 
of skeletal muscle growth and age-related muscle wasting.
miR-486-3p originates from the opposite arm of miR-486-5p, a recognised 
myomiR, and was differentially regulated with age and exercise. MiR-486-3p 
expression was downregulated in old subjects when compared to young 
subjects and upregulated in young subjects only following exercise. MiR-486-
3p has predicted targets within the MPS pathway, including several eukaryotic 
initiation factors (eIFs), RPTOR and TSC-1. The miR-486 stem-loop sequence 
is embedded within the Ankyrin-1 gene and is positively regulated by MRTF-
A and SRF (Small et al. 2010), two important regulators of muscle function. 
The differential regulation of miR-486-3p in young and old subjects may reflect 
an attenuated activity of the MRTF-A/SRF axis with age (Lamon, Wallace & 
Russell 2014). In contrast, no change was observed for miR-486-5p expression, 
suggesting that miR-486-3p and miR-486-5p expression are regulated 
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independently of each other at the post-transcriptional level. This is not without 
precedent, as differential expression of other sense and antisense miRNA pairs 
have been described when comparing metastatic and non-metastatic prostate 
cancer tissue (Watahiki et al. 2011).
miR-199a-3p and miR-199a-5p provide another example of differential 
expression of sense and anti-sense miRNA pairs. MiR-199a-3p expression was
significantly higher (p<0.05) in old subjects when compared to young subjects 
in the post exercise biopsies. On the other hand, miR-199a-5p was either 
minimally expressed or not expressed in both young and old subjects. The 
expression of miR-199a-5p in healthy adult skeletal muscle has been reported 
as low relative to disease tissue (Eisenberg et al. 2007). Two stem-loop 
sequences exist for miR-199a, which originate from the dynamin 2 and 
dynamin 3 genes. miR-199a-3p is upregulated during differentiation of 
myoblasts isolated from patients with Duchene Muscular Dystrophy (DMD) 
(Alexander et al. 2013). Overexpression of miR-199a-3p in C2C12 myoblasts 
inhibits differentiation and is associated with a decrease in Myf5, MyoD, 
myogenin and myosin heavy chain (MHC) (Jia et al. 2013). On the other hand, 
inhibition of miR-199a-3p expression results in an increase in both myogenin 
and MHC as well as myotube hypertrophy (Jia et al. 2013). This occurred with 
a concomitant increase in the protein levels of its validated targets IGF-1 and 
mTOR and a decrease in MuRF-1 protein; the latter a regulator of protein 
degradation (Witt et al. 2005). Our group has previously reported a significant 
increase in MuRF-1 mRNA, but not protein, in the muscle samples from the 
subjects in the present study (Stefanetti et al. 2014). The increase in miR-199a-
3p in old subjects may be a factor contributing to an increase in MuRF-1 mRNA 
expression in older subjects.
The loss of skeletal muscle mass in the elderly occurs in parallel with numerous 
impairments, including a loss of regenerative capacity (Carlson et al. 2001) and 
a reduced ability to maintain/replenish adenosine triphosphate (ATP) levels 
during exercise (Coggan et al. 1993). In addition to the miRNAs regulated by 
resistance exercise, I identified several miRNAs displaying differential 
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expression levels at rest in young and old subjects. Understanding the potential 
role of miRNAs in the onset and progression of age-related muscle dysfunctions 
is of major interest. The let-7 family of miRNAs is associated with ageing in 
Caenorhabditis elegans and humans (Drummond et al. 2011; Ibáñez-Ventoso 
et al. 2006). At rest, let-7b was upregulated in old subjects when compared to 
young subjects. Drummond et al. previously reported an upregulation in the 
expression levels of let-7b and let-7e, both belonging to the let-7 family of 
miRNAs, in skeletal muscle biopsy samples of old subjects (Drummond et al. 
2011). Expression levels of let-7b are associated with a negative regulation of 
the cell cycle. Drummond et al. demonstrated a concomitant decrease in the cell 
cycle regulators CDK6, CDC25A and CDC34 in old subjects, which might 
provide an explanation for reduced regeneration capacity. On the other hand 
Rivas et al. found a decrease in let-7f expression in elderly skeletal muscle and 
no difference in any other let-7 miRNAs (Rivas et al. 2014). More research is 
required to elucidate the role of let-7 miRNAs in the reduced regenerative 
capacity of aged skeletal muscle.
miR-320a is another miRNA that was elevated in the old subjects. MiR-320a 
activity is linked to glycolysis by directly downregulating phosphofructokinase, 
the rate limiting glycolytic enzyme (Tang et al. 2012). miR-320a expression is 
decreased in tissues and cells characterised by increased glycolysis, including 
lung cancer tissue, disused diaphragm and C2C12 myotubes subjected to 
oxidative stress (Tang et al. 2012). While an impairment in glycolysis has been 
demonstrated in elderly subjects (Coggan et al. 1993), the reasons for this 
dysregulation remain unclear. By negatively regulating a critical enzyme of the 
glycolysis pathway, elevated endogenous levels of miR-320a may therefore 
account for a decreased capacity of the glycolytic system in the elderly.
In this study I sought to determine if there were any impairments in the Akt-
mTOR signalling pathway in the old subject group when compared to the young 
subjects group. With regards to the expression levels of the molecular markers 
of protein synthesis, no differences were observed in the phosphorylation levels 
of the selected proteins with exercise and/or age; with the exception of phospho-
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Akt, that was elevated in most of the subjects post exercise (figure 7a), but 
reached statistical significance when considering the young subject cohort only. 
It is possible that the phosphorylation levels of these proteins may have returned 
to baseline by 2 hours post exercise as observed previously by others (Dreyer 
et al. 2008; Kumar et al. 2009). It must also be acknowledged that the old cohort 
may not be representative of the average elderly population in terms of physical 
activity levels and fitness levels; a problem faced by many exercise-based trials. 
Whilst this study only sought to investigate the expression levels of miRNAs in 
skeletal muscle 2 hours following exercise, when MPS is maximised in the 
subjects (Kumar et al. 2009), a time course analysis of miRNA expression 
following resistance exercise may be more informative as to the degree of 
regulation of Akt-mTOR signalling by miRNAs. I also observed elevated total 
Akt levels in the old subjects, a finding previously observed by our group 
(Léger et al. 2008). This increase in total Akt indicates a reduced efficiency of 
the old subjects to phosphorylate the available Akt pool following the resistance 
exercise bout.  Finally, there was a tendency (p<0.1) for the myostatin protein, 
an inhibitor of Akt signalling and therefore a negative regulator of muscle mass, 
to be elevated in the muscle from the older cohort (data not shown) when 
compared to the younger subjects; an observation reported previously (Léger et 
al. 2008; Welle et al. 2002).
The purpose of the discriminant analysis in the present study was to 
categorically group subjects into a young and old age group based on miRNA
expression. A discriminant analysis with miR-196a-5p, miR-518b, miR-935 
and miR-500a-5p misclassified one young and one old subject into the opposite 
age group. No previous studies have investigated the role of these miRNAs in 
skeletal muscle or age. miR-196a-5p had a significant interaction contrast and 
was found to be down regulated post exercise in the old subjects. MiR-518b 
was upregulated in young subjects following exercise while miR-935 was 
significantly downregulated post exercise in all subjects. Finally, miR-500a-5p 
was found to be upregulated in old subjects when compared to young subjects. 
Only miR-196a-5p had predicted targets within the Akt-mTOR pathway. 
Notably, miR-196a-5p downregulation has been linked to an upregulation in 
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TGF-ȕVLJQDOOLQJ LQFXWDQHRXV V\VWHPLF VFOHURVLV (Honda et al. 2012). MiR-
196a-5p regulates type I and II collagens, which are involved in the enrichment 
of the extracellular matrix (ECM) (Kashiyama et al. 2012). Elevated TGF-ȕ
signalling and ECM enrichment has been previously reported in elderly subjects 
and has been linked to the reduced regenerative capacity of muscle satellite cells 
(Carlson, Hsu & Conboy 2008; Williamson et al. 2003). However, the link 
between miR-196a-5p and satellite cell regeneration is yet to be investigated.
In this chapter I identified 26 miRNAs that were differentially regulated with 
age and/or exercise following an acute resistance exercise bout completed by 
young and old subjects. A subset of these miRNAs were predicted or have been 
previously associated with MPS and muscle regeneration. Further functional 
investigations that are beyond the scope of this study are required to determine 
the nature of the interactions between these miRNAs of interest and their 
targets. In addition, a time course pattern of miRNA and mRNA expression 
analysis may provide more clarity on the role and regulation of miRNAs in 
response to exercise in young and older individuals.
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3.5 Supplementary Figures
Figure S3.1 Volcano plot for the main effect of age. This volcano plot depicts interaction contrast 1, main effect of age. The red points correspond to miRNAs with a Ct<32. 
The black points correspond to miRNAs ZLWK&W6WDWLVWLFDOVLJQLILFDQFHZDVVHWDW3FRUUHVSRQGLQJWR–log10(P value)=1.3 on the y-axis and is represented by the 
dashed line plotted perpendicular to the y-axis. The dashed lines perpendicular to the x-axis represent a fold-change of 2 corresponding to log2(fold change)=1 on the x-axis.
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Figure S3.2 Volcano plot for the main effect of time. This volcano plot depicts interaction contrast 2, main effect of time. The red points correspond to miRNAs with a 
Ct<32. The black points correspond to miRNAs ZLWK&W6WDWLVWLFDOVLJQLILFDQFHZDVVHWDW30.05 corresponding to –log10(P value)=1.3 on the y-axis and is represented by 
the dashed line plotted perpendicular to the y-axis. The dashed lines perpendicular to the x-axis represent a fold-change of 2 corresponding to log2(fold change)=1 on the x-
axis.
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Figure S3.3 Volcano plot for the effect of time in the young age group. This volcano plot depicts interaction contrast 4, effect of time in the young age group. The red points 
correspond to miRNAs with a Ct<32. The black points correspond to miRNAs ZLWK&W6WDWLVWLFDOVLJQLILFDQFHZDVVHWDW3FRUUHVSRQGLQJWR–log10(P value)=1.3 on 
the y-axis and is represented by the dashed line plotted perpendicular to the y-axis. The dashed lines perpendicular to the x-axis represent a fold-change of 2 corresponding to 
log2(fold change)=1 on the x-axis.
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Figure S3.4 Volcano plot for the effect of time in the old age group. This volcano plot depicts interaction contrast 5, effect of time in the old age group. The red points 
correspond to miRNAs with a Ct<32. The black points correspond to miRNAs ZLWK&W6WDWLVWLFDOVLJQLILFDQFHZDVVHWDW3FRUUHVSRQGLQJWR–log10(P value)=1.3 on 
the y-axis and is represented by the dashed line plotted perpendicular to the y-axis. The dashed lines perpendicular to the x-axis represent a fold-change of 2 corresponding to 
log2(fold change)=1 on the x-axis.
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Figure S3.5 Volcano plot for the effect of age at the level of pre. This volcano plot depicts interaction contrast 6, effect of age at the level of pre. The red points correspond 
to miRNAs with a Ct<32. The black points correspond to miRNAs ZLWK&W6WDWLVWLFDOVLJQLILFDQFHZDVVHWDW30.05 corresponding to –log10(P value)=1.3 on the y-axis 
and is represented by the dashed line plotted perpendicular to the y-axis. The dashed lines perpendicular to the x-axis represent a fold-change of 2 corresponding to log2(fold 
change)=1 on the x-axis.
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Figure S3.6 Volcano plot for the effect of age at the level of post. This volcano plot depicts interaction contrast 6, effect of age at the level of post. The red points correspond 
to miRNAs with a Ct<32. The black points correspond to miRNAs ZLWK&W6WDWLVWLFDOVLJQLILFDQFHZDVVHWDW3FRUUHVSRQGLQJWR–log10(P value)=1.3 on the y-axis 
and is represented by the dashed line plotted perpendicular to the y-axis. The dashed lines perpendicular to the x-axis represent a fold-change of 2 corresponding to log2(fold 
change)=1 on the x-axis
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Figure S3.7 Western blot bands of proteins directly targeted by identified miRNAs as assessed by IPA. Western blot bands for total Akt (A), total mTOR (B), total 
RPTOR (C) and total IGF1R (D) and the corresponding GAPDH loading control..
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CHAPTER 4
OPTIMISATION FOR CELL CULTURE EXPERIMENTS
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4. OPTIMISATION FOR CELL CULTURE EXPERIMENTS
4.1 Introduction
In vitro and in vivo functional analysis of specific miRNAs is critical for 
establishing direct cause-and-effect relationships between miRNAs and 
positive or negative cellular adaptations. Modulation of miRNAs has a 
profound effect on the specific protein pool in a given tissue (Selbach et al. 
2008). miRNAs regulate specific proteins by targeting their mRNAs and either 
signalling for the degradation of the mRNA or temporarily suppressing protein 
translation (Brennecke et al. 2005; Hu & Bruno 2011). It is estimated that 
miRNAs can regulate up to a third of the mRNA pool (Beitzinger et al. 
2007).Therefore miRNAs represent crucial targets for selective modulation of 
cellular processes. 
Age-related muscle wasting is a significant health issue individuals and a
significant burden on global health care systems. Age-related muscle wasting 
is linked to a loss of independence, reduced quality of life and mortality. 
Understanding the onset and progression of this loss of skeletal muscle mass is 
critical for the development of innovative therapies to combat this issue. One 
mechanism contributing to age-related muscle wasting is a reduced efficiency 
for elderly muscle to maximally synthesise protein in response to an anabolic 
stimulus (Kumar et al. 2009). The first study of this thesis allowed the 
identification of a number of miRNAs that were regulated with age and protein 
synthesis-stimulating exercise and linked to protein synthesis pathways via 
bioinformatics analysis. Two miRNAs, miR-99b and miR-499, were observed 
to be dysregulated in Chapter 3 and selected for the second and third studies to 
validate if they may directly downregulate muscle protein synthesis pathways 
in human muscle cells. Bioinformatics analysis predicted mTOR, RPTOR and 
IGF1R as specific miR-99b targets and eIF4G2 as a specific target for miR-
499. These 4 proteins are critical regulators of muscle protein synthesis (Bodine 
et al. 2001b; Pyronnet et al. 1999; Rommel et al. 2001).
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To address this question miR-99b and miR-499 were specifically overexpressed 
in human primary myotubes and in vitro protein synthesis was the main 
outcome measure. I also sought to establish a direct binding intereaction 
between the selected miRNAs and their predicted targets. This chapter 
describes the optimisation steps that were taken to establish the ideal conditions 
for specific miRNA transfection and reporter assay analysis.
4.2 Methods and Results
4.2.1 Optimisation of Transfection Conditions for miR-99b and miR-
499 Mimics in Human Primary Myotubes
Human primary myotubes were grown as described in section 2.4. The specific 
miR-99b and miR-499 miRNA mimics (mirVanaTM miRNA mimic, Life 
technologies, Mulgrave, Australia) and a mimic scramble sequence 
(mirVanaTM miRNA mimic, negative control #1, Life technologies, Mulgrave, 
Australia) were transfected as described in section 2.6. The expression levels of 
the two mimics were measured at 0.1 nM, 1.0 nM, 5.0 nM and 20.0 nM 
concentrations 24 and 48 hours following transfection. Transfection efficiency 
was determined by the intracellular expression of the miRNAs of interest 
compared to the scramble control, compared to myotubes exposed to the 
transfection medium only and non-transfected wild type (wt) myotubes
normalised to U6 snRNA expression. 
Table 4.1 shows the miR-99b expression for cells transfected with miR-99b
miRNA mimic. miR-99b overexpression was most efficient using 20.0 nM 
miR-99b mimic concentration when measured 24 hours post transfection. With 
this dose and duration there was a 6.6-fold increase in miR-99b expression 
within the myotubes when compared to the scramble. There was no specific 
effect of the transfection medium or scramble on miR-99b expression when 
compared to non-transfected wt myotubes.
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Table 4.1 Expression levels of miR-99b in human primary myotubes
Wt siPORT Scramble Mimic-99b
Conc 
(nM)
24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h
0.1
0.95 0.83 1.07 1.15 0.76 1.16 0.83 0.99
1.05 1.00 1.02 0.85 1.19 1.04 1.07 1.17
1.0
0.97 1.16 0.80 0.34
1.00 1.08 1.35 1.05
5.0
1.22 1.16 1.14 0.23
0.88 0.30 1.92 2.48
20.0
1.18 1.22 6.16 3.58
1.12 1.25 5.71 4.57
Values are fold-change from 24 h wt values
miR-499 expression values are shown in table 4.2. miR-499 overexpression was 
most efficient using 20.0 nM miR-499 mimic concentration. miR-499 was 
overexpressed 428-fold and 586-fold in the myotubes at the 24 and 48 h time 
points, respectively, when compared to the scramble. There was specific effect 
of the transfection reagent and the scramble on miR-499 expression when 
compared to non-transfected wt myotubes. 
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Table 4.2 Expression levels of miR-499 in human primary myotubes2
Wt siPORT Scramble Mimic-99b
Conc 
(nM)
24 h 48 h 24 h 48 h 24 h 48 h 24 h 48 h
0.1
0.87 2.41 1.38 2.21 1.33 2.36 2.31 1.54
1.13 1.33 1.69 2.05 1.79 2.46 2.51 1.23
1.0
2.36 1.64 4.05 5.44
1.49 1.69 7.33 4.26
5.0
0.92 - 84.62 25.95
1.28 1.69 36.05 52.46
20.0
2.21 1.74 644.82 782.92
1.74 0.92 799.38 915.08
Values are fold-change from 24 h wt values
4.2.2 Optimisation of Lenti-virus Vectors for Reporter Assays
Lenti-virus vectors to be used to confirm specific binding interactions between
miR-EDQGWKHP725މ875DQGPL5-DQGWKHH,)*މ875ZHUH
purchased from ABM (British Columbia, Canada). Also including within this 
chapter are the results from a third set of lenti-virus vectors containing the SRF 
މ875 D EODQN Luc (luciferase) lenti-virus vector and a blank GFP (green 
fluorescent protein) lenti-virus vector. The details and annotation for each 
vector can be found in table 4.3. The specific P725DQGH,)*މ875DQG
PXWDWHGމ875VHTXHQFHVFORQHGLQWRWKHUHVSHFWLYHYHFWRUVFan be found in 
appendix D. A schematic representation of the lenti-virus vector is depicted in 
Figure 4.1. The viruses were stored at -Û&8SRQWKHILUVWWKDZF\FOHWKHYLUXV
was aliquoted. All experiments were performed with viruses that have 
undergone no more than 2 thaw cycles. 
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Table 4.3 Specifications for lenti-virus vectors
Target 
މ875
Name Catalogue # In-text 
reference
N/A
Lenti-UTR-GFP-Blank Virus m015 GFP vector
Lenti-UTR-Luc-Blank Virus m013 Luc vector
mTOR
0725މ875/HQWL-reporter-
Luc Virus
MV-h14922 Vector A
0725PXWDWHGމ875/HQWL-
reporter-Luc Virus
MV-h14922-
MUT
Vector B
eIF4G2
(,)*މ875/HQWL-reporter-
Luc Virus
MV-h06793 Vector C
(,)*PXWDWHGމ875/HQWL-
reporter-Luc Virus
MV- h06793-
MUT
Vector D
SRF
65)މ875/HQWL-reporter-Luc 
Virus
MV-h24580 Vector E
65)PXWDWHGމ875/HQWL-
reporter-Luc Virus
MV- h24580-
MUT
Vector F
Figure 4. 1 Schematic representation of the lenti-virus vector. LTR, long term repeats; CMV 
prom., cytomegalovirus promoter; Luc, luciferase; MCS, multiple cloning site; SV40 prom. 
Simian Virus 40 promoter; Puror, puromycin resistance; Rep. origin, replication origin’ 
Kanr,Kanamycin resistance
ϱ഻>dZ CMV prom. Luc MCS
SV40 prom
.
Rep. origin ϯ഻>dZ Puror
Ka
nr
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4.2.3 Optimisation with the GFP Vector
First the GFP vector was used to ensure that the cells could be infected with the 
virus system. All optimisations were performed in human primary myoblasts. 
Briefly, cells were maintained as described in section 2.4. At approximately 
50% confluence the cells were infected with the GFP vector at the following 
doses: 101, 102, 103, 104 and 105 inf/mL (infectious units/mL) with 2 μg/mL of 
polybrene. The cells were then centrifuged at 1800 rpm for 45 minutes at room 
temperature then incubated overnight. The virus was removed the following 
morning and GFP was observed 48 h later. Cell images were taken with an 
Olympus 1X-70 fluorescent microscope (Olympus, North Ryde, Australia) and 
Magna Fire camera (Olympus, North Ryde, Australia) and NIS-Elements D 
software (Nikon)
Figure 4.2 shows the representative images for GFP expression against phase 
contrast images of the cells. GFP expression was detectable at a doses of 103-
105 inf/mL virus. These results confirmed that the cells could be infected by the 
virus and so I proceeded to optimise the luciferase reporter assay.
Figure 4.2 Human primary myoblasts infected with Lenti-UTR-GFP-Blank Virus. Phase 
contrast images, GFP expression (green) and phase contrast merged with GFP for human 
prmary myoblasts infected with GFP vector at virus doses of 103, 104 and 105 inf/mL. A 
minimum of 5 images per treatment group were taken at 20X magnification.
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4.2.4 Optimisation of the Luc Vector
I repeated the protocol as described in section 4.2.3 using the empty Luc vector 
in 96-well plates. Luminescence was measured using the BioTek Synergy 2 
Multi-mode microplate reader (BioTek, Winooski, USA). Sensitivity settings 
were set to maximum (255 (AU)). Figure 2 shows the luminescence levels for 
Luc vector delivered to the cells for the virus dose response at 5*101, 5*102, 
5*103, 5*104 and 5*105 inf/ml. After 48 h cells were washed with 1X PBS then 
incubated in Cell Lysis Buffer (ABM, BC, Canada) for 20 minutes. An equal 
volume of Luciferase Assay Reagent (ABM, BC, Canada) was added to each 
well. Luminescence was measured immediately. Luminescence was compared 
to wild type myoblasts and myoblasts exposed to polybrene only (0 inf/mL). It 
was determined that a minimum viral dose of 5*105 inf/ml was required to 
detect luminescence above background levels (>500 RLU, relative 
luminescence units) as recommended by Bio Tek (Figure 4.3).
Figure 4.3 Human primary myoblasts infected with Lenti-Luc-Blank Virus. Relative 
luciferase activity (RLU) of wt cells and 0 inf/mL virus compared to Luc vectors delivered at 
virus doses 5*101-5*105 inf/mL.
4.2.5 Luciferase Reporter Assay Test for the 3ү UTR Reporter Vectors
7KHމ875UHSRUWHUYHFWRUVYHFWRUV$&DQG(ZHUHWKHQWHVWHGDWDYLUXV
dose of 5*105 inf/mL as described in section 4.2.4. The luciferase assay was 
completed in conjunction with the CellToxTM Green Cytotoxicity Assay 
(Promega Madison, USA) according to the manufacturer’s protocol. The 
cytotoxicity assay was to serve as a control for the luciferase reporter assays, 
controlling for any cell death occurring due to the virus protocol. There was a 
large difference in viral infection efficiencies. Figure 4.4 A shows the 
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luminescence for vectors A and E measured at maximum sensitivity (255 AU). 
The luminescence for vector C was saturated at this sensitivity. The relative 
luminescence for Vector A was less than the lower limit of detection (LLOD) 
when compared to the background. Figure 4.4 B shows the luminescence for 
the 3 viral vectors at a reduced sensitivity set to 150 AU. Some cytotoxicity was 
detected in vectors A and E (>10000 RFU, relative fluorescence units, as 
recommended by Bio Tek), however, cytotoxicity was lower than the positive 
control where all the cells were lysed (Figure 4.4 C). No cytotoxicity was 
detected for vector C.
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Figure 4.4 &RPSDULVRQRIމ875UHSRUWHUYHFWRUVLQKXPDQSULPDU\P\REODVWV Relative 
luciferase activity for uninfected (0 inf/mL) cells, vector A, vector C and vector D delivered at 
a dose of 5*105 inf/mL virus at maximum sensitivity (A) and reduced sensitivity (B). (C) 
Relative cytotoxicity for vector A, vector C and vector D delivered at a dose of 5*105 inf/mL 
virus compared to uninfected cells and lysed cells (positive control). OVRFLW indicates that 
the relative luminescence units are outside the dynamic range.
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4.2.6 Comparison of Luciferase Reporter Assays in Myoblasts Seeded 
in 24-well and 96-well Plates
The luciferase activity for vector A was LLOD when compared to the 
background Therefore the Luc vector was tested in myocytes seeded in 24-well 
and 96-well plates to see if there was improved detection efficiency in the 24-
well plates when compared to 96-well plates. The virus doses tested were 104,
5*104 and 105 inf/ml. The protocol was followed as per section 4.2.4. To harvest 
the cells from the 24-well plates, the cells in the Cell Lysis Buffer and 
Luciferase Assay Reagent mixture were transferred to a 96-well plate for the 
luminescence reading. Figure 4.5 A shows that at the highest and most efficient 
virus dose there is no difference in luciferase activity between 24-well and 96-
well plates. A cytotoxicity assay was completed in conjunction with this test in 
a 96-well plate. No significant cytotoxicity was detected with the various virus 
doses (Figure 4B).
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Figure 4.5 Comparison of Lenti-UTR-Luc-Blank Virus in human primary myoblasts 
seeded in 24-well and 96-well plates. Relative luciferase activity for uninfected (0 inf/mL) 
cells and Luc vectors delivered at virus doses of 104-105 inf/mL (A). (B) Relative cytotoxicity 
levels for Luc vectors 104-105 inf/mL compared to uninfected cells and lysed cells (positive 
control).
4.2.7 Luciferase Reporter Assay Test in HEK-293 Cells
As there was no improvement to the luminescence readings using the up-scaled 
24-well protocol I decided to test the viruses in an easy to infect cell culture 
system. HEK-293 cells were seeded in 96-well plates and maintained in DMEM 
(Life technologies, Mulgrave, Australia) supplemented with 10% FBS (French 
bovine material, Bovogen, Keilor East, Australia). Infections were carried out 
as described in 4.2.5. Vectors A, B, E and F were compared to vector C and 
uninfected cells. Luminescence was measured at maximal sensitivity (255 AU). 
Figure 4.6 A shows that the luciferase activity for vectors A and B were below 
the LLOD when compared to the background levels. Vector E and F showed 
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higher luciferase activity, but the infection efficiency was not as high as vector 
C. No significant cytotoxicity was detected in any of the vector groups (Figure 
4.6 B).
Figure 4.6&RPSDULVRQRIމ875UHSRUWHUYHFWRUVLQ+(.FHOOV (A) Relative luciferase 
activity for uninfected (0 inf/mL) cells, vector A, vector B, vector C, vector E and vector F 
delivered at a dose of 5*105 inf/mL virus. (B) Relative cytotoxicity for vector A, vector B, 
vector C, vector E and vector F delivered at a dose of 5*105 inf/mL virus compared to 
uninfected cells and lysed cells (positive control).
4.3 Discussion and Conclusion
The aim of this chapter was to establish the optimal conditions for miR-99b and 
miR-499 mimic transfections and reporter assay for functional in vitro analysis 
in subsequent chapters. The miRNA mimic transfections were optimised in 
human primary myocytes by testing various mimic concentrations at 24 and 48 
hour time points. The miR-99b mimic was overexpressed in the myotubes at 
the 20 nM concentration at the 24 h time point. miR-99b overexpression 
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appears to drop off by the 48 h time point. For this reason I decided to use the 
miR-99b mimic at a 20 nM concentration and take all measures up to 24 hours 
for chapter 5 (Study 2). On the other hand miR-499 overexpression is visible at 
the 5 nM concentration, but further elevated at the 20 nM concentrations. MiR-
499 overexpression was maintained at both 24 and 48 hours. I decided to 
complete chapter 6 (Study 3) using the miR-499 mimic at a 20 nM 
concentration, focusing on the 24 hour time point. Future directions may 
include further investigations at later time points.
Optimisation of the reporter assay presented several technical issues. The 
lentivirus system was selected as it is efficient at infecting myocytes (Bonci et 
al. 2003; Jackson et al. 2013) , IRXQG WKDWYHFWRU& (,)*މ8TR Lenti-
reporter-Luc Virus) was most efficient at infecting the myocytes. This virus was 
used in chapter 6 (Study 3) to determine if there was a binding interaction 
between miR-499 and its predicted target eIF4G2. However, I found a large 
discrepancy in virus efficiencies between different vectors. First I confirmed 
that the virus could successfully infect the myocytes by observing GFP 
expression in the myoblasts following infection. I then tested a range of viral 
doses using the Luc vector to establish the ideal viral dose to detect luciferase 
activity at a reasonable level above background readings. It was determine that 
the maximal dose (5*105 inf/ml) was required for the most efficient infection. I 
SURFHHGHGWRWHVW WKHWKUHHމ875YHFWRUVDW WKHPD[LPal concentration and 
found a large degree of variation in infection efficiency. Vector C (EIF4G2 
މ875/HQWL-reporter-Luc Virus) infected the cells at an efficiency level greater 
than all the viruses (including the Luc vector virus). Luciferase activity was also 
VXIILFLHQW LQ YHFWRU( KRZHYHU YHFWRU$ 0725މ875/HQWL-reporter-Luc 
Virus), required for Study 2, showed luciferase activity that was below the 
LLOD when compared to the background levels. The reporter assay functions 
to show a reduction in luciferase activity should miR-މ875ELQGLQJVKRXOG
occur. For this reason it was deemed that the luciferase activity for baseline 
vector A was not sufficient to show a significant and measureable reduction in 
luciferase should the miRNA bind the reporter. Cytotoxicity assays confirmed 
that the reduced infection efficiency was not due to any elevated cell death 
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caused by the infection protocol. I then sought to determine if upscaling the 
assay to use a larger population of cells would improve luciferase activity levels 
when compared to the standard 96-well experiment. However, there was no 
improvement in luciferase activity levels in the up-scaled experiment when 
compared to the standard level experiment. Finally, to rule out a cell-specific 
cause for differences in virus infection efficiencies HEK-293 cells were 
employed to determine if luciferase activity was improved in an easy to 
maintain and easy to infect cell line. However, once again it was found that 
while vector C was very efficient at infecting the cells, vectors A, B, E and F 
showed similar relative luciferase activity to what was observed in the human 
myoblasts. Optimisations for the vectors A and B will continue into the future 
to supplement the publication of chapter 5. It is important to demonstrate direct 
miRNA binding to mRNA to explain cause-and-effect mechanisms and in the 
aim of producing targeted and specific therapeutic interventions for disease 
management. 
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CHAPTER 5
MICRORNA-99B DOWNREGULATES PROTEIN 
SYNTHESIS IN HUMAN PRIMARY MYOTUBES
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5. MICRORNA-99B DOWNREGULATES PROTEIN 
SYNTHESIS IN HUMAN PRIMARY MYOTUBES
5.1 Introduction
Sarcopenia is characterised by a significant loss of skeletal muscle mass and 
function that results in severe impairments in strength, mobility, balance and 
endurance. Healthy individuals naturally experience a 1-2% decrease in skeletal 
muscle mass per year from the age of 40 years (Cuthbertson et al. 2005).
Understanding the underlying molecular mechanisms behind this decline in 
skeletal muscle mass is essential to direct the development of targeted therapies. 
One reason for the loss of skeletal muscle mass is a reduced capacity for elderly 
muscle to sufficiently synthesise new proteins in response to anabolic stimuli 
such as resistance exercise (Kumar et al. 2009). The Akt-mTOR signalling 
pathway is an important regulator of muscle mass and is strongly associated 
with protein synthesis regulation (Bodine et al. 2001b; Kumar et al. 2009;
Rommel et al. 2001). mTOR is serine/threonine kinase responsible for initiating 
protein translation directly phosphorylating its downstream targets p70S6K and 
4EBP1 (Brunn et al. 1997; Ohanna et al. 2005). mTOR itself is indirectly 
regulated by a number of factors including hormones, growth factors and amino 
acids (Khamzina et al. 2005; Song et al. 2005; Yoshizawa et al. 1998). The total 
and phosphorylated levels of the Akt-mTOR signalling proteins undergo 
significant changes with age. In the skeletal muscle of old subjects, the 
expression of the growth factor IGF1 and the phosphorylation levels of the 
downstream targets Akt and p70S6K are reduced when compared to young 
subjects (Dennis 2008; Kumar et al. 2009; Léger et al. 2008). Negative 
regulators of protein synthesis including myostatin, GSKȕDQG(%3DUHDOVR
upregulated with age (Dennis 2008; Kumar et al. 2009; Léger et al. 2008).
Currently it is not clear how and why these changes are taking place.
MicroRNAs (miRNAs) are a highly conserved class of short, non-coding RNAs 
that can regulate protein expression by binding to specific mRNA targets and 
preventing their translation (Hu & Bruno 2011). Bioinformatics tools predict 
that up to a third of the mRNA pool has a miRNA target, however this number 
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may be grossly underestimated (Beitzinger et al. 2007). There is now a need to 
experimentally validate specific mRNA targets for known miRNAs. miRNAs
play an essential role in the molecular regulation of various cellular processes 
including protein synthesis (Selbach et al. 2008). Thus far a few studies have 
drawn correlations between miRNAs and muscle protein synthesis (Davidsen 
et al. 2011; Drummond et al. 2008b; Rivas et al. 2014; Zacharewicz et al. 2014)
but no direct links have yet been made. Of interest, one study used a cell culture 
model to demonstrate an inverse relationship between miR-126 and the IGF1 
signalling pathway, although without investigating the possible outcomes to 
cellular processes such a protein synthesis. 
For the first study of my PhD I performed a large-scale PCR-based miRNA
screen using skeletal muscle biopsy samples from young and old adults 
collected before and following an acute bout of resistance exercise designed to 
stimulate protein synthesis (Zacharewicz et al. 2014). Statistic and 
bioinformatics analysis revealed a number of miRNAs differentially regulated 
between young and old subjects and linked to regulators of Akt-mTOR 
signalling. One miRNA, miR-99b, was downregulated post exercise in young 
but not in old subjects. miR-99b is part of the miR-99/100 family of miRNAs
including miR-99a, miR-99b and miR-100. MiR-99b negatively regulates 
mTOR, mTOR’s regulatory associated protein RPTOR and IGF1R (a 
membrane receptor for IGF1) mRNA and protein expression in various tissue 
types, including cancer cells, macrophages and dermal cells (Chen et al. 2012;
Jin et al. 2013; Sun et al. 2011; Wei et al. 2013). Furthermore, a direct binding 
between miR-E DQG WKH P725 މ 875 KDV EHHQ REVHUYHG LQ PXULQH
macrophage cells, human prostate cancer cells and human cervical cancer cells 
(Sun et al. 2011; Wang et al. 2014; Wei et al. 2013). As miR-99b is a negative 
regulator of mTOR, its reduction following resistance exercise in the young 
subjects may remove the inhibitory effect on mTOR expression, allowing it to 
activate signals required to activate muscle protein synthesis.
Presently, the role of miR-99b as a regulator of muscle protein synthesis has 
not been investigated. Furthermore the relationship between miR-99b and its 
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predicted targets that regulate muscle protein synthesis have not been made in 
skeletal muscle. The aim of this study was therefore to determine if miR-99b 
overexpression could repress protein synthesis in human primary myotubes and 
provide proof-of-concept for its potential role in skeletal muscle mass 
regulation. A secondary aim was to determine if miR-99b could regulate the 
Akt-mTOR signalling pathway in human primary muscle cells.
5.2 Methods
5.2.1 Primary Cell Lines and Fusion Index
Human primary cell lines were established from the muscle biopsies of 3 young 
(23.5±5.0 y.o.) subjects and 3 old (64.6±4.0 y.o.) subjects as outlined in section 
2.3 and maintained as per section 2.4. The fusion index was established as per 
section 2.5 to ensure a myogenic population of cells was present in all the cell 
lines.
5.2.2 MicroRNA Transfection
On the 7th day of differentiation myotubes were transfected with either 20 μM 
of miR-99b mimic (mirVanaTM miRNA mimic, Life Technologies) or 20 μM 
of a mimic scramble sequence (mirVanaTM miRNA mimic, negative control #1, 
Life Technologies) according to section 2.6. Protein synthesis and degradation 
assays were performed as described in section 2.7 and 2.8 respectively. Protein 
synthesis was also measured during the 8 h transfection period. RNA was 
collected every hour for the first 8 hours and then every 2 hours up to 24 hours 
after the onset of transfection. Time course measures from 0-22 hours were only 
performed in 1 cell line. Measures at the 24 h time point were made in all cell 
lines. Protein was collected at the 24 h time point only Figure 5.1 depicts an 
experimental timeline for the miRNA transfections with the harvest points 
outlined. 
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Figure 5.1 Experiment timeline for miR-99b functional analysis. Human primary myotubes 
were transfected for 8 hours with either 20 μM of miR-99b mimic or 20 μM of scramble control 
sequence. Protein synthesis and degradation were measured by either the incorporation or 
release of 3H-tyrosine, respectively, during the 16 h period following transfection. Protein 
synthesis was also measured during the 8 h transfection period. RNA was collected every 1 
hour for the first 8 hours then every 2 hours for the next 16 hours up to the 24 h time point. 
Protein was collected at the 24 h time point only. Measures from 0-22 hours was completed in 
1 cell line. Measures at the 24 h time point was collected in all 6 cell lines. 
5.2.3 Bioinformatics and Reporter Assay
Specific miR-99b predicted targets were identified using Ingenuity System 
Interactive Pathway Systems as described in section 2.11. Optimisation for the 
miR-99b-mTOR reporter assay is described in Chapter 4.
5.2.4 RNA Extraction and Real-time PCR
Total RNA was extracted as described in section 2.9. RNA quality was assessed 
by observing the A260/A280 ratio obtained from the Nanodrop 1000 
Spectrophotometer (Thermo Fisher Scientifc, MA, USA) and RNA integrity 
number (RIN) assessed by the Agilent 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, USA). The A260/A280 for over 99% of the samples 
was >1.8 and the RIN for a randomly selected group of samples was >9.6. 
Reverse transcription and qPCR was carried out as described in section 2.9. The 
following primers for human genes were used; mTOR forward 
CAAGAACTCGCTGATCCAAATG, reverse 
GCTGTACGTTCCTTCTCCTTC; RPTOR forward 
TCGTCAAGTCCTTCAAGCAG, reverse GGGTGATTTGGGTTGATTGC; 
0 1 2 3 4 5 6 7 8 10 12 14 16 18 20 22 24T (h)
Transfection period 3H-tyrosine incorporation / release
RNA collection
Protein collection
X X X X X X X X X X X X X X X X X
X
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and IGF1R forward AGTTATCTCCGGTCTCTGAGG, reverse 
TCTGTGGACGAACTTATTGGC.
For miRNA analysis a modified miRNA reverse transcription protocol was 
used that was previously validated by our group (Le Carré, Lamon & Léger 
2014) Briefly, 50 μg of RNA was reverse transcribed with a pooled primer set 
of miR-99a, miR99b, miR-100 and U6 snRNA miRNA-specific stem-loop 
primers (Life Technologies) diluted 0.02X. A total volume was 15 μL of sample 
was prepared also containing 2 mM dNTP, 10 U/μL reverse transcriptase, 0.25 
U/μL RNase inhibitor and RT buffer (1X). This mixture was reverse transcribed 
as described in section 2.9. TaqMan® MicroRNA Assays were used to assess 
the expression of hsa-miR-99b, hsa-miR-99a and hsa-miR-100 (Life 
Technologies). 
Data was analysed using the –delta Ct method and normalised to either ssDNA 
(as determined by Quant it OliGreen ssDNA Assay Kit, (Invitrgoen, Life 
Technologies)), ribosomal protein S5 (RPS5) (Life Technologies) or U6 
snRNA (Life Technologies). 
5.2.5 Protein Extraction and Western Blot
Total protein was extracted and analysed by western blot as described in section 
2.10 with the following specifications. Equal amounts of protein (20 ug) was 
separated on a 4-15% CriterionTM TGX Stain-FreeTM Precast gel (Bio-Rad, 
Parkville, Australia). Membranes were blocked in 5% BSA/TBST then 
incubated overnight at 4°C with the following primary antibodies; mTOR 
(2972), RPTOR (2280), IGF1R (3018), phospho-AktSer473 (9271), phospho-
mTORSer2448 (5536), phospho-p70S6KThr389 (9234), phospho-4EBP1Thr37/46
(9271), and phospho-p44/42 MAPK (ERK1/2)Thr202/Try204 (4370) (Cell 
Signalling Technologies, Arundel, Australia). The antibodies were diluted 
1:500 in 5% BSA/TBST. 
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5.2.6 Statistical Analysis
All data are reported as mean ±SEM. The mixed-model 2-way ANOVA was 
used to compare group means as described in section 2.12.
5.3 Results
5.3.1 Fusion Index
Primary myocytes were isolated from the vastus lateralis biopsies of 3 young 
(23.5±5.0 y.o.) and 3 (64.6±4.0 y.o.) old subjects. The fusion index was 
assessed for each cell line to confirm the satellite cell isolation protocol and to 
ensure terminally differentiated myotubes were present for the experiments. 
The mean fusion index per cell line can be seen in figure 2. These values are in 
line with published fusion index values for human primary myotubes isolated 
from young (23-36 y.o.) and old (69-84 y.o.) males and females as well as head 
and neck cancer patients (patient details not specified) (George et al. 2010;
Stern-Straeter et al. 2011). Figure 4.2 shows representative immunostaining 
pictures of the 6 cell lines, with sarcomeric myosin appearing in green and 
nuclei appearing in blue. 
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Figure 5.2 Human primary myotubes labelled for sarcomeric myosin and nuclei. Expression of sarcomeric myosin (green) and dapi stain (nuclei, blue) of human 
primary myotubes cultured from the muscle biopsies of 3 young and 3 old subjects. A minimum of 30 images per cell line was analysed at 20X magnification.
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5.3.2 miR-99b is Overexpressed in Human Primary Myotubes Within 
1 Hour of Transfection and for up to 24 Hours After Transfection
$OOFHOOOLQHVZHUHWUDQVIHFWHGZLWKHLWKHUȝ0RIPL5-99b mimic sequences 
RUȝ0RIDVFUDPEOHFRQWUROVHTXHQFHIRUK7KHH[SUHVVLRQRIPL5-99b
was then measured every hour for the first 8 hours and then every 2 hours up to 
24 h after the onset of transfection in one cell (Refer to figure 5.1 for experiment 
timeline). Figure 5.3 shows that miR-99b is already overexpressed 1800-fold 
within 1 h of the onset of transfection and these expression levels are maintained 
up to the 24 h time point (P<0.001).
Figure 5.3 Overexpression of miR-99b in human primary myotubes. Expression levels of 
miR-99b at 1 h and 24 h time points after the onset of transfection with miR- either 20 μM of 
miR-99b mimic or 20 μM of scramble control sequence. ***Significantly different from 
scramble (P<0.001). Experiments were completed in at least 1 cell line repeated in at least 3 
wells.
5.3.3 Establishing a Binding Interaction Between miR-99b and the 
mTOR 3ү UTR in Human Primary Myoblasts
An interaction between miR-99b and its predicted target sequence within the 
P725 މ 875 Figure 5.4) was predicted by Ingenuity System Interactive 
Pathway Systems and has previously been demonstrated in macrophage
(RAW264.7) cells, prostate cancer cells and human cervical cancer (HeLa) cells
(Sun et al. 2011; Wang et al. 2014; Wei et al. 2013). I wanted to confirm that 
this binding also occurs in human primary myoblasts. Optimisations were 
carried out as described in Chapter 4. At this stage, I have not been able to 
Scramble Mimic-99b 
at 1 h
Mimic-99b 
at 24 h
0
1
2
1000
2000
3000
4000
5000
m
iR
-9
9b
/U
6
(A
U
)
***
***
- 105 -
establish the successful conditions for lenti-virus infection in this particular 
model.
Figure 5.4 Predicted binding interaction between miR-99b and mTOR. A schematic 
representation of miR-E¶VSXWDWLYHWDUJHWVLWHZLWKLQWKHP725މ875
5.3.4 Overexpression of miR-99b Reduces Protein Synthesis Over a 16 
Hour Period Following Transfection
Although I could not confirm that a binding interaction between miR-99b and 
LWV SUHGLFWHG WDUJHWZLWKLQ WKHP725މ875RFFXUVZLWKLQ KXPDQ SULPDU\
myocytes I still sought to determine if overexpression of miR-99b could 
regulate protein synthesis and protein degradation in human primary myotubes. 
Eight hours of miR-99b treatment was not sufficient to induce a change in 
protein synthesis (data not shown), but by 24 hours miR-99b treatment 
significantly reduced protein synthesis by 1.6-fold (P<0.001) with no 
significant effect of age (Figure 5.5A). No change was observed in protein 
degradation levels (Figure 5.5B). As there was no significant effect of age on
protein synthesis rates in this model the data was pooled for all the experiments.
މ«Qn n A U A C G G G U U n n n«މ
މ…n n n G A U G C C C A A މ
mTOR މ875
miR-99b
Position 295
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Figure 5.5 In vitro protein synthesis and degradation in human primary myotubes with miR-
99b overexpression. Protein synthesis was assessed during the 16 hour period following 
transfection by measuring the incorporation of 3H-tyrosine (A). Protein degradation was 
measured by the amount of 3H-tyrosine released over a 16 hour period following pre-labelling 
with 3H-tyrosine (B). Myotubes were transfected with either 20 μM of miR-99b mimic or 20 μM 
of scramble control sequence. ***Significantly different from scramble (P<0.001). 
Experiments were completed in 6 cell lines repeated in 6 wells.
5.3.5 Overexpression of miR-99b Regulates its Targets mTOR and 
IGF1R Over a 16 Hour Period Following Transfection
The miR-99b targets mTOR, RPTOR and IGF1R were measured at the mRNA 
level every 2 h from the 8 h to the 24 h time point (Refer to figure 1 for 
experiment timeline). Overexpressing miR-99b significantly reduced the 
mRNA expression of mTOR and IGF1R during the 16 h period following 
transfection (P<0.001). There was no significant difference in RPTOR mRNA 
expression (Figure 5.6). No differences were observed at the protein level for 
any of the three targets (Figure 5.7).
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Figure 5.6 Time course of mTOR, RPTOR and IGF1R mRNA expression with miR-99b 
overexpression. Expression levels of mTOR (A), RPTOR (B) and IGF1R (C) every 2 hours 
for the 16 hour period following transfection. Myotubes were transfected with either 20 μM of 
miR-99b mimic or 20 μM of scramble control sequence. ***Main effect of treatment 
(P<0.001). *Significantly different from scramble at the same time point (P<0.05). Experiments 
were completed in at least 1 cell line repeated in at least 3 wells.
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Figure 5.7 Expression of mTOR, RPTOR and IGF1R proteins. Expression levels of mTOR 
(A), RPTOR (B) and IGF1R (C) proteins at the 24 h time point following transfections either 
20 μM of miR-99b mimic or 20 μM of scramble control sequence. Experiments were completed 
in 6 cell lines repeated in 3 wells.
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5.3.6 Overexpression of miR-99b Increases the Phosphorylation Levels 
of mTOR’s Downstream Target 4EBP1 24 Hours After the Onset of 
Transfection
To determine if muscle protein synthesis was reduced via Akt-mTOR signalling 
or via an alternative signalling pathway, the phosphorylation levels of several 
upstream and downstream targets of mTOR, including mTOR itself, as well as 
of some members of the MAPK signalling pathway was measured. No 
difference was observed in the phosphorylation levels of Akt, mTOR and
p70S6K (Figure 5.8 A-C) or ERK1/2, a MAPK signalling protein (Figure 7E). 
There was a significant increase in the phosphorylation levels of 4EBP1 
(P<0.001) at 24 hours (Figure 5.8 D).
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Figure 5.8 Expression of phosphorylation levels of mTOR and MAPK signalling proteins.
Expression levels of the phosphorylated forms of Akt (A), mTOR (B), p70S6K (C), 4EBP1 (D) 
and ERK1/2 (E) proteins at the 24 h time point following transfections either 20 μM of miR-
99b mimic or 20 μM of scramble control sequence. ***Significantly different from scramble 
(P<0.001). Experiments were completed in 6 cell lines repeated in 3 wells. The reported 
statistical significance is based on analysis of the transformed data but the reported 
means±S.E.M. are on the original (untransformed) scale.
5.3.7 Overexpression of miR-99b Regulates its Family Members miR-
99a and miR-100 Over a 16 Hour Period Following Transfection
Finally the expression levels of miR-99a and miR-100 was measured to 
determine if miR-99b overexpression could regulate the expression of its family 
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members. The expression levels of miR-99a and miR-100 were measured every 
2 hours from the 8 h to the 24 h time point (Refer to figure 1 for experiment 
timeline). Overexpression of miR-99b reduced the expression of miR-99a and 
miR-100 during the 16 hour period following transfections (P<0.001) (Figure 
5.9).
Figure 5.9 Time course of miR-99a and miR-100 expression with miR-99b overexpression.
Expression levels of miR-99a (A) and miR-100 (B) every 2 hours for the 16 hour period 
following transfection. Myotubes were transfected with either 20 μM of miR-99b mimic or 20 
μM of scramble control sequence. ***Main effect of treatment (P<0.001). *Significantly 
different from scramble at the same time point (P<0.05). Experiments were completed in at 
least 1 cell line repeated in at least 3 wells.
8 10 12 14 16 18 20 22 24
0.0
0.5
1.0
1.5
Time point (h)
m
iR
-9
9a
/U
6
(A
U
)
Scramble
Mimic-99b
*
* * * *
* * *
***
8 10 12 14 16 18 20 22 24
0.0
0.5
1.0
1.5
Time point (h)
m
iR
-1
00
/U
6
(A
U
)
Scramble
Mimic-99b
*
* * * *
* * *
***
A
B
- 112 -
5.4 Discussion
In this study, I demonstrate for the first time that the modulation of a miRNA
can alter protein synthesis in human primary myotubes. Overexpression of 
miR-99b reduces protein synthesis over a 16 h period in cell lines derived from 
young and old subjects. The reduction in protein synthesis was associated with 
an increase in the phosphorylation levels of 4EBP1, a decrease in the mRNA 
expression of miR-99b’s predicted targets mTOR and IGF1R and a decrease in 
the expression levels of its family members miR-99a and miR-100. In 
conjunction with the findings from chapter 3, these results illustrate a 
potentially critical role for miR-99b as a suppressor of muscle protein synthesis 
in ageing skeletal muscle. 
miR-99b was identified in chapter 3 as being downregulated in young subjects 
only following a protein synthesis-stimulating exercise. Bioinformatics 
analysis provided a strong link between miR-99b and members of the Akt-
mTOR signalling pathway. Therefore I sought to provide proof-of-concept for 
the role of miR-99b in the regulation of protein synthesis and to determine if 
miR-99b upregulation could reduce protein synthesis in human primary 
myotubes derived from young and old subjects. Overexpression of miR-99b
resulted in a significant 39% reduction in protein synthesis and no change in 
protein degradation. Importantly, no difference in protein synthesis was noted 
during the first 8 hours of treatment. Together, the data indicates that miR-99b 
regulates protein synthesis in the human primary myotubes from 8 to 24 h after 
the onset of transfection, although no changes in the investigated signalling 
proteins was observed during this timeframe. 
There was no effect of age on miR-99b-induced reduction in protein synthesis. 
So far, whether primary muscle cell lines maintain their phenotypes in culture 
is unclear. The nature of cell culture provides a very controlled environment for 
the cells and many endogenous circulating factors, including age-dependant 
factors such a growth factors, are not present in an in vitro environment. 
Therefore it has been reported that some of the ‘ageing’ phenotype of the 
myocytes derived from the old subjects are lost in a cell culture model (Carlson 
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et al. 2009; Conboy et al. 2005). Supporting this idea, I found no age-specific 
difference in the fusion index or in any other output measure, suggesting that 
the age of the satellite cell donors has no bearing on the myogenic 
differentiation capacity of the individual cell lines. For this reason the data was 
pooled for all the measured outcomes of this study.
I hypothesised that the observed reduction in protein synthesis was correlated 
with a reduction in the protein expression of miR-99b’s predicted targets 
mTOR, RPTOR and IGF1R. Such a reduction would reduce the potential of the 
respective protein to activate the Akt-mTOR signalling pathway and
consequently protein synthesis. However, there were no differences in the 
protein expression levels of mTOR, RPTOR and IGF1R 24 h after the onset of 
transfection, but a reduction in the mRNA expression of mTOR and IGF1R 
during the 16 h time period following miR-99b transfection. 
miRNAs exert their effect directly on mRNAs by either inhibiting protein 
translation or signalling for the degradation of the mRNA (Brennecke et al. 
2005; Hu & Bruno 2011), with an expected time delay, dependant on the 
turnover time of the protein, existing between the binding and a visible 
reduction in the protein levels. In PANC-1 cells mTOR protein was reduced 48 
h after transfection with miR-99b mimic (Wei et al. 2013). There is also 
evidence in the literature that miR-99 miRNAs can regulate the expression of 
their protein targets via different mechanisms (Chen et al. 2012; Jin et al. 2013).
Overexpression of any of the miR-99 miRNAs in head and neck squamous cell 
carcinoma (HNSCC) cells reduced IGF1R expression at the mRNA and protein 
level (Chen et al. 2012). On the other hand, overexpression of these miRNAs
in in the immortalised keratinocyte cell line (HaCaT) reduced IGF1R at the 
protein level only (Jin et al. 2013). This means that although I did not observe 
a reduction in RPTOR at the mRNA or protein level following miR-99b 
transfection, there may still be a reduction in the protein at a later time point.
In this study I sought to demonstrate a direct interaction between the miR-99b
PLPLFDQGLWVSUHGLFWHGWDUJHWZLWKLQWKHމ875RIP725LQKXPDQSULPDU\
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myocytes. However, I was not able to establish the conditions required to infect 
the cells with the lentiviral vector containing the P725މ875WDUJHWVHTXHQFH
(refer to Chapter 4). Although a direct interaction between miR-99b mimic and 
LWVSUHGLFWHGWDUJHWZLWKLQWKHP725މ875KDVEHHQGHPRQVWUDWHGLQRWKHU
cell lines (Sun et al. 2011; Wang et al. 2014; Wei et al. 2013), demonstrating 
that this binding occurs within our model of interest is essential. Indeed, the 
rules underlying the miRNA-mRNA binding process have not been fully 
elucidated. Specifically, there are examples in the literature where high 
complementarity sites predicted to present extremely high affinity for a miRNA
are not recognized by this miRNA in vitro, suggesting the existence of cell-
specific inhibition processes (Didiano & Hobert 2008). The observed reduction 
in both mTOR and IGF1R mRNA expression with miR-99b overexpression 
suggests that miR-99b directly targets these 2 mRNA molecules; an interaction 
that will be confirmed in the next step of this project. 
The link existing between miR-99b and its targets mTOR, RPTOR and IGF1R 
in the literature prompted me to hypothesise that protein synthesis was 
regulated via Akt-mTOR signalling in this model. One study has previously 
demonstrated that miR-99 miRNA overexpression leads to a reduction in Akt-
mTOR signalling (Jin et al. 2013). In contrast, I did not observe a difference in 
the phosphorylation levels of Akt, mTOR or p70S6K but report a significant 
increase in mTOR’s downstream target 4EBP1 phosphorylation 24 hours after 
the onset of miR-99b mimic transfection. This result was unexpected as 
phosphorylation of the 4EBP1 protein removes its inhibition on mTOR 
signalling and therefore increases protein synthesis (Brunn et al. 1997), while I 
observed a decrease in protein synthesis associated with miR-99b
overexpression. Phosphorylation of 4EBP1 is necessary for the release of the 
eukaryotic initiation factor 4E (eIF4E), allowing its phosphorylation and 
activity in translation initiation (Pause et al. 1994). I did not measure the 
expression of eIF4E phosphorylation in this study. However, it is important to 
note that the phosphorylation of eIF4E is alternatively regulated by the MAP 
kinase-activated protein kinase (Mnk1), a downstream target of the ERK1/2 
(MAPK) signalling pathway (Pyronnet et al. 1999). A link has been made 
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between miR-99b overexpression and the MAPK signalling pathway via its 
validated target FGFR3 (Kang et al. 2012; Kang et al. 2007); however, a 
functional correlation has not been investigated. The MAPK signalling pathway 
therefore represents an alternative pathway potentially able to regulate protein 
synthesis in this model (Drummond et al. 2008a; Williamson et al. 2003). The 
MAPK signalling pathway is activated following acute resistance exercise in 
young and old subjects, with an attenuated response in old subjects (Drummond 
et al. 2008a; Williamson et al. 2003). Although I observed no difference in the 
phosphorylation levels of ERK1/2 at the 24 h time point, I hypothesize that 
MAPK signalling is primarily responsible for the decrease in protein synthesis. 
Changes in signalling proteins may occur at earlier time points as protein 
phosphorylation is transient. It is likely that by the 24 h time point upstream 
regulators of 4EBP1 and translation initiation proteins may have returned to 
baseline activity levels. This will be investigated further. 
I investigated the relationship between the miR-99b and its family members, 
miR-99a and miR-100. The three members of the miR-99/100 family of 
miRNAs contain the same seed sequence and therefore share a list of common 
mRNA targets. In this study miR-99b was overexpressed by several thousand-
fold via the transfection of a miR-99b mimic. In association with miR-99b 
overexpression, there was a significant decrease in the expression of both miR-
99a and miR-100 over the 16 h period following miR-99b transfection.
Downregulation of miR-99a and miR-100 may be a compensatory response to 
the dramatic increase in miR-99b occurring due to the transfection. However, 
whether this decrease in the miR-99 miRNA family members with miR-99b
overexpression is biologically relevant would need to be investigated. A 
microRNA pull-down assay or co-immunoprecipitation of miRNAs bound to 
AGO proteins are two potential tools for investigating the direct interaction 
between miRNAs and their mRNA targets (Beitzinger et al. 2007; Hsu & Tsai 
2011). These assays could be used to investigate how miRNA families work 
together to regulate whole cellular processes by identifying mRNAs that are 
bound to specific miRNAs (Chi et al. 2009; Hsu, Yang & Tsai 2009). Overall, 
as protein synthesis was significantly reduced with miR-99b overexpression it 
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seems unlikely that the reduction in the expression of the miR-99 miRNA
family had any conflicting effect to miR-99b overexpression.
In summary this work demonstrates a role for miR-99b in the regulation of the 
protein synthesis process in human primary myotubes. Here it is shown that 
overexpression of miR-99b reduces protein synthesis in human muscle cell 
lines cultured from young and old muscle with no age-dependant effect. I 
hypothesised that miR-99b would regulate protein synthesis via its predicted 
target mTOR, RPTOR and IGF1R but found no differences in the protein levels 
of these targets during the protein synthesis timeframe. Furthermore there was 
an increase in the phosphorylation levels of mTOR’s downstream target 
4EBP1, suggesting an activation in Akt-mTOR signalling. How protein 
synthesis is being regulated with miR-99b overexpression in this model needs 
to be investigated further. There is evidence to support that miR-99b may also 
be regulating the MAPK pathway by downregulating ERK1/2 phosphorylation 
and therefore reducing the activity of protein translation initiation via eIF4E 
desphosphorylation. Subsequent experiments are required to test this 
hypothesis. Whether miR-99b may indeed attenuate protein synthesis in 
skeletal muscle warrants further in vitro and in vivo investigation. 
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CHAPTER 6
MICRORNA-499 DOWNREGULATES PROTEIN 
SYNTHESIS IN HUMAN PRIMARY MYOTUBRES 
DERIVED FROM OLD SUBJECTS
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6. MICRORNA-499 DOWNREGULATES PROTEIN 
SYNTHESIS IN HUMAN PRIMARY MYOTUBES DERIVED 
FROM OLD SUBJECTS
6.1 Introduction
Progressive loss of skeletal muscle mass is a natural phenomenon that occurs 
as we age. The loss of skeletal muscle is associated with a significant decrease 
in quality of life and independence in the elderly. Maintaining muscle protein 
synthesis rates is an essential component of maintaining skeletal muscle mass. 
However, the muscle protein synthesis response to anabolic stimuli such as 
resistance exercise is reduced with ageing (Kumar et al. 2009). This attenuated 
response is associated with a reduction in Akt-mTOR signalling, one of the 
main pathways regulating protein synthesis in the cell. The Akt-mTOR pathway 
comprises a number of upstream and downstream regulators, including Akt, 
p70S6K and 4EBP1, that are dysregulated with age (Kumar et al. 2009; Léger 
et al. 2008). mTOR signalling directly regulates protein translation by inhibiting 
4EBP1 activity to allow the release of the eukaryotic initiation factor eIF4E 
(Brunn et al. 1997; Pause et al. 1994). eIF4E then binds to the scaffold protein 
eIF4G2, making it available for phosphorylation activation (Pyronnet et al. 
1999). Another initiation factor, eIF4A, also associates with the eIF4E-eIF4G2
complex to allow WKHWUDQVODWLRQRIމWHUPLQDOROLJRS\ULPLGLQHP51$V (Pause 
et al. 1994). A disruption in this pathway can therefore significantly reduce the 
protein synthesis capacity of a tissue. 
MicroRNAs (miRNAs) are small, non-coding RNAs that are potent regulators 
of protein translation (Selbach et al. 2008). miRNAs exert their effect by 
targeting and binding specific mRNAs and preventing protein translation either 
by signalling for the degradation of the mRNA or temporarily inhibiting protein 
translation (Hu & Bruno 2011). A number of algorithms are available to predict 
specific miRNA-mRNA interactions and a third of the mRNA pool is predicted 
to have a miRNA target (Beitzinger et al. 2007). However, it is essential to 
experimentally test such interactions to elucidate specific cellular phenomenon, 
such as protein synthesis. Currently, there is limited functional evidence 
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available regarding specific miRNA-mRNA interactions involved in protein 
synthesis regulation. 
In Chapter 3 a high throughput PCR-based miRNA screen was used to identify 
miRNAs that were differentially regulated between young and old subjects 
following an acute bout of resistance exercise. The resistance exercise protocol 
used has been shown to increase muscle protein synthesis in young and old 
subjects, albeit with an attenuated response in the elderly (Kumar et al. 2009).
A myomiR, miR-499, was identified as upregulated in the skeletal muscle of 
old subjects following the exercise bout. Bioinformatics analysis predicted 
miR-499 to target the eukaryotic initiation factor, eIF4G2, therefore suggesting 
a negative role for miR-499 in muscle protein synthesis. miR-499 expression 
was reduced (effect size reported) in the skeletal muscle of elderly subjects 
following 5 months of resistance training; a response associated with an 
improvement in muscle strength and lean mass (Zhang et al. 2015). In contrast, 
an increase in miR-499 expression was observed following the ingestion of 
essential amino acids (EAA), another anabolic stimulus (Drummond et al. 
2008a; Koopman et al. 2006), in young subjects (Drummond et al. 2009).
Downregulation of miR-499 expression was also observed in a rodent atrophy 
model of hind limb suspension (McCarthy et al. 2009). MiR-499 is encoded 
and co-transcribed within the slow myosin heavy chain MYH14 (MYH7b) gene 
(van Rooij et al.) and is predominantly enriched within oxidative muscles (van 
Rooij et al.). Whether miR-499 has a fibre type specific role is not known. The 
aim of this study was to determine if miR-499 could downregulate protein 
synthesis in human primary myotubes via its predicted target, eIF4G2, a 
downstream target of mTOR signalling.
6.2 Methods
6.2.1 Primary Cell Lines
Human primary cell lines were established from the muscle biopsies of 3 young 
(23.5±5.0 y.o.) subjects and 3 old (64.6±4.0 y.o.) subjects as outlined in section 
2.3 and maintained as per section 2.4. 
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6.2.2 MicroRNA Transfection
On the 7th day of differentiation myotubes were transfected with either 20 μM 
of miR-499 mimic (mirVanaTM miRNA mimic, Life Technologies) or 20 μM 
of a mimic scramble sequence (mirVanaTM miRNA mimic, negative control #1, 
Life Technologies) according to section 2.6. Protein synthesis and degradation 
assays were performed as described in section 2.7 and 2.8, respectively. RNA 
and protein was collected 24 after the onset of transfection. Figure 6.1 depicts 
the experimental timeline.
Figure 6.1 Experiment timeline for miR-499 functional analysis. Human primary myotubes 
were transfected for 8 hours with either 20 μM of miR-499 mimic or 20 μM of scramble control 
sequence. Protein synthesis and degradation were measured by either the incorporation or 
release of 3H-tyrosine, respectively, during the 16 h period following transfection. Protein and 
RNA was collected 24 hours after the onset of transfection. 
6.2.3 Bioinformatics Analysis
Specific miR-499 predicted targets were identified using Ingenuity System 
Interactive Pathway Systems as described in section 2.11.
6.2.4 RNA Extraction and Real-time PCR
Total RNA was extracted as described in section 2.9. RNA quality was assessed 
by observing the A260/A280 ratio obtained from the Nanodrop 1000 
Spectrophotometer (Thermo Fisher Scientifc, MA, USA) The A260/A280 for 
over 99% of the samples was >1.8. Reverse transcription and qPCR was carried 
out as described in section 2.9. The following primers for the human eIF4G2 
gene was used; forward CTGCACGAAGCACTAGACGA and reverse 
TGAGGAGCTCAAGGCATAGC.
0 8 24T (h)
Transfection period 3H-tyrosine incorporation / release
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X
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For miRNA analysis 10 μg of RNA was reverse transcribed with a pooled 
primer set of miR-499 and U6 snRNA using the TaqMan® MicroRNA Reverse 
Transcription Kit (Life technologies, Mulgrave, Australia) according to the 
manufacturer’s protocol.
Data was analysed using the –delta Ct method and normalised to either ssDNA 
(as determined by Quant it OliGreen ssDNA Assay Kit, (Invitrgoen, Life 
Technologies)) or U6 snRNA (Life Technologies). 
6.2.5 Protein Extraction and Western Blot
Total protein was extracted and analysed by western blot as described in section 
2.10 with the following specifications. Equal amounts of protein (20 ug) was 
separated on a 4-15% CriterionTM TGX Stain-FreeTM Precast gel (Bio-Rad, 
Parkville, Australia). Membranes were blocked in 5% BSA/TBST then 
incubated overnight at 4°C with the following primary antibodies; eIF4G2 
(5169), phospho-AktSer473 (9271), phospho-mTORSer2448 (5536), phospho-
p70S6KThr389 (9234), phospho-4EBP1Thr37/46 (9271), and phospho-p44/42 
MAPK (ERK1/2)Thr202/Try204 (4370) (Cell Signalling Technologies, Arundel, 
Australia). The antibodies were diluted 1:500 in 5% BSA/TBST. 
6.2.6 Reporter Assay
The reporter assay was performed in human primary myoblasts maintained in 
HAMs F-10 medium (Life technologies, Mulgrave, Australia) supplemented 
with 20% FBS (French bovine material, Bovogen, Keilor East, Australia), 25 
ng/mL bFGF (Promega, Madison, USA), 1% penicillin/streptomycin (Life 
technologies, Mulgrave, Australia) and 0.5% amphoteromycin (Life 
technologies, Mulgrave, Australia). At approximately 50% confluence the cells 
were infected with either 5*105 inf/mL of either Lenti-UTR-Luc Blank Virus 
$%0%&&DQDGDRU(,)*މ875/HQWL-reporter-Luc Virus (ABM, BC, 
Canada). Briefly, cells were incubated in growth medium containing the virus
DQG  ȝJP/ RI polybrene (Sigma-Aldrich, Castle Hill, Australia) and 
centrifuged at 1800 rpm for 45 minutes at room temperature. An uninfected 
group of cells was also prepared in the same way. The cells were incubated at 
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37°C and 5% CO2 overnight and the medium was changed the following 
morning. Forty-eight hours after the delivery of the virus to the cells the cells 
were transfected with either 20 μM of miR-499 mimic (mirVanaTM miRNA
mimic, Life Technologies) or 20 μM of a mimic scramble sequence 
(mirVanaTM miRNA mimic, negative control #1, Life Technologies) as 
described in section 2.6. After 24 hours the cells were washed with 1X PBS and 
then incubated in Cell Lysis Buffer (ABM, BC, Canada) for 20 minutes. An 
equal volume of Luciferase Assay Reagent (ABM, BC, Canada) was added to 
each well. Luminescence was measured immediately on the BioTek Synergy 2 
Multi-mode microplate reader (BioTek, Winooski, USA). 
6.3 Results
6.3.1 MiR-499 is Overexpressed in Human Primary Myotubes 24 Hours 
After the Onset of Transfection
Primary myocytes were isolated from the vastus lateralis biopsies of 3 young 
(23.5±5.0 y.o.) and 3 old (64.6±4.0 y.o.) subjects. All cell lines were transfected 
with either 20 ȝ0RIPL5-499PLPLFVHTXHQFHVRUȝ0RIDVFUDPEOHFRQWURO
sequence for 8 h. The expression of miR-499 was then measured 24 h after the 
onset of transfection. Figure 6.2 shows that miR-499 is overexpressed over 
3000-fold in the cells at the 24 h time point.
Figure 6.2 Overexpression of miR-499 in human primary myotubes. Expression levels of 
miR-499 24 hours after the onset of transfection with either 20 μM of miR-499 mimic or 20 
μM of scramble control sequence. ***Significantly different from scramble (P<0.001). 
Experiments were completed in 6 cell lines repeater in 6 wells
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6.3.2 Overexpression of miR-499 Reduces Protein Synthesis Over a 16 
Hour Period Following Transfection in Human Primary Myotubes 
Derived From Old Subjects
Protein synthesis and degradation was measured in all the cell lines during the 
16 h period following transfection (refer to figure 1 for experimental timeline). 
There was significant age x treatment interaction (P<0.001) in protein synthesis 
during this period. A post hoc analysis revealed that overexpression of miR-
499, when compared to the scramble control, reduced protein synthesis by 20% 
(P<0.05) in the cell lines from old subjects only. Following miR-499 
overexpression, protein synthesis levels were lower in the older subjects when 
compared to the young subjects (p<0.05) (Figure 6.3 A). MiR-499 did not affect 
protein degradation during this period (Figure 6.3 B). 
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Figure 6.3 In vitro protein synthesis and degradation in human primary myotubes with 
miR-499 overexpression. Protein synthesis was assessed during the 16 hour period following 
transfection by measuring the incorporation of 3H-tyrosine (A). Protein degradation was 
measured by the amount of 3H-tyrosine released over a 16 hour period following pre-labelling 
with 3H-tyrosine (B). Myotubes were transfected with either 20 μM of miR-499 mimic or 20 
μM of scramble control sequence. ### Significant age x treatment interaction (P<0.001). 
*Significantly different from scramble within the same age group (P<0.05). $ Significantly 
different from young within the same treatment group (P<0.05). Experiments were completed 
in 6 cell lines repeated in 6 wells.
6.3.3 Overexpression of miR-499 Regulates its Predicted Target 
eIF4G2
The eIF4G2 gene is a predicted target of miR-499. I measured the mRNA and 
protein levels of eIF4G2 24 h after the onset of transfection. Overexpression of 
miR-499 reduced eIF4G2 by 40% at the mRNA level with no significant
difference between age groups (Figure 6.4 A). The protein levels of eIF4G2 
were not significantly altered by miR-499 overexpression (Figure 6.4 B).
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Figure 6.4 Expression of eIF4G2 mRNA and protein with miR-499 overexpression.
Expression levels of eIF4G2 mRNA (A) and protein (B) 24 hours after the onset of transfection 
with either 20 μM of miR-499 mimic or 20 μM of scramble control sequence. *** Main effect 
of treatment (P<0.001). Experiments were completed in 6 cell lines repeated in 6 wells for 
mRNA expression and 3 wells for protein expression. 
6.3.4 Absence of a Binding Interaction Between miR-499 and its 
Predicted Target Sequence Within the eIF4G2 3ү UTR
To determine if miR-499 overexpression could downregulate eIF4G2 
expression by directly interacting with its predicted target sequence within the 
H,)*މ875,SHUIRUPHGDOXFLIHUDVHDVVD\,QJHQXLW\6\VWHPV,QWHUDFWLYH
Pathway Systems was used to identify a potential target site for miR-499 within 
WKHމ875RIH,)*)LJXUH$)LJXUH%FRQILUPVWKDWPL5-499 is 
efficiently overexpressed in human primary myoblasts following the lentivirus 
transfection. Luciferase activity was not altered by miR-499 overexpression in 
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B
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eIF4G2
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myoblasts infected with the reporter vector containing the predicted target with 
WKHH,)*މ875)LJXUH&
Figure 6.5 Predicted interaction between miR-499 and eIF4G2. (A) A schematic 
representation of the putative miR- WDUJHW VLWH ZLWKLQ WKH H,)* މ 875 %
Overexpression of miR-499 in human primary myoblasts 24 hours after the onset of transfection 
with either 20 μM of miR-499 mimic or 20 μM of scramble control sequence. (C) Relative 
luciferase activity (RLU, relative luminescence units) of uninfected cells (no virus), blank 
vector (Luc-%ODQNDQGH,)*މ875YHFWRU/XF-eIF4G2) with either 20 μM of miR-99b 
mimic or 20 μM of scramble control sequence. ***Significantly different from scramble 
(P<0.001). Experiments were completed in 1 cell line repeated in 3 wells for miRNA expression 
and 6 wells for luciferase activity.
6.3.5 Phosphorylation Levels of 4EBP1 is Altered in Myotubes 
Derived From Old Subjects
To determine if protein synthesis was reduced via the Akt-mTOR signalling 
pathway or via an alternative signalling pathway, the phosphorylation levels of 
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several upstream and downstream targets of mTOR, including mTOR itself, as 
well as some of the members of the MAPK signalling pathway were measured.
No difference was observed in the phosphorylation levels of Akt, mTOR and 
p70S6K (Figure 6.6 A-C) or ERK1/2, a MAPK signalling protein (Figure 6.6 
E). There was a significant age x treatment interaction for the phosphorylation 
levels of 4EBP1. Post hoc analysis revealed that the phosphorylation levels of 
4EBP1 were significantly lower in the scramble control group in myotubes 
derived from old subjects than in the myotubes derived from young subjects. In 
addition, in the myotubes derived from old subjects, the phosphorylation levels 
of 4EBP1 were increased 1.5-fold with miR-499 overexpression when 
compared to their scramble control (P<0.05) (Figure 6.6 D).
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Figure 6.6 Expression of the phosphorylation levels of mTOR and MAPK signalling proteins. Expression levels of the phosphorylated forms of Akt (A), mTOR (B), 
p70S6K (C), 4EBP1 (D) and ERK1/2 (E) proteins at the 24 h time point following transfections either 20 μM of miR-499 mimic or 20 μM of scramble control sequence. ### 
Significant age x treatment interaction (P<0.001). Experiments were completed in 6 cell lines repeated in 3 wells. *Significantly different from scramble within the same age 
group (P<0.05). $ Significantly different from young within the same treatment group (P<0.05). The reported statistical significance is based on analysis of the transformed 
data but the reported means±S.E.M. are on the original (untransformed) scale.
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6.4 Discussion
miR-499 was identified in Chapter 3 as being upregulated in old, but not young 
subjects post resistance exercise. Bioinformatics analysis predicted that 
eIF4G2, a eukaryotic initiation factor downstream of mTOR signalling, was a 
potential target of miR-499. It was hypothesised that an upregulation of miR-
499 expression in the skeletal muscle of old subjects may be partly responsible 
for inhibiting muscle protein synthesis following an acute bout of resistance 
exercise. The purpose of this study was to determine if miR-499 overexpression 
could reduce protein synthesis in human primary myotubes derived from young 
and old subjects, a hypothesis that was confirmed in the myotubes derived from 
old subjects only. This reduction in protein synthesis was associated with a 
significant increase in the phosphorylation levels of 4EBP1. Additionally, miR-
499 induced a significant decrease in eIF4G2 mRNA expression in all cell lines, 
although the eIF4G2 protein levels were not altered and no miR-499-eIF4G2 
3’UTR binding interaction was observed.  
In order to confirm that a myogenic population of cells was present in the 
primary muscle cell lines, the fusion index was determined for each cell line in 
Chapter 5. All of the cell lines successfully developed multinucleated myotubes 
in accordance with fusion index values published in the literature (George et al. 
2010; Stern-Straeter et al. 2011), with no significant difference in the 
differentiation capacity between cell lines derived from young and old subjects. 
This can be explained by the absence of some of the extrinsic factors (such as 
hormones and growth factors) contributing to the ageing phenotype in an in 
vitro model (Carlson et al. 2001; Conboy et al. 2005; Stern-Straeter et al. 2011).
However, there is evidence to suggest that satellite cells isolated from muscle 
biopsies take on the metabolic features of the muscle that they were sourced 
from in culture (Feldman & Stockdale 1991; Zhu et al. 2013). Ageing is 
associated with a significant shift towards a more oxidative muscle phenotype 
(Larsson, Sjödin & Karlsson 1978; Léger et al. 2008; Lexell et al. 1983) and 
this suggests that there may be a greater proportion of oxidative type fibres in 
the cultures derived from old subjects compared to the cultures derived from 
young subjects. In the present study it was observed that miR-499 
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overexpression reduced protein synthesis in the cells lines derived from old 
subjects only, suggesting an age-dependent response to increased levels of miR-
499. However, no age-related differences could be observed in miR-499 
baseline expression levels. The fibre type of these cell lines would need to be 
determined in order to elucidate if there may be a fibre type bias contributing 
to the function of miR-499. In addition, it is likely that the elderly subjects in 
this study are not representative of the general, elderly population, an idea that 
was proposed in Chapter 3. 
I hypothesised that miR-499 would reduce protein synthesis by downregulating 
its predicted target eIF4G2, a eukaryotic initiation factor directly involved in 
protein translation (Pause et al. 1994). eIF4G2 acts as a scaffolding protein for 
other initiation factors, including the downstream regulator of mTOR signalling 
eIF4E (Pause et al. 1994), and is also critical for the activation of eIF4E by 
phosphorylation (Pause et al. 1994; Pyronnet et al. 1999). A reduction in 
eIF4G2 mRNA was observed in all cell lines. However, surprisingly, a binding 
interaction between miR-DQGLWVSUHGLFWHGWDUJHWZLWKLQWKHH,)*މ875
was not observed by reporter assay. One possible explanation for this 
discrepancy is that the reduction in eIF4G2 mRNA was observed in myotubes, 
while the reporter assay was performed in myoblasts. In this study, I was able 
to successfully overexpress miR-499 in both myotubes and myoblasts. 
However, there are intrinsic cell differences with the specific signalling 
cascades that are being activated or deactivated depending on the degree of 
differentiation of a myocyte (Moran et al. 2002) that may affect the interaction 
EHWZHHQWKHH,)*މ875DQGPL5-499. Cell specific inhibition of miRNA-
mRNA binding has been proposed in the literature (Didiano & Hobert 2008).
Optimising the reporter assay for myotubes is warranted in this case to 
determine if the eIF4G2 reduction in human primary myotubes is caused by 
miR-499 overexpression. Investigating whether miR-499 overexpression in 
myoblasts reduces eIF4G2 mRNA expression may also help to determine if 
miR-499 regulation of eIF4G2 is specific to the differentiation level of a 
myocyte. Alternatively, it is also possible that the reduction in eIF4G2 mRNA 
expression is not directly regulated by miR-499. Translation initiation factors 
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are predominantly upregulated following acute fasting in rodents although 
eIF4E, which associates with eIF4G2, is downregulated in conjunction with an 
upregulation of its repressor 4EBP1 (Jagoe et al. 2002). Although changes in 
eIF4G2 expression were not reported in the fasting study, this demonstrates that 
a complex mechanism exists in the regulation of translation initiation factors at 
the mRNA level in conjunction with reduced protein synthesis (Cherel et al. 
1991; Li & Goldberg 1976).
As eIF4G2 is a positive regulator of mTOR signalling and no reduction in the 
eIF4G2 protein levels was observed following miR-499 overexpression, I 
investigated if the activation levels of other members of the Akt-mTOR 
signalling pathway and the MAPK signalling pathway, another major regulator 
of protein synthesis, were altered with miR-499 overexpression. No differences 
were observed in the phosphorylation levels of Akt, mTOR, p70S6K and 
ERK1/2, however a significant age x treatment interaction for the 
phosphorylation levels of 4EBP1 was observed. 4EBP1 phosphorylation was 
reduced in the cells lines derived from old subjects in the control group when 
compared to the control group of the young subjects. Overexpression with miR-
499 increased 4EBP1 phosphorylation in the cell lines derived from old subjects 
to levels that were similar to those observed at baseline in the cell lines derived 
from young subjects. This suggests that there is an insufficient compensatory 
mechanism occurring in response to the reduction in protein synthesis with 
miR-499 overexpression. 4EBP1 is an inhibitory protein that impedes protein 
translation by sequestering the initiation factor eIF4E (Brunn et al. 1997; Pause 
et al. 1994). Measuring the rate of protein synthesis beyond the 24 hour time 
point would be necessary to determine if the increase in 4EBP1 phosphorylation 
can positively regulate protein synthesis in this model. Phosphorylation of 
4EBP1 is regulated by mTOR, which has another downstream target, p70S6K 
(Inoki et al. 2002a). Interestingly, no differences in the phosphorylation levels 
of p70S6K were observed in this model suggesting that 4EBP1 is being 
regulated independent of mTOR signalling. This observation has been made in 
another cell culture model where chemotherapy treatment on urothelial 
carcinoma cells reduced the phosphorylation levels of Akt, mTOR and p70S6K 
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but not 4EBP1 (Nawroth et al. 2011). mTOR specific inhibitors can be used to 
determine if miR-499 can regulate 4EBP1 phosphorylation in this model 
independently of mTOR signalling. Investigating protein synthesis regulators 
at a time point prior to the 24 hour harvest point may also be necessary to 
determine the mechanisms of action for miR-499.
In conclusion, overexpression of miR-499 in human primary myotubes reduces 
protein synthesis in cell lines derived from old subjects only. This reduction in 
protein synthesis was associated with a significant increase in the 
phosphorylation levels of 4EBP1 protein. miR-499 is predicted to target and 
inhibit the eukaryotic initiation factor, eIF4G2. The reduction in eIF4G2 was 
the proposed mechanisms for miR-499’s regulation of protein synthesis. 
Although there was a significant reduction in eIF4G2 mRNA expression across 
all cell lines there was no significant difference in the protein expression of 
eIF4G2. Furthermore, a binding interaction between miR-499 and its predicted 
WDUJHWZLWKLQWKHH,)*މ875FRXOGQRWEHHVWDEOLVKHGZLWKLQWKLVPRGHO
Further investigation is required in order to elucidate how miR-499 regulated 
protein synthesis and where there is an age specific effect in the protein 
synthesis response and protein signalling response to miR-499 overexpression 
in human primary myotubes. 
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CHAPTER 7
GENERAL DISCUSSION AND FUTURE DIRECTIONS
- 137 -
7. GENERAL DISCUSSION AND FUTURE DIRECTIONS
7.1 Introduction
MicroRNAs (miRNAs) are small non-coding RNAs that are potent regulators 
of cellular processes. The discovery of miRNAs has altered our perception of 
gene expression regulation, consequently complicating our understanding of 
adaptation and maladaptation mechanisms in the body. Since their discovery in 
the early nineties, the research community has investigated the role and 
regulation of miRNAs in various models of health and disease in an attempt to 
discover novel therapeutic targets to modulate both naturally, with lifestyle 
interventions, and pharmaceutically. In theory miRNAs are good candidate 
therapeutic targets due to their small size and simple structure. If the expression 
of a miRNA is reduced, the reintroduction of this miRNA with miRNA delivery 
tools could restore appropriate target gene regulation. Likewise, where a 
miRNA is inappropriately overactive, targeted miRNA inhibitors can 
downregulate this miRNA. The efficacy of miRNA targeted therapies has been 
described in the literature (van der Ree et al. 2014). For example, Miravirsen is 
a locked nucleic acid (LNA) that was recently tested in a phase 2a clinical trial 
and that specifically targets miR-122, a liver-enriched miRNA involved in the 
propagation of the hepatitis C virus (HCV). Miravirsen was well received by 
the patients with no long-term adverse effects reported. A sustained reduction 
in HCV was achieved in 58% of the patients who received the treatment. One 
key characteristic of miR-122 is that it is highly abundant in liver tissue 
(Haussecker & Kay 2010) so its manipulation has highly specific outcomes, in 
this case contributing to the reduction in HCV propagation with little side 
effects. 
Skeletal muscle is a highly abundant tissue in the body, making up ~40% of the 
body’s total mass and constituting the locomotive unit of the body. However, 
skeletal muscle is also essential in respiratory function, where respiratory 
failure is the leading cause of death in Australia and the world (Australian 
Centre for Asthma Monitoring 2011) , and an essential fuel source for the brain 
and immune system during periods of serious illness (Rasmussen & Phillips 
2003). Serious, chronic disease is often characterised by a significant loss of 
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skeletal muscle mass, a key marker used to determine prognosis by medical 
practitioners (Dewys et al. 1980). The turnover of muscle proteins, particularly 
structural proteins, drives the regulation of skeletal muscle mass. In order to 
increase muscle mass, the rate of muscle protein synthesis (MPS) must exceed 
the rate muscle protein degradation (MPD). MPS can be stimulated by 
resistance exercise and protein ingestion (Koopman et al. 2006; Kumar et al. 
2009). On the other hand when MPD exceeds MPS there is a net loss of muscle 
mass (Wang et al. 1998). Skeletal muscle loss is a clinical consequence of 
diseases such as Duchenne muscular dystrophy (DMD), amyotrophic lateral 
sclerosis (ALS), chronic obstructive pulmonary disease (COPD), sepsis, 
chronic heart failure (CHF), rheumatoid arthritis and cancer cachexia. Skeletal 
muscle loss is also a natural process that occurs with ageing (Evans & Campbell 
1993).
Understanding the underlying molecular mechanisms that regulate protein 
turnover in skeletal muscle is essential for the development of effective and 
targeted therapies to correct protein balance and recover muscle mass. One of 
the key signalling pathways regulating muscle mass, the Akt-mTOR signalling 
pathway (Bodine et al. 2001b; Rommel et al. 2001), was the main focus of this 
thesis. Upstream, mTOR is regulated by a signalling cascade mediated by 
growth factors, including IGF1, insulin and growth hormone, all of which drive 
protein synthesis by fine-tuning protein translation factors. Conversely, growth 
IDFWRUV VXFK DV 71)Į DQG P\RVWDWLQ QHJDWLYHO\ LPSDFW SURWHLQ WXUQRYHU
(Amirouche et al. 2009; Frost, Nystrom & Lang 2003). The role of miRNAs in 
the regulation of signalling pathways, such as protein synthesis/degradation
pathways will enrich the current body of knowledge surrounding the control of 
cellular health and disease. 
The overall aim of my PhD was to identify and characterise the role of specific 
miRNAs associated with age related muscle wasting as regulators of protein 
synthesis. Specifically, chapter 3 involved a large-scale miRNA screen within 
the skeletal muscle of young and older adults following an acute bout of 
resistance exercise designed to stimulate MPS. The aim was to identify 
miRNAs that were differentially regulated between young and old subjects 
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predicted to regulate members of the Akt-mTOR signalling pathway. This 
allowed the identification of two miRNAs to investigate in vitro. The aims for 
chapters 5 and 6 were to determine if the miRNAs of interest, miR-99b and 
miR-499, could reduce MPS by downregulating predicted targets within the 
Akt-mTOR signalling pathways.
7.2 Summary of Results
The aim for chapter 3 was to perform a large-scale miRNA screen within the 
skeletal muscle of young and old subjects following an acute bout of resistance 
exercise. A high throughput PCR-based miRNA array allowed me to identify 
26 miRNAs that were differentially regulated with age and/or exercise. Of these 
26 miRNAs, 14 were influenced by age and exercise and 8 were predicted to 
regulate members of the Akt-mTOR signalling pathway. The 8 miRNAs with 
predicted targets within the Akt-mTOR signalling pathways are miR-99a, miR-
99b, miR-100, miR-149-3p, miR-186, miR-196b, miR-199a and miR-499. Two 
miRNAs were selected for further investigation in vitro.
In chapter 5 I sought to demonstrate a proof-of-concept for miR-99b as a 
regulator of muscle protein synthesis via its predicted targets mTOR, RPTOR 
and IGF1R. Overexpression of miR-99b in the cells resulted in a significant 
reduction in protein synthesis rates. In parallel, there was also a decrease in the 
mRNA expression of mTOR and IGF1R, however the protein levels of these 
targets and RPTOR were not altered by miR-99b overexpression. The only Akt-
mTOR signalling protein altered by miR-99b overexpression was 4EBP1, 
which was hyperphosphorylated, a finding that does not support the decrease in 
protein synthesis. In addition, I found a significant decrease in miR-99a and 
miR-100, members of the miR-99/100 family of miRNAs, with miR-99b
overexpression. 
In chapter 6 I investigated whether miR-499 could regulate protein synthesis 
via its predicted target eIF4G2, a translation initiation factor. Overexpression 
of miR-499 reduced protein synthesis in the myotubes derived from old subjects 
140
only, demonstrating an age-specific role. This finding was paralleled with an 
increase in 4EBP1 phosphorylation. I also found that miR-499 overexpression 
downregulated eIF4G2 at the mRNA level in an age-independent manner. 
However, a binding interaction between miR-499 and eIF4G2 was not observed 
and the protein levels of eIF4G2 were unaltered. 
7.3 Future Directions
This thesis represents a broad, general approach to identifying and 
understanding the roles of specific miRNAs within an ageing model. One 
important outcome of chapter 3 was that myomiRs remained relatively 
unaffected by age and the specific exercise bout used. A number of studies have 
used in vivo and in vitro models in order to study the regulation of myomiRs, a 
suite of just 8 miRNAs, in muscle atrophy and hypertrophy conditions 
(McCarthy & Esser 2007; McCarthy, Esser & Andrade 2007; McCarthy et al. 
2009). However, chapter 3 demonstrates the importance of taking a general 
approach when exploring novel targets in a particular model. The results from 
the PCR-based miRNA array in chapter 3 represent the most comprehensive 
investigation of human skeletal muscle miRNAs performed to date. Of the 754 
miRNAs investigated 257 miRNAs were classified as ‘expressed’ in skeletal 
muscle. These 257 miRNAs represent 257 potential regulators of muscle cell 
functions. To further expand on the growing list of miRNAs that are expressed 
in skeletal muscle, next generation sequencing (NGS) can be employed to 
confirm the absolute abundance of known miRNAs and to discover new 
miRNAs in any specific model (Creighton, Reid & Gunaratne 2009; Tam et al. 
2014).
In chapter 3 I identified 26 miRNAs that were differentially regulated with age, 
exercise or a combination of both factors. The specific role of many of these 
miRNAs is not known in skeletal muscle and warrant in depth investigation. 
The main focus of this thesis was the regulation of protein synthesis, with a 
specific focus on Akt-mTOR signalling, linked to age-related muscle wasting. 
However, there are a number of other factors contributing to age-related muscle 
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wasting including reduced regenerative capacity, loss of motor units, changes 
in hormone secretions and altered metabolism (Campbell, McComas & Petito 
1973; Roberts et al. 1996; Schlenska & Kleine 1980). An in-depth investigation 
of the predicted targets and the literature may provide some clues as to which 
miRNAs may be contributing to some of these other age-related processes. A 
similar approach as described in chapters 5 and 6 can then be employed in order 
to determine specific roles of these miRNAs in the development of age-related 
muscle wasting. However, one limitation of the methodology used in chapter 3 
is that the specific cohort of subjects, particularly the elderly subjects, are not 
representative of the general population. The elderly subjects used in this group 
are generally healthy and physically active. It is likely that the miRNAs
identified are associated with mild changes in muscle physiology and 
morphology. A similar investigation using a sarcopenic population may reveal 
other miRNAs that are contributing to the onset and progression of age-related 
muscle wasting. 
Eight miRNAs were identified in chapter 3 as being highly predicted to regulate 
members of the Akt-mTOR signalling pathway. Unfortunately time did not 
permit the investigation of all of these miRNAs for this thesis. The role of these 
miRNAs in the regulation of protein synthesis should be investigated further. A 
number of these miRNAs, including the miR-99/100 family of miRNAs, miR-
149, miR-196 and miR-199 have validated targets within the Akt-mTOR 
signalling pathway in other cells (Doghman et al. 2010; Fornari et al. 2010; Hou
et al. 2014; Jia et al. 2013; Lin, Lin & Yu 2010; Wei et al. 2013). However, 
these interactions need to be confirmed in myocytes in conjunction with 
functional changes to protein synthesis. 
For the completion of this dissertation two miRNAs were selected for selective 
modulation in vitro. A proof-of-concept approach was taken to confirm that 
miR-99b and miR-499 could regulate protein synthesis in human primary 
myocytes. The work from chapters 5 and 6 confirms that overexpression of both 
miRNAs negatively regulates protein synthesis. At this stage the mechanism of 
action for both miRNAs is not clear and requires further investigation into the 
regulation of protein synthesis signalling pathways (outlined in detail within the 
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respective chapters). This work will be completed in preparation for publication 
of chapters 5 and 6. However, for the first time, two miRNAs are directly 
involved in the regulation of protein synthesis in myocytes. The next step is to 
determine whether downregulating endogenous levels of miR-99b and miR-
499 can positively influence protein synthesis. This has important implications 
for the future development of therapies to counteract skeletal muscle wasting. 
This can be investigated further in vitro using specific LNA based miRNA
inhibitors. A specific focus on miRNA families should be employed here. The 
findings from chapter 3 and 5 demonstrate that the expression of the members 
of the miR-99/100 family of miRNAs is complex and likely to be dependent on 
each other. Artificially overexpressing a miRNA at high levels is likely to 
override any inhibitory mechanisms. On the other hand, the effects from 
knocking down endogenous miR-99b may be masked by a rescuing mechanism 
initiated by changes to miR-99a and miR-100 expression levels. miRNA family 
inhibitors are available on the market and may need to be considered for future 
studies into the role of miR-99 miRNAs in the regulation of protein synthesis. 
Following the completion of the in vitro investigation of miR-99b and miR-499
miRNA targets knockout studies would need to be performed in vivo to 
determine the efficacy of modulating these miRNAs from a systemic point of 
view. This can be achieved with the use of specific plasmid containing the MCK 
(muscle isoenzyme of creatine kinase) enhancer that ensures a tissue specific 
activity (Sternberg et al. 1988) and has been successfully used to generate 
skeletal muscle specific miRNA knockout mice in the past (van Rooij et al. 
2009). This system was used in the past to generate skeletal muscle specific 
miR-499-/- mice and to investigate skeletal muscle fibre typing. Knockout of 
miR-499 alone was not sufficient to influence muscle fibre type, however a 
miR-499-/- and miR-208b-/- double knockout had profound consequences on the 
architecture of the muscle. However, the study did not report on changes to 
muscle mass or measure protein synthesis rates. It may also be important to 
consider the role and regulation of miR-208b when investigating the role of
miR-499 in protein synthesis. 
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Another area of miRNA expression that has captured the imagination of many 
researchers is the exploitation of miRNAs as biomarkers in bodily fluids. 
Certainly, an elevation in the presence of specific miRNA species in circulation 
may be indicative of a tissue or organ in ‘distress’. A number of studies have 
been investigating plasma miRNAs and made correlations with disease 
presence including cancer, type 2 diabetes and coronary diseases (Chen et al. 
2008; Goren et al. 2012; Ortega et al. 2014). In skeletal muscle the majority of 
circulating miRNAs have been investigated in relation to various exercise 
models (Aoi et al. 2010; Baggish et al. 2011; Sawada et al. 2013; Uhlemann et 
al. 2014). Circulating miRNAs have also been investigated in the context of 
muscle disease and injury (Roberts et al. 2013) and with exercise and ageing 
(Zhang et al. 2015). Changes in circulating miRNAs, particularly the presence 
of myomiRs, may be indicative of muscle breakdown processes, resulting in a 
leakage of miRNAs into circulation. However, unless miRNAs are specifically 
tissue specific, drawing correlations between circulating miRNAs and disease 
presence is a significant challenge. Extraction protocols and hemolysis can 
introduce biases into the miRNA expression levels (McAlexander, Phillips & 
Witwer 2013; Pritchard et al. 2012). A significant amount of work is still 
required in this area before concrete correlations can be made between 
circulating miRNAs as biomarkers for disease.
7.4 Concluding Remarks
The area of miRNA regulation is still novel but is becoming increasingly 
relevant and important in the regulation of health and disease. The overall aim 
of this PhD was to identify and characterise the role of specific miRNAs in the 
regulation of muscle mass using age-related muscle wasting as a model. In 
chapter 3 I identified 26 miRNAs that were regulated by age, exercise or a 
combination of both factors. Of the 26 miRNAs 14 where specifically regulated 
by age and exercise and 8 were strongly predicted to regulate MPS via the Akt-
mTOR signalling pathways. For chapters 5 and 6 involved a more in-depth 
analysis of two of the miRNAs identified from study 1. This PhD thesis shows 
for the first time that overexpression of miR-99b and miR-499 negatively 
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regulates protein synthesis in human primary myotubes. In addition, the 
mechanism of action for miR-499 appears to be age-dependent. Both miRNAs
were strongly predicted to regulate key members of the Akt-mTOR signalling 
pathway including mTOR, RPTOR and IGF1R for miR-99b and eIF4G2 for 
miR-499. However, the results from this thesis show that it is unlikely that 
protein synthesis is being regulated via any changes to the protein expression 
of these targets. Furthermore, Akt-mTOR signalling could not be linked to 
changes in protein synthesis. Further work is required to elucidate the 
mechanisms regulating protein synthesis by miR-99b and miR-499.
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Appendix D
mTOR 3' UTR – Original sequence
ġ
ġ
1 CUGGAGGCCC AGAUGUGCCC AUCACGUUUU UUCUGAGGCU UUUGUACUUU AGUAAAUGCU 
61 UCCACUAAAC UGAAACCAUG GUGAGAAAGU UUGACUUUGU UAAAUAUUUU GAAAUGUAAA 
121 UGAAAAGAAC UACUGUAUAU UAAAAGUUGG UUUGAACCAA CUUUCUAGCU GCUGUUGAAG 
181 AAUAUAUUGU CAGAAACACA AGGCUUGAUU UGGUUCCCAG GACAGUGAAA CAUAGUAAUA 
241 CCACGUAAAU CAAGCCAUUC AUUUUGGGGA ACAGAAGAUC CAUAACUUUA GAAAUACGGG 
301 UUUUGACUUA ACUCACAAGA GAACUCAUCA UAAGUACUUG CUGAUGGAAG AAUGACCUAG 
361 UUGCUCCUCU CAACAUGGGU ACAGCAAACU CAGCACAGCC AAGAAGCCUC AGGUCGUGGA 
421 GAACAUGGAU UAGGAUCCUA GACUGUAAAG ACACAGAAGA UGCUGACCUC ACCCCUGCCA 
481 CCUAUCCCAA GACCUCACUG GUCUGUGGAC AGCAGCAGAA AUGUUUGCAA GAUAGGCCAA 
541 AAUGAGUACA AAAGGUCUGU CUUCCAUCAG ACCCAGUGAU GCUGCGACUC ACACGCUUCA 
601 AUUCAAGACC UGACCGCUAG UAGGGAGGUU UAUUCAGAUC GCUGGCAGCC UCGGCUGAGC 
661 AGAUGCACAG AGGGGAUCAC UGUGCAGUGG GACCACCCUC ACUGGCCUUC UGCAGCAGGG 
721 UUCUGGGAUG UUUUCAGUGG UCAAAAUACU CUGUUUAGAG CAAGGGCUCA GAAAACAGAA 
781 AUACUGUCAU GGAGGUGCUG AACACAGGGA AGGUCUGGUA CAUAUUGGAA AUUAUGAGCA 
841 GAACAAAUAC UCAACUAAAU GCACAAAGUA UAAAGUGUAG CCAUGUCUAG ACACCAUGUU 
901 GUAUCAGAAU AAUUUUUGUG CCAAUAAAUG ACAUCAGAAU UUUAAACAUA UGUAAAAAAA 
961 AA 
ġ
ġ
ġ
mTOR 3' UTR – Mutated sequence
ġ
ġ
1 CUGGAGGCCC AGAUGUGCCC AUCACGUUUU UUCUGAGGCU UUUGUACUUU AGUAAAUGCU 
61 UCCACUAAAC UGAAACCAUG GUGAGAAAGU UUGACUUUGU UAAAUAUUUU GAAAUGUAAA 
121 UGAAAAGAAC UACUGUAUAU UAAAAGUUGG UUUGAACCAA CUUUCUAGCU GCUGUUGAAG 
181 AAUAUAUUGU CAGAAACACA AGGCUUGAUU UGGUUCCCAG GACAGUGAAA CAUAGUAAUA 
241 CCACGUAAAU CAAGCCAUUC AUUUUGGGGA ACAGAAGAUC CAUAACUUUA GAAAUAGC-- 
301 UUUUGACUUA ACUCACAAGA GAACUCAUCA UAAGUACUUG CUGAUGGAAG AAUGACCUAG 
361 UUGCUCCUCU CAACAUGGGU ACAGCAAACU CAGCACAGCC AAGAAGCCUC AGGUCGUGGA 
421 GAACAUGGAU UAGGAUCCUA GACUGUAAAG ACACAGAAGA UGCUGACCUC ACCCCUGCCA 
481 CCUAUCCCAA GACCUCACUG GUCUGUGGAC AGCAGCAGAA AUGUUUGCAA GAUAGGCCAA 
541 AAUGAGUACA AAAGGUCUGU CUUCCAUCAG ACCCAGUGAU GCUGCGACUC ACACGCUUCA 
601 AUUCAAGACC UGACCGCUAG UAGGGAGGUU UAUUCAGAUC GCUGGCAGCC UCGGCUGAGC 
661 AGAUGCACAG AGGGGAUCAC UGUGCAGUGG GACCACCCUC ACUGGCCUUC UGCAGCAGGG 
721 UUCUGGGAUG UUUUCAGUGG UCAAAAUACU CUGUUUAGAG CAAGGGCUCA GAAAACAGAA 
781 AUACUGUCAU GGAGGUGCUG AACACAGGGA AGGUCUGGUA CAUAUUGGAA AUUAUGAGCA 
841 GAACAAAUAC UCAACUAAAU GCACAAAGUA UAAAGUGUAG CCAUGUCUAG ACACCAUGUU 
901 GUAUCAGAAU AAUUUUUGUG CCAAUAAAUG ACAUCAGAAU UUUAAACAUA UGUAAAAAAA 
961 AA 
ġ
240
EIF4G2 original sequence - 3' UTR Sequence
ġ
ġ
1 AGAACCAGCC AAAGCCUUAA AUUGUGCAAA ACAUACUGUU GCUAUGAUGU AACUGCAUUU 
61 GACCUAACCA CUGCGAAAAU UCAUUCCGCU GUAAUGUUUU CACAAUAUUU AAAGCAGAAG 
121 CACGUCAGUU AGGAUUUCCU UCUGCAUAAG GUUUUUUUGU AGUGUAAUGU CUUAAUCAUA 
181 GUCUACCAUC AAAUAUUUUA GGAGUAUCUU UAAUGUUUAG AUAGUAUAUU AGCAGCAUGC 
241 AAUAAUUACA UCAUAAGUUC UCAAGCAGAG GCAGUCUAUU GCAAGGACCU UCUUUGCUGC 
301 CAGUUAUCAU AGGCUGUUUU AAGUUAGAAA ACUGAAUAGC AACACUGAAU ACUGUAGAAA 
361 UGCACUUUGC UCAGUAAUAC UUGAGUUGUU GCAAUAUUUG AUUAUCCAUU UGGUUGUUAC 
421 AGAAAAAUUC UUAACUGUAA UUGAUGGUUG UUGCCGUAAU AGUAUAUUGC CUGUAUUUCU 
481 ACCUCUAGUA AUGGGCUUUA UGUGCUAGAU UUUAAUAUCC UUGAGCCUGG GCAAGUGCAC 
541 AAGUCUUUUU AAAAGAAACA UGGUUUACUU GCACAAAACU GAUCAGUUUU GAGAGAUCGU 
601 UAAUGCCCUU GAAGUGGUUU UUGUGGGUGU GAAACAAAUG GUGAGAAUUU GAAUUGGUCC 
661 CUCCUAUUAU AGUAUUGAAA UUAAGUCUAC UUAAUUUAUC AAGUCAUGUU CAUGCCCUGA 
721 UUUUAUAUAC UUGUAUCUAU CAAUAAACAU UGUGAUACUU GAUGUAGUGA 
ġ
ġ
EIF4G2 mutated sequence - 3' UTR Sequence
ġ
1 AGAACCAGCC AAAGCCUUAA AUUGUGCAAA ACAUACUGUU GCUAUGAUGU AACUGCAUUU 
61 GACCUAACCA CUGCGAAAAU UCAUUCCGCU GUAAUGUUUU CACAAUAUUU AAAGCAGAAG 
121 CACGUCAGUU AGGAUUUCCU UCUGCAUAAG GUUUUUUUGU AGUGUAAUGA CAAAAUCAUA 
181 GUCUACCAUC AAAUAUUUUA GGAGUAUCUU UAAUGUUUAG AUAGUAUAUU AGCAGCAUGC 
241 AAUAAUUACA UCAUAAGUUC UCAAGCAGAG GCAGUCUAUU GCAAGGACCU UCUUUGCUGC 
301 CAGUUAUCAU AGGCUGUUUU AAGUUAGAAA ACUGAAUAGC AACACUGAAU ACUGUAGAAA 
361 UGCACUUUGC UCAGUAAUAC UUGAGUUGUU GCAAUAUUUG AUUAUCCAUU UGGUUGUUAC 
421 AGAAAAAUUC UUAACUGUAA UUGAUGGUUG UUGCCGUAAU AGUAUAUUGC CUGUAUUUCU 
481 ACCUCUAGUA AUGGGCUUUA UGUGCUAGAU UUUAAUAUCC UUGAGCCUGG GCAAGUGCAC 
541 AAGUCUUUUU AAAAGAAACA UGGUUUACUU GCACAAAACU GAUCAGUUUU GAGAGAUCGU 
601 UAAUGCCCUU GAAGUGGUUU UUGUGGGUGU GAAACAAAUG GUGAGAAUUU GAAUUGGUCC 
661 CUCCUAUUAU AGUAUUGAAA UUAAGUCUAC UUAAUUUAUC AAGUCAUGUU CAUGCCCUGA 
721 UUUUAUAUAC UUGUAUCUAU CAAUAAACAU UGUGAUACUU GAUGUAGUGA 
241
SRF original sequence - 3' UTR Sequence
1 UCCGCCCGCC GCCCUGGACA GAUGGCCCAA GGGAUGGCAC CACUUAUUUA UUGUUGCCUU 
61 UUCACGUUUU CUUUACACAC ACGUUGACGG GCCGCAGGAG GGAGGCGGGG AGGAGGAACG 
121 GGCAGCCACA GGACUGAGCC CUCUCACUCC AGCCAAAGAA AUGGGCCUGC CUGCCUCCAC 
181 CCGUCCUCCC UCAGCCUCCC CUUCUUCCCG CCCCACCUCC CAUUUCUGUU GCUGGAGGGG 
241 CUGUCCUCCU UCCUGGGACC CCCUCGCCAG CUUGGCUCGA UGUUUGCCAU GAGUAUUAGC 
301 UUACCCAAUG GGACCGUGCC CCACCUCCCC ACACACAGGC CUUCUGUGGG GCUGGGCACC 
361 GUGUCCUCCU CUGAGGAAGC AGUUGGGGCC CUCUUGCCAG CCUCCUUGCU GACCCCAGGU 
421 CAGCCCUGUG UCUGUCACAG GCUGGGUCAA AAGAGCCCUG GCUCUGCCCC UCAGGGGGCC 
481 AGCUGGGGAG AUGGGGGCUU CUUCCUCACA CUGCUGUCCU CUCCCCCUUC AGCUCCUGAG 
541 UAGCUGGGCC UGUGCACUGG GCAGGUUCCU GGGGCCGCCU GCCCUGCCUU GCCGCUCCCC 
601 UUGGACCUCC AGGGGCUCCU GGGUUGGAGG GAACCACCAG CGUUCCCUUC UCCCCCUUGU 
661 CUUCCCCCCU CUCCUCCCAG CUGCUUUACU UAAAGUUGAU UUUGAACUUU UUAUUUGAGG 
721 AGACGAAGUG AAAACAAAUC UAUAAAUAUA UAUUUUUAAA AUAUUUAACU UUUUUUUAUG 
781 GCGUUUUUCU CGUCCCCCUC CCUGCCCAAA CUCCCCUUCC CUGGGGAGCC CUCAGGCUCC 
841 CCAGAACUGG CUGGGCCCCU GGGGACAGAG CCACCCCAUG AGCUCGGGGU CCACCAGUGU 
901 GUGGGGGAGA UUCUGGGUUU GCCCAGUCCU GGGUUGUUUC CAGGAGAAAG CCGGGGGAGG 
961 GGCCCUCAGG CCAUUCCCCA ACGGGGUGGG GAGGGUGACC CACAGCUCUG GGCCUCUUUU 
1021 UGCCCUUUAG GGCUGUUGCU AGGGAGAGGG AAGAGGGAGA CCAAAUGUCG GGGUUGGGGU 
1081 GGGAGGGCGU CAGGCAGAGG CAACUGACUU CAUUUGUGCC ACACGCAUGG GCAUUGCAGC 
1141 CUUGCGCUGU CCCAGGCAUG CAGCUGCCUG GGGCCCAAGU UGCAGUGAGC AGGGUGGGGU 
1201 CUGGGAGGGG GUGAGAGGCA GGAAUGGGGG UCAGAAGAAG UGGGAGCAGC UUCUUGGGCU 
1261 GAGUGCAGCC AAAGGGGAGC CAGAAAUGGG CAGUUCUCCC AGGGAGUGAG CAGCUACUGU 
1321 AACUUUUUUA AAUUAAGACA AAAAGCCUUG AAGAAAAUGA CUUUAUUUUU CUAAGUGUAA 
1381 CCUCAGUAUU UAUGUAAUUU GUACAGGGGC CAUGCCCCAC CCCCCUCCUC CCCCUUUGGG 
1441 GUAGACCUUG AGGGUGGGCC AGCAUAGGGG GGAGGGUCUU UUACCCUGUG UCAGAGCCUA 
1501 CCUUCACCAC CUAUAUCCAG AAGGGGAGCU UUUUCAGAAA CAGGGCAGCA GUGGGGUGAA 
1561 AUUUUCUUAA CCCCUAAGAC UGCCUUCAGU AGGAACAAGC UGGCUUCUGU GAUUAGGUGA 
1621 AGGGAUGGGG GAAGAUUUUA UGCACAGCCU AGUUAUCAAG GGGAUGAUUU GCCGACAUGU 
1681 UUGAGAACCC CCUAACCUCU AACCCUCAUU GCUGUCUUGC CCCAGUUUGG GGUGCCAAGA 
1741 UGGAAGUCAC CUUUCUGGGC UUUCUCCUGG AGAUAGCUGG GGCUUAUGGG UGGCUUUCAA 
1801 GGCUGGGGCA UGGCAAAUCA GGGGCCAGAG AGCAGGGGAG CUUGGGACUC AGGUCUGUAA 
1861 CUGCCCAGCC CCUUUUCUCU GCUCUUGUUU CACUCCACCA UCACUCACUC ACUCCCCACU 
1921 CCCCCACCCA UGGGGAGGAG ACCUUUGAUG AAUUCUUCCU CUCCUUCCCA CAAAAGACAG 
1981 ACCCAGUGAG UGAAUCAGGC AAAGUGCUUA UAAUGUGUGU UGUGUGAGCG UGGCCUUGGG 
2041 AGGACAUGCG UGUGUCAGGG AUGAGUUGAG GUGAUAUUUU UAUGUGCAGC GACCCUUGGU 
2101 GUUUCCCUUC CUCGGUGGCU CUGGGGUAUG UGUGUGUGGG UGUGUGCGCC UGAGUGAGUG 
2161 UGUGUGCUUG AAUGUGAGUG UGUAUGUCAG UGGUUUCUAC UUCCCCUGGG AUGCUGACCC 
2221 AGGAAUAGUG GACAUGGUCA CAGUCCUAUG UACAGAGCUU UCUUUUGUAU UAAAAAAAAA 
2281 UACUCUUUCA AUAAAUGUAU CAUUUUUGUG CACAGAAAAA AAAAAAAAAA AAAAAAAAAA 
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SRF mutated sequence - 3' UTR Sequence
1 UCCGCCCGCC GCCCUGGACA GAUGGCCCAA GGGAUGGCAC CACUUAUUUA UUGUUGCCUU 
61 UUCACGUUUU CUUUACACAC ACGUUGACGG GCCGCAGGAG GGAGGCGGGG AGGAGGAACG 
121 GGCAGCCACA GGACUGAGCC CUCUCACUCC AGCCAAAGAA AUGGGCCUGC CUGCCUCCAC 
181 CCGUCCUCCC UCAGCCUCCC CUUCUUCCCG CCCCACCUCC CAUUUCUGUU GCUGGAGGGG 
241 CUGUCCUCCU UCCUGGGACC CCCUCGCCAG CUUGGCUCGA UGUUUGCCAU GAGUAUUAGC 
301 UUACCCAAUG GGACCGUGCC CCACCUCCCC ACACACAGGC CUUCUGUGGG GCUGGGCACC 
361 GUGUCCUCCU CUGAGGAAGC AGUUGGGGCC CUCUUGCCAG CCUCCUUGCU GACCCCAGGU 
421 CAGCCCUGUG UCUGUCACAG GCUGGGUCAA AAGAGCCCUG GCUCUGCCCC UCAGGGGGCC 
481 AGCUGGGGAG AUGGGGGCUU CUUCCUCACA CUGCUGUCCU CUCCCCCUUC AGCUCCUGAG 
541 UAGCUGGGCC UGUGCACUGG GCAGGUUCCU GGGGCCGCCU GCCCUGCCUU GCCGCUCCCC 
601 UUGGACCUCC AGGGGCUCCU GGGUUGGAGG GAACCACCAG CGUUCCCUUC UCCCCCUUGU 
661 CUUCCCCCCU CUCCUCCCAG CUGCUUUACU UAAAGUUGAU UUUGAACUUU UUAUUUGAGG 
721 AGACGAAGUG AAAACAAAUC UAUAAAUAUA UAUUUUUAAA AUAUUUAACU UUUUUUUAUG 
781 GCGUUUUUCU CGUCCCCCUC CCUGCCCAAA CUCCCCUUCC CUGGGGAGCC CUCAGGCUCC 
841 CCAGAACUGG CUGGGCCCCU GGGGACAGAG CCACCCCAUG AGCUCGGGGU CCACCAGUGU 
901 GUGGGGGAGA UUCUGGGUUU GCCCAGUCCU GGGUUGUUUC CAGGAGAAAG CCGGGGGAGG 
961 GGCCCUCAGG CCAUUCCCCA ACGGGGUGGG GAGGGUGACC CACAGCUCUG GGCCUCUUUU 
1021 UGCCCUUUAG GGCUGUUGCU AGGGAGAGGG AAGAGGGAGA CCAAAUGUCG GGGUUGGGGU 
1081 GGGAGGGCGU CAGGCAGAGG CAACUGACUU CAUUUGUGCC ACACGCAUGG GCAUUGCAGC 
1141 CUUGCGCUGU CCCAGGCAUG CAGCUGCCUG GGGCCCAAGU UGCAGUGAGC AGGGUGGGGU 
1201 CUGGGAGGGG GUGAGAGGCA GGAAUGGGGG UCAGAAGAAG UGGGAGCAGC UUCUUGGGCU 
1261 GAGUGCAGCC AAAGGGGAGC CAGAAAUGGG CAGUUCUCCC AGGGAGUGAG CAGCUACUGU 
1321 AACUUUUUUA AAUUAAGACA AAAAGCCUUG AAGAAAAUGA CUUUAUUUUU CUAAGUGUAA 
1381 CCUCAGUAUU UAUGUAAUUU GUACAGGGGC CAUGCCCCAC CCCCCUCCUC CCCCUUUGGG 
1441 GUAGACCUUG AGGGUGGGCC AGCAUAGGGG GGAGGGUCUU UUACCCUGUG UCAGAGCCUA 
1501 CCUUCACCAC CUAUAUCCAG AAGGGGAGCU UUUUCAGAAA CAGGGCAGCA GUGGGGUGAA 
1561 AUUUUCUUAA CCCCUAAGAC UGCCUUCAGU AGGAACAAGC UGGCUUCUGU GAUUAGGUGA 
1621 AGGGAUGGGG GAAGAUUUUA UGCACAGCCU AGUUAUCAAG GGGAUGAUUU GCCGACAUGU 
1681 UUGAGAACCC CCUAACCUCU AACCCUCAUU GCUGUCUUGC CCCAGUUUGG GGUGCCAAGA 
1741 UGGAAGUCAC CUUUCUGGGC UUUCUCCUGG AGAUAGCUGG GGCUUAUGGG UGGCUUUCAA 
1801 GGCUGGGGCA UGGCAAAUCA GGGGCCAGAG AGCAGGGGAG CUUGGGACUC AGGUCUGUAA 
1861 CUGCCCAGCC CCUUAUCUCU GCA-AAGUUU CACUCCACCA UCACUCACUC ACUCCCCACU 
1921 CCCCCACCCA UGGGGAGGAG ACCUUUGAUG AAUUCUUCCU CUCCUUCCCA CAAAAGACAG 
1981 ACCCAGUGAG UGAAUCAGGC AAAGUGCUUA UAAUGUGUGU UGUGUGAGCG UGGCCUUGGG 
2041 AGGACAUGCG UGUGUCAGGG AUGAGUUGAG GUGAUAUUUU UAUGUGCAGC GACCCUUGGU 
2101 GUUUCCCUUC CUCGGUGGCU CUGGGGUAUG UGUGUGUGGG UGUGUGCGCC UGAGUGAGUG 
2161 UGUGUGCUUG AAUGUGAGUG UGUAUGUCAG UGGUUUCUAC UUCCCCUGGG AUGCUGACCC 
2221 AGGAAUAGUG GACAUGGUCA CAGUCCUAUG UACAGAGCUU UCUUUUGUAU UAAAAAAAAA 
2281 UACUCUUUCA AUAAAUGUAU CAUUUUUGUG CACAGAAAAA AAAAAAAAAA AAAAAAAAAA 
2341 A 
243
